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ABSTRACT 
METABOLIC REGULATION OF MYOCARDIAL  
ADAPTATION TO EXERCISE 
Andrew Alan Gibb 
September 1, 2017 
While the benefits of exercise affect several organs, a significant adaptive 
response occurs within the heart. Exercise promotes cardiac growth, increases 
angiogenesis, and enhances cardiac function and these adaptations are 
associated with a cardioprotective phenotype. Additionally, extensive evidence 
shows that exercise dynamically regulates myocardial metabolism. This can be 
attributed to both changes in hormonal stimulation, increases in bioenergetic 
demand, and the bioavailability of circulating substrates. However, it is unclear 
whether these changes in metabolism contribute to physiologic cardiac growth. We 
reason that exercise-induced changes in metabolism are required to balance the 
catabolic and anabolic reactions needed for growth. Specifically, we hypothesize 
that exercise-induced changes in myocardial glycolytic activity are essential for 
activation of the physiological growth program and the synthesis of metabolites 
required for growth. Prior to investigating the effects of exercise on cardiac 
metabolism, we established a model of cardiac adaptation to exercise training in 
mice (Chapter II). Once established, as discussed in Chapter III, we found that the 
exercise-adapted heart demonstrates enhanced glycolytic activity; however, 
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during exercise glycolytic rate in the heart is diminished. To determine whether 
high or low glycolytic rates may be a stimulus for cardiac growth, we assessed the 
effect of cardiac-specific overexpression of phosphofructokinase isoforms that 
decrease or increase myocardial glycolytic rate. We found that constitutive 
reduction in glycolytic rate was sufficient to structurally and functionally phenocopy 
the exercise-adapted heart, replete with activation of the physiologic growth 
program; however, metabolic inflexibility invoked by constitutive changes in 
glycolysis results in mild mitochondrial dysfunction. To assess how glycolytic 
activity affects anabolic metabolism, we utilized stable isotope labeling in an in vitro 
model to interrogate flux of carbon into collateral biosynthetic pathways of glucose 
metabolism. Results from these studies, discussed in Chapter IV, show that PFK1 
and glycolytic activity coordinate the allocation of glucose into pathways that would 
be important for cardiac growth. Collectively, our results indicate that physiological 
growth of the heart is intricately regulated by exercise-induced changes in 
intermediary metabolism, and that preservation of metabolic flexibility is essential 
for mitochondrial health. Importantly, these findings suggest a causal role of 
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Significance of Physical Activity 
 Physical activity is firmly embedded in human culture. The ability to adapt 
to periods of increased physical activity likely played a critical role in the evolution 
of human physiology. For instance, our early ancestors with low “physical fitness,” 
likely did not fare well at a time when hunting, gathering, shelter building, and 
evasion from predators were a necessity. This period in time likely contributed to 
the evolutionary physiologic advancement of the human species. Much later in 
ancient Greece, Hippocrates was the first to realize the importance of physical 
activity and stated that “eating alone will not keep a man well; he must also take 
exercise. For food and exercise…work together to produce health.”1 Today, 
physical activity as a way of life is simply an afterthought. With the obvious 
transition from manual labor jobs to sedentary desk jobs and the technological 
advancements made over the last century, a sedentary lifestyle has become the 
new “normal” for human physiology. Unfortunately, this new “normal” could be 
considered evolutionarily “abnormal.” While exercise has been labeled as 
providing “health benefits,” it is in fact the lack of exercise that carries health risks.2 
This deviation from “normal” and change in lifestyle led the World Health 
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Organization (WHO) to classify physical inactivity as the fourth leading risk factor 
for global mortality.3  
  While physical inactivity is a health risk, it is a modifiable one. The first 
documented study of the beneficial effects of an active lifestyle was in 1953. This 
study showed that those in more physically active jobs (e.g., train conductors and 
postmen) in London had a lower incidence of cardiovascular events and a lower 
early mortality-rate than their sedentary, desk-based, civil servant counterparts.4 
Along with this observation, the benefits of physical activity have only become 
more noticeable over the years. Regular exercise has been shown to promote 
cardiovascular health,5-7 augment skeletal muscle function,8 and increase both 
healthspan8-10 and lifespan.5, 11-13 An individual’s level of physical fitness, 
commonly measured by their exercise capacity, is a more powerful predictor of 
mortality among men than other established cardiovascular risk factors such as 
hypertension, blood lipids, and smoking.12 The indication that physical fitness is 
the most powerful predictor of mortality risk highlights the importance of an active 
lifestyle.  
Despite irrefutable evidence that exercise imparts health benefits, or 
perhaps more accurately prevents sedentary health risks, the mechanisms by 
which exercise does so remain poorly understood. For instance, epidemiologic 
evidence suggests that while exercise training significantly lowers traditional 
cardiovascular risk factors (i.e. hypertension, inflammation, and blood lipids), only 
half of the reduction in event risk can be explained by these changes.6, 7 These 
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observations suggest that a large portion of the benefits of exercise remain 
unexplained and warrant further investigation.  
 
Exercise and the Cardiovascular System 
The complexity of studying exercise is rooted in the coordinated response 
of the body’s organ systems. For example, even before beginning exercise (e.g. 
running), the centers in the brain prime the body for an increase in energy 
expenditure by increasing respiratory and heart rates (refs). At the onset of 
exercise, skeletal muscle contracts in response to the increased workload, 
requiring an increase in the utilization of fuel substrates such as glucose, glycogen, 
and fatty acids to meet the higher energy demand. This increase in muscle 
metabolism must be met by an equal increase in oxygen delivery, which is 
accomplished by a further increase in pulmonary respiratory rates and heart rates 
to increase oxygen delivery. These changes from homeostasis in the muscular, 
respiratory and circulatory systems are driven in part by changes in both the 
autonomic tone of the nervous system and the release of circulating hormones and 
catecholamines from the endocrine system. Interestingly, exercise profoundly 
affects the cardiovascular system in particular, resulting in significant adaptive 
responses of the heart. For instance, exercise promotes cardiac growth, increases 
perfusion, and enhances cardiac function and substrate utilization, all of which 
contribute to cardioprotection (Fig. 1). Understanding the mechanisms that 
underlie this response could lead to therapeutic strategies to improve cardiac 
health in disease.   
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The heart is highly susceptible to changes in workload brought upon by 
exercise. Simply put, the primary response of the circulatory system is to increase 
blood flow to active areas (e.g. skeletal muscle) and to decrease it to non-working, 
less critical ones (e.g. GI tract). This is critical as the working muscle requires an 
increase in oxygen delivery to match the increase in metabolic demand required 
for the maintenance of contractile function. Not surprising, the heart is quite 
efficient at matching oxygen delivery to metabolic demand, resulting in little 
energetic waste. To accomplish this, the heart increases cardiac output, the 
product of heart rate (HR) and stroke volume (SV). Several factors determine 
cardiac performance and are discussed below: 
 
1) Heart rate: The single greatest factor determining cardiac output is heart 
rate. Under resting conditions, the human heart beats approximately 70 
times per minute (bpm); however, during intense exercise this can 
increase nearly 3-fold to 200 bpm. Under parasympathetic control via 
the Vagus nerve, vagal tone is diminished during exercise and 
sympathetic stimulation predominates, leading to an increased HR. In 
addition to its significant contributions to cardiac output, heart rate is the 
most important factor determining myocardial oxygen consumption. This 
increase in oxygen utilization is essential to match the increase in 
metabolic demand. For this reason, increases in HR and cardiac output 
are tightly regulated to be directly proportional to the increase in oxygen 
requirements of not only the skeletal muscle, but the heart itself. Lastly, 
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HRs are useful in estimating the myocardial metabolic cost of exercise. 
For example, the product of HR and systolic blood pressure is the rate-
pressure product (RPP), a rough index of the coronary blood flow 
myocardial oxygen consumption. 
 
2) Preload: Several factors contribute to SV with preload being one of 
them. Preload, also known as end diastolic volume (EDV), is the volume 
of blood that stretches the ventricles to their greatest dimensions prior 
to contraction. Preload directly contributes to SV by means of the Frank-
Starling law. This law describes the positive relationship between SV 
and EDV and is driven by the length-tension relationship of the 
cardiomyocyte sarcomeres. As blood fills the ventricles, the myocyte 
myofibrils are stretched, creating more opportunities for cross-bridge 
interactions. An increased number of possible cross-bridges promotes 
greater contractile force, resulting in a larger volume of blood ejected, 
i.e., SV. Preload is directly related to the venous return of blood to the 
heart: its increase during exercise is caused by augmented skeletal and 
respiratory muscle pump function, higher venous tone (i.e. 
venoconstriction), and elevated cardiac output. Interestingly, it has been 
suggested that high heart rates may in fact decrease preload due to the 
loss of filling time; however, this remains controversial.14 
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3) Afterload: Unlike preload, afterload is referred to as a pressure and is 
negatively correlated to SV and cardiac output. Afterload is defined as 
the load which the ventricles must overcome to eject blood. The typical 
afterload (systolic blood pressure) in a healthy adult is 120 mmHg; 
however, during resistance exercise, such as weight lifting, arterial 
pressures can reach 480 mmHg and is due to the arterial constriction of 
contracting skeletal muscle.15 These pressures, however, are not 
maintained as weight lifting is typically intermittent and dynamic. While 
this acute increase in afterload causes an immediately and relatively 
large decrease in SV, this leads to an increase in preload during the next 
cardiac cycle, increasing the effect size of Frank-Starling’s law and 
increasing SV on the subsequent beat. While the increase observed with 
endurance exercise is much less severe (~ 100 mmHg), this increase in 
afterload is overcome by the heart due to the increases in preload and 
contractility. 
 
4) Contractility: Contractility can be defined as the degree of force the heart 
muscle produces to eject blood and is positively correlated with SV. 
Unlike skeletal muscle, which is capable of recruiting additional fibers, 
the myocardium is fully engaged. Therefore, changes in contractility are 
completely dependent on intracellular Ca2+ availability, critical for muscle 
excitation-contraction coupling. When intracellular Ca2+ levels rise, Ca2+ 
binds to troponin-C causing a conformation change allowing actin-
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myosin cross-bridge interactions to occur. Utilizing ATP, the actin and 
myosin filaments slide past each other, shortening the sarcomeres and 
contracting the cell. Increased sympathetic stimulation and circulating 
catecholamines released during exercise increase intracellular Ca2+, 
resulting in enhanced myocardial contractility during exercise. 
 
Similar to the effects on skeletal muscle,8 the plasticity of the heart allows 
for adaptation to repetitive bouts of exercise. This adaptive state following training 
elicits significant cardioprotection from cardiac insults including myocardial 
ischemia,16, 17 pressure-overload (i.e. TAC),18 and diabetic cardiomyopathy.19 Part 
of this cardioprotection is associated with improvements in cardiac function. The 
exercise-adapted heart, also known as athlete’s heart, is associated with modestly 
enhanced diastolic function, whereas systolic function is primarily unaffected.20 
This improvement in diastolic function can be linked back to those factors affecting 
preload. Endurance exercise training has been well documented to result in 
hypervolemia21 which contributes to increases in preload and cardiac output. 
Additionally, exercise reduces not only resting HR, but also the HR achieved at 
submaximal workloads, providing additional filling time for preload.14 The chronic 
effects of exercise on decreasing afterload in heathy individuals are not as large, 
as systolic blood pressures are only slightly reduced; however, in hypertensive 
individuals, exercise has a slightly greater effect size.22 At the cellular level, 
enhanced cardiac contractility contributes significantly to the improvement in 
cardiac performance. In exercise-trained rodents, fractional shortening improves 
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40-50% while relaxation rates improve 20-40%.23 These improvements are, in part, 
explained by an increase in myofilament sensitivity to Ca2+.24 Additionally, exercise 
has been shown to increase the activity of SERCA2a and phospholamban, 
contributing not only to enhanced Ca2+ release required for excitation-contraction 
coupling but also Ca2+ reuptake into the sarcoplasmic reticulum for relaxation.23, 25  
In addition to improving Ca2+ handling, regular exercise promotes cardiac 
growth, also referred to as physiological hypertrophy. This form of remodeling is 
characterized by a 10-20% increase in cardiac mass. Endurance exercise 
selectively induces an eccentric form of hypertrophy, wherein an increase in left 
ventricular (LV) volume is met with an equal increase in LV and septal wall 
thicknesses, coordinated by an increase in cardiomyocyte width and length. This 
is in stark contrast to a pathologic form of hypertrophy, where a much larger 
increase in LV volume is accompanied by a preferential myocyte lengthening, 
leading to wall thinning. Concentric hypertrophy, more prominent in pathology due 
to chronic elevations of afterload, is characterized by wall thickening as 
cardiomyocytes increase in width more so than length, reducing LV volume. While 
some strenuous exercise, such as weight training may induce a milder form of 
concentric hypertrophy, it is not believed to pathologic.26, 27 Also, different from 
pathological hypertrophy is the observation that following only a few weeks of 
detraining in college and Olympic athletes, physiological hypertrophy regresses, 
indicating exercise-induced cardiac growth is a reversible phenotype.28, 29  
Other important factors also clearly distinguish these different forms of 
hypertrophy. For example, physiologic and pathologic hypertrophy differ 
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significantly in their signaling mediators and transcriptional responses. In 
particular, while pathological hypertrophy is associated with the induction of the 
fetal gene program (e.g. ANP, BNP, β-MHC, smooth muscle α-actin), physiological 
hypertrophy is not.30 Additionally, the molecular signaling events driving 
physiologic growth of the myocardium following exercise training are distinct. The 
most well established signaling and transcriptional events governing exercise-
induced physiologic growth are discussed below and in Fig. 2: 
 
1. IGF1: Insulin-like growth factor 1 (IGF1), and its receptor (IGF1r) is the 
best described and potentially most important signaling event governing 
exercise-induced cardiac growth. Acute exercise increases the release 
of growth hormone (GH) from the anterior pituitary gland which acts 
distally on the liver to increase IGF1 production.31 Additionally, exercise 
increases local IGF1 production in several target tissues, including the 
heart, thereby acting in an autocrine and/or paracrine fashion.32 Several 
transgenic mouse models have demonstrated the critical role of IGF1 in 
regulating physiologic cardiac growth. Both Igf1- and Igf1r1-null mice 
display a growth retardation phenotype with high perinatal mortality33 
while Igf1 overexpressing mice display a physiologic form of cardiac 
hypertrophy.34 Furthermore, cardiomyocyte-specific deletion of Igf1r1 in 
adult mice prevents exercise-induced cardiac growth.35 These results 
clearly demonstrate the importance of IGF1 signaling in not only 
exercise-induced cardiac growth, but perinatal development as well.  
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Figure 2: Exercise-mediated cardiac adaptive signaling pathways. Signaling 
pathways involved in the adaptation to exercise training. Physiologic growth is 
initiated by IGF1 through the IGF1/PI3K/AKT axis. Activation of AKT 
downregulates Cebpb transcription, allowing the upregulation of CITED4. This 
cascade leads to the upregulation of gene sets specific to promote cardiomyocyte 
growth. Inactivation of PTEN is also associated with the upregulation of the 
IGF1/PI3K/AKT signaling cascade. Nrg1, through ErbB, also activates AKT and 
leads to adaptive signaling events. Mitochondrial biogenesis also occurs through 
the IGF1/PI3K axis that may or may not involve AKT signaling. However, AKT 
signaling does upregulate the transcription of Pgc1α, resulting in the upregulation 
of adaptive metabolic gene sets. Catecholamine surges during exercise activate 
β-adrenergic receptors, leading to eNOS activation and the production of NO to 
increase cardiac perfusion. AMPK, an cellular sensor of the energy state of the 
cell, is also involved in the activation of eNOS as well as AKT, contributing to the 
overall adaptive response. Abbreviations: IGF1, insulin-like growth factor-1; IGF1r, 
insulin-like growth factor-1 receptor; Nrg1, neureglin1; ErbB, member of epidermal 
growth factor receptors; β-AR, beta-adrenergic receptor; PI3K, phosphoinositide-
3 kinase; PTEN, phosphatase and tensin homolog; Akt, protein kinase B; C/EBPβ, 
CCAAT/enhancer binding protein β; Cited4, cbp/p300-interacting transactivator 
with Glu/Asp-gamma co-activator 1α; PGC1α, peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha; eNOS, endothelial nitric oxide synthase; NO, 

























2) PI3K: IGF1r phosphorylation causes the activation of PI3-kinase, an 
intracellular family of signal transducing enzymes. Specifically, the 
activity of the PI3K (110 α) isoform appears to be necessary and 
sufficient for IGF1-mediated physiologic growth, as expression of a 
cardiac-specific dominant-negative PI3K (110 α) prevented exercise-
induced cardiac growth in mice.36 Conversely, constitutive activation of 
PI3K (110 α) in the heart promotes a physiologic form of hypertrophy.36, 
37 In addition to the direct role of PI3Ks in regulating cardiac growth, 
deletion of Pten (phosphatase and tensin homolog), which 
dephosphorylates PI3Ks, has also been shown to mediate cardiac 
growth.38 Thus, the signaling events propagated by PI3K, and its 
regulation by PTEN, are critical for the physiologic growth response. 
 
3) AKT: The serine/threonine-specific protein kinase B, also known as 
AKT, also plays a critical role in physiologic hypertrophy. Functioning 
downstream of PI3K, exercise training enhances the phosphorylation 
state of AKT at both the threonine 308 and 473 residues.35, 39-42 This 
activation of AKT is required for the hypertrophic response as mice with 
genetic deletion are resistant to exercise-induced cardiac growth.43 
Interestingly, cardiac-specific overexpression of a constitutively active 
form of AKT, while initially promoting a physiologic form of hypertrophy, 
progressed to a pathologic form, suggesting that duration, and likely also 
intensity, determine the cardiac response to AKT signaling.44  
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4) C/EBPβ and CITED4: Recent studies have identified transcriptional 
events downstream of AKT activation that are essential for exercise-
induced physiologic growth. For example, exercise training was shown 
to downregulate cardiomyocyte expression of the CCAAT/enhancer 
binding protein-β (C/EBPβ), in an AKT-dependent manner. In that study, 
cardiomyocyte-specific overexpression of C/EBPβ resulted in 
physiological hypertrophy and resistance to the pathologic response to 
pressure overload.45 Additionally, the exercise-induced transcriptional 
downregulation of Cebpb led to the transcriptional upregulation of 
Cited4,45 and overexpression of Cited4 was show to be sufficient to drive 
physiologic cardiac growth and promote recovery from ischemic injury.46 
While C/EBPβ and CITED4 are important for mediating the response to 
exercise, additional mechanisms of activation and downstream targets 
require further investigation. 
 
5) Additional effectors of physiologic cardiac growth: Several other factors 
have been shown to be involved to some degree in the response to 
exercise. Nueregulin 1 signaling through the ErbB family of tyrosine 
kinase receptors produces similar effects to that observed in the 
exercise-adapted heart, in part, through the activation of AKT.47 AMP-
activated protein kinase (AMPK), important for its role in cellular energy 
homeostasis, has been suggested to play a role in the development of 
both physiologic and pathologic hypertrophy.27  Additionally, signaling 
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though MAPK (mitogen-activated protein kinase)48 and mTOR 
(mechanistic target of rapamycin)44 have also been suggested to play 
roles in governing the cardiac hypertrophic program. 
 
Recent evidence suggests that cardiomyocytes, once thought incapable of 
regeneration and proliferation, may in fact do so at a low rate in the adult heart.49-
51 Increasing lines of evidence also suggest that exercise not only stimulates 
cardiomyocyte hypertrophy, but potential hyperplasia as well. Rodents subjected 
to exercise show elevated makers of proliferation such as PCNA expression, Ki67 
positivity, and BrdU incorporation in the heart along with the activation of c-kit+ and 
Sca-1+ cells, believed to be cardiac progenitor cells.45, 52-54 While these results 
suggest that exercise-activated cardiomyocyte proliferation may contribute to 
physiological growth, more detailed studies, such as cell fate-mapping are required 
before more definitive conclusions can be drawn. 
As cardiomyocytes grow in response to exercise, several other adaptive 
responses, both intrinsic to the cardiomyocyte and within the myocardium as a 
whole, must occur as well. One such response is an enhancement of cardiac 
perfusion. This is a critical adaptive response as both increases in workload and a 
larger myocyte both have a higher energy and oxygen demand. This increase in 
cardiac perfusion occurs primarily through two modes of action, vasodilation and 
angiogenesis. First, exercise results in the release of catecholamines which, in 
addition to their effect on Ca2+ dynamics and contractility, increases the 
phosphorylation of endothelial nitric oxide synthase (eNOS).55 Enhanced eNOS 
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activity increases nitric oxide (NO) bioavailability, a potent vasodilator. This effect 
is also driven by the exercise-induced activation of AKT and AMPK, both of which 
promote the phosphorylation of eNOS.56, 57 Secondly, chronic exercise training 
induces an angiogenic response within the myocardium, resulting in de novo 
capillary formation.58 This angiogenic response is in part associated with exercise-
mediated increases in VEGF secretion59 and circulating angiogenic progenitor 
cells.60 
The most common metabolic adaptation of the heart to exercise is 
mitochondrial biogenesis.61-63  While various signaling events likely lead to an 
increase in mitochondrial mass, exercise-induced increases in peroxisome 
proliferator-activated receptor 𝛾	 coactivator 1α (PGC-1α) play a critical role.64 
Interestingly, induction of PGC-1α in response to exercise was prevented in IGF1r 
knockout mice, and it has been shown that signaling through PI3K, but not AKT, 
is required for this biogenic response.35, 65 Accompanying the increase in 
mitochondrial mass, respiratory function and capacity appears to be enhanced in 
the physiologically hypertrophied heart. In both isolated permeabilized cardiac 
muscle fibers65 and the isolated perfused heart,40, 66 exercise training increased 
the rate of mitochondrial fatty acid oxidation (FAO). This is in part due to the 
increase in mitochondrial mass, but also the upregulation of genes associated with 
FAO.67  
In addition to FAO rates, others have shown an increase in glucose 
oxidation (GO) as well.66 This enhanced metabolic capacity of the exercised heart 
is a hallmark characteristic, distinguishing it from pathologic forms of hypertrophy 
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where it is well accepted that metabolic flexibility and energy homeostasis are 
compromised. Therefore, studying the metabolic phenotype of the physiologically 
hypertrophied heart may provide therapeutic avenues to treat or delay the onset 
of maladaptive pathologic remodeling. In the following section, the acute and 
chronic effects of exercise on cardiac metabolism will be discussed in detail. 
 
Cardiac Metabolism in Exercise 
The heart has an incredibly high energy demand, which requires continuous 
adenosine triphosphate (ATP) generation to sustain contractile function, ionic 
homeostasis, metabolic processes, and signaling. While myocardial ATP turnover 
is high (~30 µmol ● g wet wt−1 ● min−1), ATP content is relatively low (~5 µmol ● g 
wet wt−1) resulting in complete turnover approximately every 10 s.68-70 The heart 
fuels this turnover by generating >95% of its ATP from mitochondrial oxidative 
phosphorylation with the remaining 5% derived primarily from glycolysis.70, 71 
Although the majority (60-70%) of the ATP generated supports contractile function, 
30−40% is necessary to maintain ionic homeostasis through ion pumps, 
specifically the Ca2+-ATPase in the sarcoplasmic reticulum.72, 73  
Basally, it is well accepted that the oxidation of free fatty acids (FFA) 
contributes 70−90% to oxidative phosphorylation with glucose, glycogen, lactate, 
ketones, and amino acids contributing the remaining 10−30%. With the ability to 
utilize a myriad of substrates, the heart is considered a metabolic “omnivore”, 
utilizing whichever substrates are available at a given time; however, with multiple 
substrates consistently available for use, competition for utilization exists. The 
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competition of substrates has long been demonstrated in both in vivo arterial-
coronary sinus difference studies74-77 and perfused heart preparations ex vivo.78, 
79 The first observation of substrate competition was observed in the isolated 
perfused heart by Philip Randle in 196380 In this study, Randle demonstrated that 
increasing delivery of FFAs to the heart increased FAO and decreased glucose to 
pyruvate conversion and oxidation. Interestingly, exercise is also associated with 
the competition of substrates for utilization. 
Acute exercise (i.e. an acute increase in workload) has a robust effect on 
not only cardiac metabolism. For example, it is estimated that TCA cycle flux 
increases 70- to 100-fold in an effort to match energy production to the large 
increase in consumption in working muscle.81 In the heart, exercise increases LV 
contractile power and myocardial oxygen consumption 4- to 6-fold above resting 
rates, which requires a significant increase in the generation of NADH and FADH2, 
from substrate oxidation.82 Several ex vivo78, 83 and in vivo84-87 studies demonstrate 
that an increase in myocardial workload is accompanied by significant, yet 
selective, increases in the metabolism of various substrates. This increase in 
myocardial metabolism is accomplished by increased substrate availability and 
delivery to the myocardium as well as through extensive intracellular signaling that 
regulates substrate selection and utilization, coordinating myocardial metabolism. 
The effects of exercise on individual substrate metabolism is discussed below and 
in Fig. 3: 
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Fatty Acids: As already mentioned, the oxidation of FFA contributes the most to 
energy provision in the normal healthy heart. Because of their hydrophobic 
properties, FFA are bound to albumin for transport in circulation at a concentration 
of 0.2−0.6 mM;88, 89 however, during an acute bout of exercise, these levels can 
increase to 2.4 mM.89 Because the availability of circulating FFAs is a primary 
determinant of their uptake by the myocardium,74 the exercising heart 
demonstrates enhanced rates of FFA uptake.90 This increase in circulating FFAs 
during exercise is primarily due to elevations in catecholamines, which activate 
hormone sensitive lipase in adipose and skeletal muscle tissues to de-esterifies 
FFAs and promote their release into circulation.91 Exercise likely also facilities the 
translocation of fatty acid translocase (FAT)/CD36, the primary protein carrier-
mediated transporter for FFA uptake, as it has been shown that contracting 
skeletal muscle acutely increased its localization to the plasma membrane;92, 93 
however, this effect has yet to be confirmed in the heart. 
Following uptake, FFAs are esterified to fatty acyl-coenzyme A (CoA) by 
fatty acyl CoA synthase and either transported into the mitochondria for eventual 
beta-oxidation or used for the synthesis of triacylglycerides (TAGs). At rest, human 
isotopic labeling studies measuring 14CO2 production in coronary venous blood 
indicate that 84% of the FFA taken up by the cell are immediately oxidized, leaving 
~26% available for entry into the TAG pool.94 This contribution to the TAG pool is 
not trivial, as intramyocardial TAG turnover occurs in as little as 5 h and contributes 
10% to the total energy expenditure of the heart.82, 95 Interestingly, myocardial TAG 
utilization rates were found to be increased considerably under exercise conditions 
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as measured by a significant release of free glycerol, suggesting increased 
hydrolysis of intramyocardial stores.87 In an ex vivo heart preparation, this increase 
in TAG turnover was a function of increased lactate availability, suggesting that 
lactate, which is elevated during exercise, stimulates FAO and the turnover of TAG 
stores. This conclusion was made by the observation that lactate in the perfusion 
buffer increased intracellular fatty acid content and free glycerol release, while 
maintaining TAG levels in the myocardium.96 With respect to FAO rates, elevated 
circulating FFA levels, as occurs during exercise, enhances myocardial utilization 
for beta-oxidation and ATP production as indicated by isotopic labeling studies 
measuring 14CO2 production.94  
 
Lactate: While the heart produces a considerable amount of lactate at rest, 14C-
lactate tracer studies calculating arterial-coronary sinus differences indicate the 
heart consumes an even greater amount of lactate, making the heart a net lactate 
consumer.77, 90, 97, 98 Myocardial lactate uptake, which is positively correlated with 
arterial lactate concentration, is almost entirely used for oxidation.84 Under 
conditions of elevated arterial concentrations (e.g. exercise), lactate oxidation is 
significantly enhanced.79, 85 This increase in lactate oxidation appears to be 
correlated with exercise intensity, which determines arterial lactate levels. Under 
lower exercise intensities, the contribution of lactate oxidation to myocardial 
oxidative metabolism increased from 13% to 28% and was considerably higher 
than glucose oxidation (8-14%).84 However, during intense exercise lactate levels 
can increase 10-fold, from 1 mM to 10 mM, and it has been suggested that the   
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Figure 3: Myocardial metabolism during exercise. Schematic of cardiac 
metabolism in exercise. Acute exercise results in changes in the bioavailability and 
utilization of both external (arterial concentrations) and internal (intracellular 
storage depots) energy substrates for ATP production. Arrows are indicative of 
changes in both bioavailability and utilization by the myocardium during exercise. 
For diagrammatic simplicity, the mitochondrion is shown as a single membrane, 
with CPT1/2 shown as an aggregate of the canitinylation and reCoAcylation steps 
required for entry of fats into the mitochondrion for beta oxidation. Similarly, as 
several GLUT and MCT isoforms are present in the heart, they are 
diagrammatically represented as a family of transporters. Abbreviations: FFA, free-
fatty acids; FAT/CD36, fatty acid translocase; GLUTs, glucose transporters; MCTs, 
monocarboxylate transporters; G6P, glucose-6-phosphate; F6P, fructose-6-
phosphate; F-1,6-P2, fructose-1,6-bisphosphate; F-2,6-P2, fructose-2,6-
bisphosphate; GAP, glyceraldehyde-3-phosphate; DHAP, dihydroxyacetone 
phosphate; PFK1, phosphofructokinase 1; PFK2, phosphofructokinase-
bisphosphatase 2; LDH, lactate dehydrogenase; PDC, pyruvate dehydrogenase 





































contributions of lactate to total oxidative metabolism under these conditions may 
in fact be much higher, accounting for 60-90% of substrate utilization.85, 99-101 
The effects of exercise training on myocardial lactate metabolism are not 
well known and is complicated by the fact that a primary effect of training is the 
reduction of arterial lactate levels for a given sub-maximal intensity.102 Because 
lactate utilization is a consequence of its availability, this would suggest that lactate 
oxidation and its contribution to myocardial oxidative metabolism may be 
diminished in the trained heart. However, it is likely that training results in metabolic 
adaptations similar to those seen for fatty acid metabolism. For example, recent 
studies have suggested that training increases LDH activity,103 decreases the Km 
for conversion of lactate to pyruvate,104 and increases the monocarboxylic 
transporter (MCT1) responsible for lactate uptake,105 all of which would contribute 
to enhanced lactate oxidation at a given concentration. Often rarely considered as 
a myocardial substrate, the importance of lactate to energetics and performance 
should not be understated. In a recent study by Levy et. al., systemic lactate 
deprivation resulted in cardiac energy deprivation and dysfunction,106 highlighting 
the importance of lactate as an energy source. 
 
Glucose:  Under resting conditions, glucose is the most abundant substrate 
available to the myocardium with a circulating concentration of 4–5.5 mM in healthy 
individuals. While availability is not an issue, the heart preferentially utilizes FFA 
for oxidative metabolism with contributions of glucose equal to that of lactate 
(~17%).107 This is somewhat surprising considering that glucose is a much more 
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efficient carbon source than FFAs, indicated by the phosphate to oxygen ratio 
(P/O) for complete oxidation of substrates,108 which would make glucose a more 
efficient source of energy during increased workloads. As with FFAs and lactate, 
glucose uptake by the myocardium is also dependent on arterial concentrations; 
however, arterial glucose concentrations are tightly controlled and do not generally 
fluctuate. During highly intense (e.g. weightlifting) and prolonged endurance 
exercise, arterial glucose concentrations have been shown to diminish,89 while 
others report that high intensity aerobic exercise resulted in an increase in blood 
glucose.86 Interestingly, this increase in arterial glucose was not associated with 
an increase in glucose uptake indicated by positron emission tomography utilizing 
2-[18F]fluoro-2-deoxy-D-glucose; however, during lower intensities glucose uptake 
was increased with no change in arterial levels.86 These results of glucose uptake 
under lower intensities were in agreement with a previous report by Gertz et al.;84 
however, others have reported diminished glucose uptake during exercise.87, 109 
Glucose uptake is facilitated by protein carrier-mediated transport through 
a family of glucose transporters (GLUT), with the insulin-dependent GLUT4 as the 
most abundant in cardiac tissue.110 Exercise increases the translocation of GLUT4 
to the cellular membrane in part by catecholamine activated β-adrenergic 
signaling111, 112 and through the exercise-induced activation of AMPK.113 
Interestingly, this translocation appears to be insulin-independent as circulating 
insulin levels are diminished during exercise.114 Activation of AMPK also increases 
phosphorylation of phosphofructokinase 2 (PFK2) at the S483 residue, which 
increases the levels of fructose-2,6-bisphosphate (F-2,6-P2), a potent activator of 
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PFK1 activity in the heart. If this occurs in the exercising heart, glycolytic rates 
would likely be elevated. Interestingly, increased utilization of glucose during 
exercise does not increase lactate release from the myocardium but rather 
promotes enhanced glucose oxidation,84 in part, by increasing muscle pyruvate 
kinase activity.115 This would suggest that a primary effect of exercise is to increase 
the coupling of glycolysis to glucose oxidation. Improved coupling of glycolysis and 
glucose oxidation, especially if glucose uptake is diminished during exercise, 
would be advantageous as it would increase the proportion of glucose that 
contributes to energy production. 
Another source of glucose for the myocardium is the intracellular storage of 
glycogen. Although the glycogen pool is only 20% of that of skeletal muscle, 
myocardial glycogen turnover can be high.116 Interestingly, a small amount of 
glucose that enters the glycogen pool is immediately cycled back out for eventual 
conversion to pyruvate;117 the significance of this cycling, however, and its 
relevance in exercise, is not well understood. The effects of glycogen content are 
more well defined under increased workloads. Acute increases in work stimulated 
by epinephrine increase glycogen breakdown via glycogen phosphorylase,83, 117, 
118 which is preferentially used for oxidation rather than lactate production as 
shown by isotopically (13C) saturating the glycogen pool.118, 119 Conversely, 
glycogen synthesis by glycogen synthase, increases during fasting120-122 and when 
competing substrates (FFA and lactate) predominate in their oxidation.123, 124 
Because catecholamines, FFA, and lactate are all elevated during exercise, the 
effects of exercise on glycogen content are likely subject to duration, intensity, and 
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the time at which such measurements are made. For instance, it is likely that at 
the onset of exercise, prior to an increase in substrate availability, glycogen is 
broken down to meet the abrupt increase in ATP demand. Once arterial FFA and 
lactate levels rise over time, glycogen breakdown is inhibited and synthesis occurs. 
Because of these competing effectors of glycogen metabolism, a well-controlled 
study is required to fully understand the effects of exercise intensity and duration 
on glycogen metabolism. 
 
Ketones and Amino Acids: Ketone bodies, acetoacetate and β-
hydroxybutyrate, can contribute to oxidative metabolism through their conversion 
to acetyl-CoA, and similar to FFA and carbohydrates, uptake and oxidation is 
positively correlated to their arterial concentration.125 However, ketone bodies 
themselves are insufficient to meet the energetic need of the heart, both in vivo126 
and ex vivo.127 While ketone bodies may play a significant role in energy provisions 
in the pathologic heart,128 their contributions to the exercising and physiologically 
hypertrophied heart are likely minimal. 
Amino acids play an important role in contributing several carbon-based 
intermediates to the TCA cycle. For instance, alanine can undergo transamination 
to form pyruvate for oxidation, glutamine can enter at the point of α-ketoglutarate, 
and aspartate can be converted to oxaloacetate, all providing TCA intermediates. 
Additionally, the malate-aspartate shuttle is important in transferring the reducing 
equivalent NADH generated from cytosolic glycolysis and lactate to pyruvate 
conversion, into the mitochondria for the ETC. This reaction in turn regenerates 
	 28	
cofactor levels of NAD+, required for glycolysis and LDH activity. In the working 
heart, only leucine, a branched chain amino acid, has been shown to contribute to 
oxidative substrate utilization, albeit to a minimal (0.4%) degree.129 Similar to 
ketone bodies, amino acid metabolism in the context of exercise is not well 
understood. 
 
While understanding how exercise affects the metabolism of individual 
substrates provides invaluable information, integration of the metabolism of all 
substrates becomes much more complex, but provides a more complete picture. 
A more complete and thorough interrogation of myocardial metabolism can be 
obtained by measuring the utilization of all substrates and the regulation each 
imposes on the other. For example,  in a study by Schonekess, hearts perfused at 
a constant workload had significantly diminished contributions of glycolysis and 
glucose oxidation to ATP production when FFA levels were increased to a 
physiologic range associated with exercise; interestingly, this observation was also 
made when lactate in the perfusion buffer was increased to physiologic exercising 
levels.79 In a similar ex vivo study, workload was increased by epinephrine in the 
presence of exercising levels of lactate and FFAs, which blunted the increase in 
glucose utilization.78 Similar results from in vivo studies further support that 
although an increase in cardiac workload is typically associated with an increase 
in glucose uptake and oxidation in the myocardium,78, 83, 84, 86 when concentrations 
of lactate and FFAs were increased, glucose uptake and oxidation were 
diminished.78, 86, 87, 109  
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The diminishment in glucose utilization most likely occurs through allosteric 
inhibition of key glucose-metabolizing enzymes. For instance, acetyl-CoA derived 
from the oxidation of FFA in the mitochondria inhibits PDH activity, reducing the 
oxidation of glucose-derived pyruvate. Furthermore, the subsequent increase in 
citrate is inhibitory to the rate-limiting and committed step of glycolysis, 
phosphofructokinase 1, and to a lesser extent glucose uptake. The magnitude of 
inhibition increases along the glycolytic pathway with PDH inhibition being the most 
severe and glucose uptake the least.130, 131 Lactate oxidation also acts to inhibit 
glycolytic flux by reducing the bioavailability of NAD+, a cofactor for 
glyceraldehyde-3-phosphate dehydrogenase, and decreasing H+ extrusion which 
is inhibitory to PFK1. Collectively these results suggest that during exercise, when 
arterial lactate and FFAs increase, glucose utilization is likely diminished. 
 
Metabolism as a Contributing Factor to Growth 
In tissues such as skeletal muscle, adaptive changes in gene expression 
are thought to be initiated by the repetitive bouts of metabolic stress triggered by 
strenuous physical activity.8 As acute and chronic exercise alter cardiac 
metabolism, it could be hypothesized that these changes could contribute to the 
adaptive response; however, understanding the mechanisms and pathways 
involved is difficult due to the complex and integrative nature of metabolism. Of 
particular interest is the metabolism of glucose via glycolysis, which is highly 
regulated during exercise. A central pathway of intermediary metabolism, the fate 
of glucose is not only limited to pyruvate or lactate for energy production, but it also 
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contributes to several ancillary pathways of glucose metabolism, such as the 
pentose phosphate pathway (PPP) and the glycerolipid synthesis pathway (GLP). 
These pathways provide the first rationale for how changes in glucose utilization 
could contribute to the cardiac adaptation to exercise.  
The simplest explanation as to why changes in metabolism would precede 
and contribute to cardiac growth is by providing a material cause necessary for 
that growth. This material cause comes in the form of the DNA, amino acids, 
proteins, and phospholipids that are required for cellular growth.  For example, in 
the oxidative phase of the PPP, the metabolism of glucose-6-phosphate (G6P) 
reduces NADP+ to NADPH which is required for glutathione recycling and anabolic 
reactions. End products of the non-oxidative phase, however, are critical in the 
generation of ribose 5-phosphate, the precursor for purine and pyrimidine 
nucleotide biosynthesis. These nucleotides are the organic structure serving as 
the basis for the synthesis of DNA, RNA, and nucleic acids, without which growth 
cannot occur. In the heart, the PPP is activated during pathological hypertrophy132-
134 and heart failure,135 and modulating pathway activity regulates the severity of 
cardiac pathology.136-141 Similarly, growth of a cell cannot occur without expansion 
of the cellular membrane which requires increased bioavailability of phospholipids 
derived from the GLP. Although less is known about the GLP, increased pathway 
activity may in fact contribute to pathologic cardiac hypertrophy.142 In the 
exercising heart, very little is known with regards to pathway flux through the PPP 
and GLP. However, during exercise when FFA and lactate oxidation increase, 
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allosteric inhibition at the point of PFK1 may in fact coordinate flux through these 
pathways, as has been shown in several non-cardiac cell types.143-146 
Another biosynthetic pathway branching off glycolysis is the hexosamine 
biosynthetic pathway (HBP), which could also be influenced by changes in PFK 
and glycolytic activity. Requiring a sugar donor, the synthesis of O-linked β-N-
acetylglucosamine (O-GlcNAc), a monosaccharide donor for nuclear and cytosolic 
proteins, can alter protein function, gene transcription, and modulates cell survival 
under conditions of stress.147-150 While several molecular signaling pathways are 
well understood in the exercised heart, post-translational O-GlcNAcylation is a 
relatively new area of investigation. In rats, an acute bout of swim training resulted 
in a 30% increase in skeletal muscle UDP-hexosamine concentrations that 
persisted for 16 h following exercise;151 however, in mouse hearts following 15 
mins of treadmill exercise, O-GlcNAc levels were diminished. Interestingly, in these 
same mice, de-O-GlcNAcylation of O-GlcNAc transferase (OGT), the enzyme 
responsible for catalyzing the addition of the GlcNAc moiety to proteins, resulted 
in dissociation from the repressor element 1 silencing transcription factor complex 
and initiation of physiological growth signaling.152 Following training, the 
physiological hypertrophied heart is associated with decreased O-GlcNAc levels 
and a reduced expression of several regulatory enzymes in the HBP.153, 154 The 
results from these studies suggest that exercise-induced changes in metabolism 
and coordinate changes in HBP flux could contribute to the physiologic growth 
program. 
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Another potential role for metabolism in regulating the cardiac adaptive 
response to exercise is through direct intracellular signaling of metabolites 
themselves. For instance, an increase in G6P levels in ex vivo hearts subjected to 
increased workload, which is likely to occur in vivo during exercise when glucose 
utilization rates are diminished, leads to the activation of mTOR.155 Another 
example of a metabolite acting in a direct signaling manner is 5-Aminoimidazole-
4-carboxamide ribonucleotide (AICAR), an intermediate of the PPP. An analog of 
adenosine monophosphate (AMP), AICAR stimulates AMPK, increasing its 
activation state.156 As mTOR and AMPK are implicated to play a role in the 
exercise-induced adaptation, metabolites as direct signalers may play a critical role 
in the activation of the physiologic growth program.  
Based on the literature discussed within this section, there appears to be 
ample evidence to suggest that metabolism may play a contributing role to the 
adaptive response to exercise, preceding and triggering physiologic growth of the 
heart. This raises several questions: How does exercise acutely and chronically 
affect myocardial metabolism?; Do changes in metabolism contribute to the 
exercise-induced adaptation of the heart?; and if so, how does metabolism activate 
the programs of exercise-induced physiologic growth? These questions and 
fundamental concepts led to the development of the following studies, which 





FVB/NJ MICE ARE A USEFUL MODEL FOR EXAMANING CARDIAC 
ADAPTATIONS TO TREADMILL EXERCISE 
 
Introduction 
Regular exercise improves cardiovascular health,5-7 augments 
musculoskeletal function,8 and increases both healthspan8-10 and lifespan.5, 11-13 
Nevertheless, the molecular mechanisms by which exercise promotes health are 
poorly understood.157 Exercise studies commonly use murine models, which are 
valuable for identifying critical gene programs that contribute to exercise 
adaptation, primarily, because they offer the benefit of relatively rapid and 
controlled genetic modification [e.g., 25, 40, 158, 159]. Nevertheless, sources of 
variability in such studies could confound our understanding of how exercise 
mitigates disease or increases overall health. Minimization of confounding factors 
is an important consideration for designing exercise studies as well as for 
interpreting the results obtained. 
Although mouse models cannot perfectly recapitulate the complex 
physiological changes occurring in humans with physical activity, they can 
phenocopy particular aspects of physiological adaptation.  For this purpose, three 
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models of mouse exercise are used frequently: treadmill training, forced swimming, 
and voluntary wheel running. While each of these models have advantages and 
limitations,158, 160 treadmill training provides the investigative advantage of 
controlling the amount of work performed in each training session, which is critical 
for understanding dependency of (patho)physiological adaptations on exercise 
workload and becomes increasingly important in studies of mice having different 
masses (e.g., obesity studies). Unlike the treadmill modality, work cannot be 
calculated easily in swimming or voluntary wheel exercise. For these reasons, 
treadmill training is a reliable, well-controlled, and often superior model of exercise 
for research studies. Nevertheless, several factors contribute to treadmill exercise 
(non)compliance and to exercise-induced adaptations. These include, but are not 
limited to, mouse strain, exercise environment, acclimatization, motivation, and 
assessments of exhaustion.52, 161 
Of these, mouse strain is of principal importance. Inbred strains of mice and 
rats have pronounced differences in their ability to exercise, or their choice to do 
so.162-166 A preponderance of genetic mouse models are on the C57BL/6J or the 
FVB/NJ background167, 168; however, these strains show strikingly different 
preferences and capacities for exercise. For instance, C57BL/6J mice appear to 
be poor treadmill runners, yet display superior capacity on voluntary exercise 
wheels, while the opposite is true for FVB/NJ mice.163, 166 The reason(s) for these 
differences in training modality preference remain unclear. One reason could relate 
to the fact that laboratory mice are primarily nocturnal animals, demonstrating the 
highest activity and food consumption during the night cycle169-171; however, to our 
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knowledge, the impact of time of exercise (day or night) on treadmill exercise 
capacity and compliance has not been investigated. The goals of this study were: 
(1) to test for differences in treadmill exercise capacity and compliance between 
C57BL/6J and FVB/NJ mice; (2) to delineate whether diurnal or nocturnal training 
influences exercise compliance and adaptive responses to training; and (3) to 
assess systemic and cardiac-specific exercise adaptations in mice compliant with 
treadmill exercise protocols. Our study demonstrates that FVB/NJ mice are a 
superior strain for treadmill exercise and that the timing of treadmill exercise, at 
least in this strain, does not influence compliance or exercise-induced adaptation.  
 
Experimental Procedures 
Animals. All procedures were approved by the University of Louisville Institutional 
Animal Care and Use Committee. C57BL/6J and FVB/NJ mice were ordered from 
Jackson Laboratory (Bay Harbor, ME) at 12 weeks of age and allowed to acclimate 
at the University of Louisville animal facility for three weeks. At 15 weeks of age, 
male mice were assigned randomly by strain to sedentary (SED) or exercise (EXE-
Day or EXE-Night) groups. Food and water were provided ad libitum, and the mice 
were maintained on a 12:12-h light-dark schedule. Because the majority of 
published studies regarding exercise in mice have utilized male mice, we chose 
this gender for our study, which enables comparison with the literature. At the 
conclusion of the study and 24 h after the last exercise session, the mice were fully 
anaesthetized with sodium pentobarbital (40 mg/kg, i.p.), followed by euthanasia 
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via excision of the heart. These procedures are consistent with the AVMA 
Guidelines on Euthanasia. 
 
Metabolic phenotyping. To assess for differences in basal metabolism and 
diurnal/nocturnal behavior, metabolic cage analyses were performed in naïve 15-
week-old C57BL/6J and FVB/NJ mice, essentially as described.172, 173 Body weight 
was recorded prior to the initial and final exercise capacity tests to assess for 
changes in total body mass. Oxygen consumption rates, carbon dioxide production 
rates, respiratory exchange ratios, food consumption, water consumption and 
activity (sum of ambulatory and fine movements) were measured using a 
physiological/metabolic cage system (TSE PhenoMaster System, Bad Homberg, 
Germany) as previously described.172, 173 
 
Exercise capacity testing. We performed exercise familiarization and capacity 
testing in a manner similar to that outlined previously,166 with minor modifications 
(Fig. 4A,B). Mice were familiarized to the motorized rodent treadmill (Columbus 
Instruments, Columbus OH) on the Wednesday and Thursday before the first week 
of training. Familiarization consisted of an initial 10 min period where the treadmill 
speed and incline were set to zero with shock grid settings of 25 V, 0.34 mA, and 
2 Hz. The treadmill speed was then increased steadily to 10 m/min (Wed) and 12 
m/min (Thurs) for an additional 10 min. 
On the Friday immediately following familiarization to the treadmill, we 
subjected mice to an exercise capacity test (Fig. 4B). For this, the mice were 
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acclimated to the treadmill for 10 min, with the speed and incline set initially to 
zero. The treadmill speed was then increased to 8.5 m/min with an angle of 
inclination set to 0° for 9 min. Next, the treadmill speed and incline were increased 
to 10 m/min and 5°, respectively, for 3 min. The speed was then increased by 2.5 
m/min every 3 min to a maximum speed of 40 m/min, while inclination increased 
by 5° every 9 min until a maximum incline of 15° was achieved.   
We developed strict a priori criteria for exercise-induced exhaustion. These 
criteria were: 1) 10 consecutive seconds on the electric grid; 2) spending more 
than 50% of time on the grid; and/or 3) lack of motivation to manual prodding. Each 
mouse was removed immediately from their respective lane once one or more of 
these criteria was reached. Following the protocol, the mice were housed 
separately for 30 min to avoid noticeable aggressive behavior following exercise.  
Following 4 weeks of training, we repeated this testing protocol to assess 
changes in exercise capacity. Exercise capacity was measured using the 
parameters of distance run (meters achieved prior to exhaustion) and work 
accomplished [calculated as the product of body weight (kg) and vertical distance 
(m); vertical distance = (distance run)(sinθ), where θ = the angle of inclination of 
the treadmill from 0°-15°] as outlined previously.166 
 
Exercise training. Mice assigned to exercise training groups were subjected to a 
4-week protocol of forced treadmill running. The training protocol commenced the 
Monday after the initial exercise capacity testing with mice exercising 5 d/wk (Mon-
Fri) at 70 or 75% of the maximal speed achieved during the initial exercise capacity  
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Figure 4: Exercise testing and training design. Schematic of the familiarization, 
testing, and treadmill training design: (A) General treadmill training design 
including: familiarization, pre- and post-exercise capacity testing, and exercise 
training regimen; (B) Exercise capacity testing protocol; and (C) Treadmill training 







test and an inclination appropriate to the speed (Fig. 4C). Prior to each training 
bout, we provided mice with a “warm-up” period of 10 min at 0 m/min and 10 min 
at 12 m/min to promote exercise protocol compliance and to minimize risk of injury. 
For strain comparison and night versus day training groups, training intensity was 
set at 20.8 m/min, 10° incline for FVB/NJ mice and 16.4 m/min, 5° incline for 
C57BL/6J mice, which corresponded to 70% of the maximal speed and the 
appropriate incline at the calculated speed for each strain during the initial exercise 
capacity test. In subsequent studies of FVB/NJ mice, mice were exercised only 
during the day, and in these groups, we implemented a more intensive training 
protocol to further examine systemic, cardiometabolic and skeletal muscle 
adaptations to treadmill running.  For this, training intensity was set at 75% of the 
maximal initial exercise capacity, which corresponded to 22.3 m/min at a 10° 
incline. In all groups, we progressively increased the workload of the mice, such 
that they trained for 40 min during week 1, 50 min during week 2, and 60 min during 
weeks 3 and 4. We chose this progressive intensity protocol to prevent training 
plateau and to stimulate systemic as well as cardiovascular and skeletal muscle 
adaptations.166, 174-176  
 
Assessment of protocol compliance. To prevent injury and record protocol 
compliance, we monitored the mice carefully during each exercise session. Upon 
meeting pre-established indicators of exhaustion, mice were removed from the 
treadmill, and the time run was recorded (See Table 1). We used the percentage 
of total sessions and total minutes completed throughout the 4-week training 
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program as a measure of compliance. Before and after the initial exercise capacity 
test, we measured blood lactate levels, which provided a biochemical indicator of 
exercise-induced exhaustion at or near maximal oxygen consumption 
(VO2max).177-180 We recorded lactate concentration in 0.7 μl of blood from a small 
tail clip (Lactate Plus meter; Nova Biomedical) prior to the protocol and upon 
meeting the exhaustion criteria defined above. High lactate levels increase 
confidence in a successful exercise capacity test by ensuring that failure to 
continue is due to exhaustion at or near VO2max and not a failure to comply with 
the protocol.181-183  
 
Histology. Following euthanasia, tissue was excised and rapidly fixed for 
immunohistochemical analysis or immediately snap frozen in liquid nitrogen and 
stored at –80 °C. Tissue was fixed in 10% formalin, paraffin embedded, and 
sectioned at 4 µm. Heart cross-sections were stained with 4'6-diamidino-2-
phenylindole (DAPI; Invitrogen) and wheat germ agglutinin (WGA; ThermoFisher) 
for quantification of cardiomyocyte cross-sectional area. Quantitative 
measurements were determined using Nikon Elements software. 
 
Relative mitochondrial DNA measurements. Mitochondrial abundance in heart 
tissue was estimated by measuring mitochondrial DNA (mtDNA) abundance 
relative to nuclear DNA (nDNA), similar to our previous studies.172, 184 Briefly, total 
DNA was isolated using a QIAamp DNA Mini Kit (Qiagen). A 25-mg aliquot of the 
tissue was homogenized, followed by overnight digestion in proteinase K at 55 °C. 
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Following isolation, relative amounts of mtDNA and nDNA were compared using 
quantitative real-time PCR, using 2 ng of the isolated DNA. Primers for cytochrome 
b (mtDNA) and β-actin (nDNA) were used. The sequences are: cytochrome b, 5’-
TTGGGTTGTTTGATCCTGTTTCG-3’ and 5’-
CTTCGCTTTCCACTTCATCTTACC-3’; and β-actin, 5’-
CAGGATGCCTCTCTTGCTCT-3’ and 5’-CGTCTTCCCCTCCATCGT-3’.  
 
Statistical analysis: Unpaired or paired Student’s t test was used for direct 
comparisons; multiple groups were compared by one-way and two-way ANOVA 
followed by Bonferroni or Sidak Multiple Comparison test, as appropriate. For ratio-
based statistical comparisons, the data were log-transformed, and unpaired 
Student’s t test was applied for assessing statistical significance between groups; 
we used a one-sample t test for intragroup differences from a ratio of 1 (used to 
determine significant chronobiological differences in metabolic cage endpoints, 
i.e., food and water intake, physical movement, VO2, VCO2, RER).  A p value of ≤ 
0.05 was considered statistically significant. 
 
Results 
FVB/NJ mice are not nocturnal. Laboratory mice, in general, are a nocturnal 
species,169-171 and they typically choose to participate in voluntary exercise at 
night.185 Thus, the time at which treadmill protocols are executed could be critical 
for ensuring exercise regimen compliance and adaptation. Therefore, we first 
examined the circadian characteristics of the mouse strains by measuring their 
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food and water intake, locomotion, VO2, VCO2 and RER by placing untrained 
(naïve) mice in metabolic chambers. To assess differences between day and night 
behavior, a ratio (night values:day values) was calculated for each parameter. 
Although overall food consumption was not different between the two strains, the 
C57BL/6J mice consumed, on average, 3-fold more food at night. In contrast, the 
FVB/NJ mice showed no difference in food consumption in the night compared 
with the day (Fig. 5A). Cumulative water intake was not different between the 
strains; however, C57BL/6J mice showed significantly higher water intake at night 
(Fig. 5B). Similarly, C57BL/6J mice were more active at night compared with 
FVB/NJ mice (Fig. 5C). In general, FVB/NJ mice had fewer total beam breaks per 
hour (C57BL/6J = 2583 ± 711; FVB/NJ = 1736 ± 582; p < 0.01), indicating that 
cage behavioral activity is lower in this strain.   
Metabolic analysis yielded analogous results. In C57BL/6J mice, oxygen 
consumption (VO2; Fig. 5D), carbon dioxide production (VCO2; Fig. 5E), and 
respiratory exchange ratios (RER; Fig. 5F) were higher at night compared with the 
day. Conversely, the FVB/NJ mice did not show metabolic differences in the day 
versus the night. Thus, the behavioral and metabolic qualities of C57BL/6J mice 
are supportive of their known nocturnal nature and are in stark contrast to FVB/NJ 
mice which demonstrate a relative lack of features characteristic of the nocturnal 
phenotype. Additionally, FVB/NJ mice had higher rates of oxygen consumption 
(C57BL/6J = 3,713 ± 327 ml/h/kg; FVB/NJ = 4058 ± 346 ml/h/kg; p < 0.05) which 
contributed to lower respiratory exchange ratios (C57 BL/6J = 0.93 ± 0.02; FVB/NJ 
= 0.86 ± 0.02; p < 0.0001).    
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Figure 5: Chronobiological characteristics of C57BL/6J and FVB/NJ mice. 
Ratios of the average night and day values from metabolic cage analysis: (A) Food 
intake, (B) Water intake, (C) Total activity, (D) VO2, (E) VCO2, and (F) Respiratory 
exchange ratio (RER). n = 10 per group. (*) significance between C57BL/6 and 







Effect of strain and time of treadmill running on initial exercise capacity. To 
determine the effects of mouse genetic background on initial exercise capacity, we 
subjected 15-week-old C57BL/6J and FVB/NJ mice to exercise capacity testing. 
The mice were exercised either during the day (i.e., between 9 am–12 pm) under 
normal laboratory lighting or at night (i.e., between 7:00 pm–10:00 pm) under dark 
room conditions (safelight red lamp). We chose the latter time based on metabolic 
cage activity data, which showed increased voluntary locomotor activity starting at 
6 pm. Compared with C57BL/6J mice, the FVB/NJ strain ran ~1.5-fold farther (Fig. 
6A) and demonstrated ~2-fold greater initial capacity for treadmill work (Fig. 6B), 
regardless of when the mice were tested. Despite an apparent trend toward lower 
initial exercise capacity at night, we found no statistically significant differences 
between C57BL/6J mice exercised during the day or the night (Fig. 6B&C);  
however, FVB/NJ mice showed significantly lower levels of work performed at night 
(Fig. 6B).   
In preliminary assessments, we observed that C57BL/6J mice received 
more shocks than FVB/NJ mice during treadmill exercise. Therefore, to confirm 
that reliable exercise capacity values were obtained and to rule out non-
compliance to the testing protocol, we recorded blood lactate levels prior to and 
immediately following the initial exercise capacity test. Resting blood lactate values 
were similar in C57BL/6J and FVB/NJ mice (Fig. 6C). Although it should be noted 
that the night C57BL/6J group had a slightly higher resting lactate level, in general, 
blood lactate increased by 2–4-fold in both strains upon meeting criteria for 
exhaustion (Fig. 6C); both resting and maximal lactate abundances are within the  
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Figure 6: FVB/NJ mice display a higher initial exercise capacity than 
C57BL/6J mice. Measurements of exercise capacity and fatigue in 15-week old 
C57BL/6J and FVB/NJ mice tested during the day or at night: (A) Comparison of 
distance achieved; (B) comparison of work accomplished; (C) Blood lactate levels 
in C57BL/6J and FVB/NJ mice basally and following fatigue from exercise testing. 












ranges previously published for resting mice and mice exercising at or near their 
VO2max, respectively.178-180 Collectively, these results suggest that FVB/NJ mice 
demonstrate a superior ability to perform treadmill work compared with C57BL/6J 
mice, and they have higher initial exercise capacities when tested during the day. 
 
Effect of strain and time of training on exercise compliance and adaptation. To 
determine if mouse strain or the time of training (i.e., day vs. night) influences 
exercise protocol compliance and adaptive responses to exercise, C57BL/6J and 
FVB/NJ mice were subjected to a 4-week training program, with one group from 
each strain training at night, and one group training during the day. Each day, we 
recorded compliance to the training program for individual mice (Table 1). The 
C57BL/6J mice completed only 50–60% of their training sessions (Fig. 4A&C), 
resulting in less time exercising in general (Fig. 7D). Interestingly, compliance in 
C57BL/6J mice diminished progressively with duration of the training protocol (Fig. 
4A, Table 1).  While FVB/NJ mice were generally compliant when exercised during 
the day or the night, 100% of the day FVB/NJ group complied with the protocol, 
whereas FVB/NJ mice exercising at night appeared to show modestly 
compromised compliance (Fig. 7B&D); however, this did not achieve statistical 
significance.  
Pre-training and post-training exercise capacity tests showed that, while 
both FVB/NJ exercise groups significantly increased exercise capacity after four 
weeks of training, the C57BL/6J mice showed either no improvement or a   
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Figure 7: Compliance of FVB/NJ and C57BL/6J to the treadmill training 
protocol. Compliance to a four-week treadmill training protocol in mice: (A,B) 
Compliance curves indicating the % of mice that completed each training session; 
(C) Compliance measured as the % of total sessions; or (D) total minutes 
completed by mice throughout the exercise training program. n = 10 per group. * 







Table 1. Exercise compliance chart. Daily records of minutes completed each 










decrease in the distance run or the work accomplished following training (Fig. 
8A&B). This lack of response to exercise in the C57BL/6J mice is likely due to poor 
compliance to the protocol.   
To determine if compliance of C57BL/6J mice to the protocol correlated with 
improvements in exercise capacity, we plotted the percent improvement in 
distance and work against the percent time completed during the exercise 
regimen. As shown in Fig. 8C&D, there is a significant, albeit weak, correlation 
between the percent time completed and exercise capacity in this strain. 
Collectively, these results show that, unlike FVB/NJ mice, C57BL/6J mice are not 
compliant with this extended treadmill exercise protocol, and that the time at which 
FVB/NJ mice exercise does not markedly influence their exercise capacity. 
 Physiological cardiac growth is a common endpoint used to verify 
cardiometabolic adaptation to exercise.27 Exercise training increased heart weight 
to tibia length (HW/TL) in both FVB/NJ exercise groups, whereas the C57BL/6J 
mice showed no changes in heart size (Table 2). We did not find a significant 
correlation between exercise  
time completed and HW/TL in the C57BL/6J strain (data not shown). These results 
indicate that exercise causes cardiac growth in FVB/NJ mice and that C57BL/6J 
mice, likely due to lack of compliance to this treadmill protocol, fail to demonstrate 
physiological cardiac growth.   
 
FVB/NJ mice display robust adaptations following exercise training. It is known 
that, compared with the C57BL/6J strain, FVB/NJ mice can achieve higher critical   
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Figure 8: Treadmill training-induced improvements in exercise capacity in 
C57BL/6J and FVB/NJ mice. Changes in exercise capacity in the mouse strains: 
(A) Distance run and (B) work accomplished during initial and final exercise testing 
following four weeks of treadmill training. n = 10 per group. *p < 0.05, ***p < 0.001.  
Panels C and D show correlations of compliance and (C) % distance and (D) % 
work improved (in the C57BL/6J strain). n = 20 mice (includes the C57BL/6J day 







Table 2: Measurements of exercise-induced cardiac growth. Mice were trained 
for 4 weeks at 70% of their initial exercise capacity. Values are means ± SD; 
n=10/group. HW/BW, heart weight-to-body weight ratio; HW/TL, heart weight-to-
tibia length ratio. Statistical comparisons are between SED and EXE-Day and SED 





 C57BL/6J FVB/NJ 
Body Mass, g   
 SED 28.2±2.3 30.5±2.6 
 EXE-Day 27.3±1.4 29.9±1.7 
 EXE-Night 26.4±1.8 28.5±1.0 
Heart Mass, mg   
 SED 123.7±15.0 115.4±6.1 
 EXE-Day 118.7±10.1 135.8±5.5*** 
 EXE-Night 118.0±13.0 130.5±9.1* 
HW/BW, mg/g   
 SED 4.4±0.4 3.8±0.3 
 EXE-Day 4.3±0.2 4.6±0.2**** 
 EXE-Night 4.5±0.4 4.6±0.2**** 
HW/TL, mg/mm   
 SED 6.9±0.9 6.3±0.3 
 EXE-Day 6.6±0.5 7.6±0.3*** 
 EXE-Night 6.6±0.7 7.3±0.4* 
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running speeds on the treadmill,181 which indicates that their training regimen could 
be intensified further to evoke more robust adaptations to exercise. To test this, 
we trained an independent group of FVB/NJ mice at a slightly higher intensity (75% 
of their initial maximum exercise capacity) for 4 weeks. Compared with pre-training 
exercise capacity values, this more intensive protocol yielded a ~1.7-fold 
improvement in distance run and a ~2.4-fold increase in work in the mice (Fig. 
9A&B). As expected, cardiac size was significantly higher in exercised mice (Fig. 
9C&D). In exercise-adapted hearts, myocyte cross sectional area was found to be 
22% higher than that found in hearts of sedentary mice, and the myocyte area 
distribution curves were shifted to the right (Fig. 9E-G), indicating that the exercise-
induced cardiac growth in this strain is due primarily to an increase in 
cardiomyocyte size. Furthermore, mitochondrial biogenesis, estimated using the 
ratio of relative mtDNA to nDNA content, was 53% higher in the exercise-adapted 
mice (Fig. 9H). These findings indicate that treadmill training in FVB/NJ mice 
promotes robust increases in systemic exercise capacity and elicits physiological 
cardiac growth. Collectively, these results indicate that treadmill exercise in 
FVB/NJ mice elicits robust systemic and cardiac muscle adaptations.  
 
Discussion 
The goals of this study were to examine treadmill exercise capacity, compliance, 
and adaptation in two commonly used strains of laboratory mice. We found that 
C57BL/6J mice have significantly lower treadmill exercise capacity compared with 
FVB/NJ mice. C57BL/6J mice, in our hands, became progressively non-compliant  
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Figure 9: FVB/NJ mice display robust cardiometabolic adaptations to 
treadmill exercise training. Adaptations to a 4-week treadmill training program in 
FVB/NJ mice, where the training regimen was set based on 75% of their initial 
exercise capacity:  (A) Distance run and (B) work accomplished during exercise 
testing; (C) Representative images of hearts from Sed and Exe mice; (D) HW/TL; 
(E) Representative cross section; (F,G) quantification of cross sectional area in 
heart sections stained with WGA and DAPI; and (H) Mitochondrial biogenesis, as 
indicated by relative mitochondrial (mt) DNA content. n = 6-10 mice per group. *p 







with the exercise protocol, which is a likely reason underlying their lack of 
adaptation to exercise. Conversely, FVB/NJ mice demonstrated near perfect 
compliance and showed robust increases in exercise capacity as well as cardiac 
adaptations. Because laboratory mice are typically nocturnal, we also compared 
night and day behavior in the strains as well as exercise compliance and capacity. 
Our metabolic cage data suggest that, contrary to the C57BL/6J strain, FVB/NJ 
mice have no proclivity for activity and feeding at night, and that their metabolic 
phenotype lacks circadian variation. Moreover, despite the nocturnal nature of 
C57BL/6J mice, exercising them at night did not improve compliance or exercise 
capacity. Collectively, these results indicate that FVB/NJ mice are a superior model 
for examining systemic and tissue-specific adaptation to treadmill exercise and that 
diurnal training appears to promote higher exercise compliance and capacity.    
The increase in exercise capacity and cardiac adaptations in FVB/NJ mice 
are likely a consequence of their remarkable compliance as well as their superior 
ability to perform treadmill work.  Indeed, other studies show that the FVB/NJ strain 
has a higher critical running speed181 and is able to run farther than C57BL/6J 
mice.163, 166 To compare exercise capacity and adaptations between the strains in 
a controlled manner, we used equivalent relative intensities of training in the 
strains, which equated to 70% of the speed achieved during initial exercise 
capacity tests.  These experiments showed that FVB/NJ mice could improve their 
exercise capacity and that exercise in this strain causes physiologic cardiac 
growth. Training FVB/NJ mice at a higher workload (initiated at 75% of their initial 
maximum speed) appeared to evoke superior improvements in distance run and 
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work and provoked physiologic cardiac growth. These results indicate that the FVB 
strain is useful for examining intensity-dependent adaptations to exercise. 
The usefulness of the treadmill model lies in its ability to control the level of 
exercise-associated work and to relate biochemical and physiological adaptations 
to workload. This is, of course, dependent on compliance to the treadmill protocol. 
We show that C57BL/6J mice completed the protocol during the first week of 
training, but that they become increasingly unwilling to run thereafter.  It is unlikely 
that this decrease in compliance is due to overtraining because it occurred upon 
only the second week of training (and after a two-day rest period), and the mice 
did not resume their ability to exercise, even after long periods of refusing to 
comply with the protocol.  Furthermore, the mice did not lose weight during the 
protocol, which can be an indicator of overtraining.186 Although it remains unclear 
why the C57BL/6J mice choose to run less after the first week, it could be that their 
tendency to receive more shocks is a negative stimulus for running, or that they 
associate the shocks with a positive outcome, i.e., removal from the treadmill. 
Interestingly, C57BL/6J mice are prone to footshock-induced analgesia,187, 188 and 
they show progressively decreased shock avoidance behavior compared with 
other strains.189 It is also conceivable that this strain is more susceptible to 
negative stress in the brain caused by forced running,190 as opposed to voluntary 
running. Thus, it is possible that this strain acclimates to the repeated treadmill 
shocks that they receive during training.  
Escape behavior is another potential contributing factor to the lack of 
compliance of C57BL/6J mice.  A study by Mori and Makino showed that C57BL/6J 
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mice escape and avoid shock by moving to an adjacent compartment in an L-type 
movement pattern rather than an R-type (rearing and jumping forward) pattern.191 
This is of particular importance because the R-type pattern must be invoked to 
escape shock in our treadmill apparatus.  Regardless, it would appear that the lack 
of both physiologic cardiac growth and improvements in exercise capacity in 
C57BL/6J mice is a result of non-compliance with the treadmill protocol. 
We also show that FVB/NJ mice lack biological rhythmicity compared with 
C57BL/6J mice and that the time of day does not appear to affect compliance to 
the treadmill protocol. Lack of circadian behavior in FVB/NJ mice is a likely 
consequence of expression of the retinal degenerative (rd) mutation, which 
renders them blind to visual images and appears to underlie aberrant circadian 
wheel running behavior and spatial awareness.192 Conversely, C57BL/6J mice 
appear to see well: they demonstrate entrainment to a 12:12 h light:dark cycle, and 
they re-entrain to phase advances.192 Of note, while FVB/NJ mice are blind, 
C57BL/6J mice become deaf, progressively losing their hearing during the first 
year of life.193-195 Nevertheless, despite the impaired senses of these strains, the 
lack of circadian variation in the FVB/NJ strain, and the presence of a nocturnal 
phenotype in C57BL/6J mice, the timing at which the mice were tested and trained 
did not appear to have a strong impact.  However, we do show that, for FVB/NJ 
mice, running during the day is associated with a higher initial exercise capacity.  
Because calculations for the 4-week training regimen are based on this initial 
capacity, it is possible that testing initial exercise capacities of mice during the day 
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could result in a higher training workload, which could equate to increased 
physiological adaptations.   
Although it is unclear whether the mutations that underlie loss of sight or 
hearing in FVB/NJ or C57BL/6J mice contribute to their compliance to exercise 
protocols, it is clear that C57BL/6J and FVB/NJ mice have different exercise 
capabilities and preferences. Consistent with previous studies,163, 166 we found that 
C57BL/6J mice have lower treadmill exercise capacity, which did not improve even 
when they were tested at night. Nevertheless, several studies show that C57BL/6J 
mice are quite adept at voluntary wheel exercise [e.g., 163, 166, 196-201], even load 
bearing wheels which simulate resistance training202; and, consistent with their 
nocturnal behavior, wheel activity in C57BL/6J mice peaks during the night.192 This 
suggests that the C57BL/6J strain is more amenable to the wheel running modality 
than treadmill exercise. While several investigators have exercised C57BL/6J mice 
using a treadmill protocol successfully [reviewed in 161], only a few studies 
document robust increases in exercise capacity or physiological adaptations to 
extended treadmill training in this strain.203-205 Most studies show adaptations that 
appear relatively minimal compared with other strains [e.g., 166, 206, 207] or 
demonstrate that additional exercise mimetics (e.g., AMPK or PPARδ agonists) 
may be required to promote robust physiological adaptations to treadmill exercise 
in C57BL/6J mice.208  
Several limitations of our study deserve mention. We did not measure VO2 
max or identify anaerobic thresholds, which can delineate metabolic crossover 
points209; however, we used stringent criteria for determining fatigue (i.e., 
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behavioral criteria decided upon a priori) as well as blood lactate measurements 
to ensure that mice meeting these criteria were fatigued and not simply incompliant 
with the exercise capacity protocol. Although we show that FVB/NJ mice are 
proficient treadmill runners, their lack of circadian behavior suggests that they may 
not be suitable for investigating chronobiological changes associated with exercise 
(e.g., exercise-induced changes in clock genes). In addition, we did not test 
whether lower speeds in C57BL/6J mice or different motivating stimuli would 
increase compliance to the protocol. Some studies in rats,210 as well as C57BL/6J 
mice,203 use chocolate as a reward-based incentive to comply with the protocol. 
We did not test the use of reward in our study, nor did we examine whether 
alternative aversive stimuli (e.g., air puffs instead of shocks) would improve 
exercise compliance in the C57 strain. Thus, we do not rule out the possibility that 
C57BL/6J mice could be coaxed to run with an intensity and compliance similar to 
that of FVB/NJ mice; however, it is clear to us that improved treadmill compliance 
in C57BL/6J mice would appear to require a different protocol than that used here, 
or a reward that encourages continual compliance.  
In summary, our findings indicate that FVB/NJ mice are a useful strain for 
testing treadmill exercise-mediated adaptations. This strain complies well with 
forced treadmill training and shows a robust capacity for cardiac exercise 
adaptation. Unlike C57BL/6J mice, FVB/NJ mice do not have a strong nocturnal 
nature, and they appear to show higher initial exercise capacities and comply 
better when trained during daytime hours. We also found that, in our hands, 
C57BL/6J mice show poor compliance to the treadmill exercise regimen, 
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regardless of when they exercise. These findings demonstrate that FVB/NJ mice 
are a suitable and robust model for understanding the mechanisms underlying 
cardiac adaptations to exercise.i
i This chapter previously appeared as an article in the journal Frontiers in Physiology. The 
original citation is as follows: Gibb AA, et al. FVB/NJ mice are a useful model for examining 
cardiometabolic adaptations to treadmill exercise. Front Physiol, 2016. 
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CHAPTER III 
EXERCISE−INDUCED CHANGES IN GLUCOSE METABOLISM PROMOTE 
PHYSIOLOGIC CARDIAC GROWTH 
 
Introduction 
Exercise promotes cardiovascular wellness,211 augments musculoskeletal 
function,8 and lengthens lifespan.212 These salutary effects of exercise are 
dependent on the ability of the body to adapt to recurrent bouts of physical activity. 
Cumulative adaptation of the circulatory, pulmonary, and musculoskeletal systems 
augment exercise capacity,213 which is the strongest indicator of cardiovascular 
health and a robust predictor of mortality.214 Cardiovascular adaptations to 
exercise are particularly critical to enable adequate oxygen and nutrient delivery 
to peripheral tissues, and they help preserve circulatory system health with age.215, 
216  Physiological cardiac growth due to exercise is a key component of these 
cardiovascular adaptations and contributes not only to exercise capacity, but 
protects the heart from injury as well.217 Nevertheless, the mechanisms by which 
regular exercise triggers and sustains cardiac adaptation remain unclear. 
Understanding how exercise promotes healthy cardiac remodeling could provide 
the knowledge required to delay the progression of heart disease or reverse tissue 
pathology. 
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Previous studies have identified signaling pathways and gene programs 
essential for cardiac adaptation.27, 218 For example, C/EBPβ and CITED4 are 
known to be critical for regulating the transcriptional programs that instigate cardiac 
growth45, 46, 219; however, the mechanisms by which such transcriptional programs 
are activated with exercise are unclear. In tissues such as skeletal muscle, 
adaptive changes in gene expression are thought to be initiated by the repetitive 
bouts of metabolic stress triggered by strenuous physical activity.8 While it follows 
that the heart should conform to this paradigm, this has not been tested and it 
remains unclear which metabolic pathways and flux control steps may be important 
to provoke tissue adaptation to exercise.  
In this study, we examined exercise-induced changes in glucose 
metabolism and their relationship to cardiac remodeling. We provide evidence that 
exercise regulates the activity of myocardial phosphofructokinase 1 (PFK1) and 
that the resulting changes in metabolism are sufficient to activate a transcriptional 
program influencing exercise-induced cardiac growth. Nonetheless, our data also 
indicate that chronically low or high relative levels of glycolysis, such as occurs in 
type II diabetes or heart failure, are damaging to mitochondria. These findings 
suggest that changes in myocardial glucose metabolism, brought about by regular 
exercise, regulate transcriptional programming and physiologic remodeling of the 






Experimental Animals. All procedures were approved by the University of Louisville 
Institutional Animal Care and Use Committee. The mice used in this study include 
transgenic mice expressing a kinase-deficient (kd) form of PFK2 under the control 
of the α-MHC promoter (i.e., GlycoLo mice), transgenic mice expressing a 
phosphatase-deficient form of PFK2 under the control of the α-MHC promoter (i.e., 
GlycoHi mice), and wild-type (WT) littermates.220, 221 Male mice on the FVB/NJ 
background were used for all studies, except for F-2,6-P2 measurements in 
isolated cardiomyocytes, where both male and female mice were used. All studies 
began at 15 weeks of age; food and water were provided ad libitum; and the mice 
were maintained on a 12:12-h light-dark schedule, as described previously.63 At 
the conclusion of animal experiments, and following a 6 h fast, mice were 
anaesthetized with sodium pentobarbital (150 mg/kg, i.p.), followed by euthanasia 
via excision of the heart.  
 
Exercise Capacity Testing. Mice were familiarized to the motorized rodent treadmill 
(Columbus Instruments, Columbus OH) on the Wednesday and Thursday before 
the first week of training. Familiarization consisted of an initial 10 min period where 
the treadmill speed and incline were set to zero with shock grid settings of 25 V, 
0.34 mA, and 2 Hz. The treadmill speed was then increased steadily to 10 m/min 
(Wed) and 12 m/min (Thurs) for an additional 10 min.    
On the Friday immediately following treadmill familiarization, we subjected 
mice to an exercise capacity test. For this, the mice were acclimated to the 
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treadmill for 10 min, with the speed and incline set initially to zero. The treadmill 
speed was then increased to 8.5 m/min with an angle of inclination set to 0° for 9 
min. Next, the treadmill speed and incline were increased to 10 m/min and 5°, 
respectively, for 3 min. The speed was then increased by 2.5 m/min every 3 min 
to a maximum speed of 40 m/min, while inclination increased by 5° every 9 min 
until a maximum incline of 15° was achieved.   
A priori criteria for exercise-induced exhaustion were: 10 consecutive 
seconds on the electric grid; spending more than 50% of time on the grid; and/or 
lack of motivation to manual prodding. Each mouse was removed immediately 
from their respective lane once one or more of these criteria was reached. Blood 
lactate levels provided a biochemical indicator of exercise-induced exhaustion at 
or near maximal oxygen consumption (VO2max).177-180 We recorded lactate 
concentration in 0.7 μl of blood from a small tail clip (Lactate Plus meter; Nova 
Biomedical) prior to the protocol and upon meeting the exhaustion criteria defined 
above. High lactate levels increase confidence in a successful exercise capacity 
test by ensuring that failure to continue is due to exhaustion at or near VO2max 
and not a failure to comply with the protocol.181-183 
 Following 4 weeks of training, we repeated this testing protocol to assess 
improvements in exercise capacity. Exercise capacity was measured using the 
parameters of distance run (meters achieved prior to exhaustion) and work 
accomplished [calculated as the product of body weight (kg) and vertical distance 
(m); vertical distance = (distance run)(sinθ), where θ = the angle of inclination of 
the treadmill from 0°-15°] as outlined previously.63, 166 
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Exercise Training. Mice assigned to exercise training groups were subjected to a 
4-week protocol of forced treadmill running. The training protocol commenced the 
Monday after the initial exercise capacity testing with mice exercising 5 d/wk (Mon–
Fri) at 75% of their maximal speed achieved during the initial exercise capacity test 
and an inclination appropriate to the speed. Prior to each training bout, we provided 
mice with a “warm-up” period of 10 min at 0 m/min and 10 min at 12 m/min to 
promote exercise protocol compliance and to minimize risk of injury. In all groups, 
we progressively increased the workload of the mice, such that they trained for 40 
min during week 1, 50 min during week 2, and 60 min during weeks 3 and 4. We 
chose this progressive intensity protocol to prevent training plateau and to 
stimulate systemic and cardiac adaptations.63 
 To test the effects of chronic exercise in the adapted and recovery state, 
mice were euthanized 24 h or 1 h after the last training session of the 4 wk training 
regimen, respectively. To interrogate the effects of an acute, single-bout of 
exercise on cardiac metabolism, mice were subjected to familiarization as 
previously outlined and euthanized immediately following the completion of a 1 d, 
single exercise training session; 40 min at 75% intensity.  Mice were excluded from 
the study if they were non-compliant with the exercise protocol or if they were found 
to be injured or in poor health, e.g., due to fighting, etc.  
 
Echocardiographic Assessment. Transthoracic echocardiography of the left 
ventricle was performed as previously described.222, 223 Measurements were made 
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on the Vevo 770 echocardiography instrument. Body temperature was maintained 
(36.5–37.5°C) using a rectal thermometer interfaced with a servo-controlled heat 
lamp. Mice were anesthetized with 2% isoflurane, maintained under anesthesia 
with 1.5% isoflurane, and examined. Using short-axis B-modes and endocardial 
values, stroke volume (SV) was calculated as: diastolic volume – systolic volume; 
ejection fraction (EF%) as SV/diastolic volume × 100%; cardiac output as SV × 
heart rate (HR). Left ventricular diameters during diastole (LVIDd), left ventricular 
diameters during systole (LVIDs), and heart rate were determined from long-axis 
M-modes. Relative wall thickness was calculated as (diastolic posterior wall 
thickness + diastolic anterior wall thickness)/LVIDd. To prevent bias, the 
individuals performing echocardiography and image tracing were unaware of the 
group assignments. 
 
Radiometric measurement of myocardial glucose utilization. Hearts were excised 
and perfused in non-recirculating Langendorff mode with Krebs-Henseleit (KH) 
buffer (37ºC; 5% CO2/95% O2; containing in mmol/L: 118.5 NaCl, 25 NaHCO3, 4.7 
KCl, 1.2 MgSO4, 1.2 KH2PO4, 2.5 CaCl2 and 5 mM glucose; pH 7.4). Glycolytic flux 
was assessed by measuring the amount of 3H2O released through the metabolism 
of exogenous [5-3H]glucose (Perkin Elmer), as previously described.220, 221 Briefly, 
following a 20 min period of perfusion (equilibration), KH buffer containing 25 
μCi/ml of [5-3H]glucose was infused into the cannula via a syringe infusion pump 
(Harvard Apparatus) at a proportion 1:100 to that of the flow rate (final 
concentration = 0.25 μCi/ml). The perfusate was collected in two separate 5-min 
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intervals. From the collected perfusate, 400 μl of perfusate was added to 25 µl of 
0.6 M HCl in a microcentrifuge tube.  The microcentrifuge tube was then placed in 
a scintillation vial containing 2 ml of H2O to allow for evaporation diffusion of [3H]2O 
in the microcentrifuge tubes into the water contained in the scintillation vial. To 
account for incomplete equilibration of [3H]2O, in parallel vials, known amounts 
(µCi) of [5-3H]glucose and [3H]2O (Moravek Biochemicals) were placed in 
microcentrifuge tubes, and placed into separate scintillation vials containing 0.5 ml 
dH2O. After 72 h incubation at 37°C, the microcentrifuge tube was removed from 
the vial, 10 ml of scintillation fluid was added, and scintillation counting was 
performed using a Tri-Carb 2900TR Liquid Scintillation Analyzer (Packard 
Bioscience Company). Glucose utilization was then calculated using the formula 
reported by Ashcroft,224 with considerations for: the specific activity of [5-
3H]glucose; incomplete equilibration and background; the dilution of [5-3H]- to 
unlabeled-glucose; and scintillation counter efficiency. Glucose utilization was 
normalized to total heart weight and represented as a fold change to the control 
group. To prevent bias, the individual assisting in hanging the hearts for perfusion 
was unaware of the group assignments. 
 
Measurement of blood glucose and lactate. Blood lactate concentration was 
measured in 0.7 μl of blood from a small tail clip using a Lactate Plus meter (Nova 
Biomedical). Blood glucose concentration was measured from the same tail clip 
using the Accu-Check Aviva blood glucose monitoring meter (Roche).  
 
	 76	
Assessment of plasma free fatty acid.: Circulating plasma free fatty acids (FFA) 
were assessed via a colorimetric enzymatic assay, per manufacturers guidelines 
(Sigma-Aldrich). Briefly, plasma was incubated with acyl-CoA synthetase for 30 
min at 37ºC, in a 96-well microplate. A master reaction mix was added to each well 
and samples were again incubated for 30 min at 37ºC. Absorbance was then 
measured at 570 nm wavelength and the concentration of FFA in each sample 
was calculated based on a standard curve.  
 
Measurement of plasma IGF-1. Plasma IGF-1 was quantified using a mouse/rat 
IGF-1 quantikine ELISA kit (R&D Systems, Minneapolis, MN). Briefly, plasma was 
diluted 500-fold, added to microplate, and incubated for 2 h at room temperature 
with constant shaking. The microplate was then washed 5× followed by addition of 
secondary antibody and incubation at room temperature for 2 h with constant 
shaking. The microplate was then washed five times. For colorimetric 
determination, substrate solution was added to each well for 30 min, followed by 
addition of stop solution and determination of color intensity by measuring at 450 
nm with wavelength correction at 540 nm. The concentration of IGF-1 was 
calculated using a standard curve.  
 
Mitochondrial function. Heart mitochondria were isolated and subjected to 
respiratory function assays using the Seahorse XF24, similar to that described 
previously.225 Briefly, whole hearts were washed 5× with cold buffer A (220 mM 
mannitol, 70 mM sucrose, 5 mM MOPS, 1 mM EDTA; pH 7.2 with KOH) followed 
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by homogenization using a glass-col homogenizer in 2 ml of buffer A containing 
0.2% fatty acid-free BSA. Homogenate was then subjected to centrifugation at 
800g for 10 min followed by supernatant collection and centrifugation at 10,000g 
for 10 min. The pellet containing mitochondria was then resuspended in 1 ml fresh 
buffer A (without BSA) and centrifuged at 10,000g, with this step repeated once. 
The washed mitochondrial pellet was then resuspended in 150 µl respiration buffer 
(120 mM KCl, 25 mM Sucrose, 10 mM HEPES, 1 mM MgCl2, 5 mM KH2PO4; pH 
7.2 with KOH) and kept on ice.  
 To determine mitochondrial function, samples were diluted to a 
concentration of 5 µg (protein) in 50 µl respiration buffer per well, and centrifuged 
onto XF24 microplates at 500g for 3 min at 4ºC. State 3 respiration in response to 
substrates were measured after injection of pyruvate + malate (5.0 mM + 2.5 mM, 
final concentrations), succinate + rotenone (10 mM + 1 µM, final concentrations), 
or palmitoylcarnitine + malate (50 µM + 0.5 mM, final concentrations). The oxygen 
consumption rates recorded after injection of oligomycin (1 µg/ml), an inhibitor of 
ATP synthase, served as a measure of State 4 respiration. Respiratory control 
ratios, state 3/state 4, was calculated as a measure of the coupling of oxygen 
consumption to ATP production. 
 
Measurement of F-2,6-P2 metabolite concentration. Metabolite levels of F-2,6-P2 
were measured in isolated cardiac myocytes as outlined previously.220, 221  
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Glycogen Assay. To assess myocardial glycogen content, 15 mg of heart tissue 
powder was added to 100 µl of ice-cold dH2O, homogenized using a glass col 
homogenizer, boiled for 10 min, and centrifuged at 16,000g for 10 min. Glycogen 
was then hydrolyzed in a 384-well plate for 1 h at 37°C followed by addition of 
reaction mix containing the OxiRed probe for 1 h at 37°C. Absorbance was then 
measured at 590 nm. The amount of glycogen was determined against a standard 
curve and normalized to tissue wet weight. 
 
Histology. Following euthanasia, the heart tissue was excised, flushed with 1 M 
KCl solution, and fixed in 10% formalin, embedded in paraffin, and sectioned at 4 
µm. Heart cross-sections were stained with 4'6-diamidino-2-phenylindole (DAPI; 
Invitrogen, Carlsbad, CA) and wheat germ agglutinin (WGA; ThermoFisher, 
Waltham, MA) for quantification of cardiomyocyte cross-sectional area. 
Additionally, sections were stained with isolectin B4 (Vector Laboratories, 
Burlingame, CA) to assess capillary density and sirius red for fibrosis. Quantitative 
measurements were determined using Nikon Elements software, with no less than 
100 myocytes with centrally located nuclei assessed for area measurements. To 
prevent bias, the individual analyzing all histology was unaware of the group 
assignments. A subset of slides from each group was used based on power 
calculations to detect a 20% difference in cross-sectional area and 
capillary:myocyte ratio at α < 0.05. 
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Protein and mRNA Expression Analysis. For measuring protein abundance, 
tissues and cells were homogenized in buffer containing 50 mM HEPES (pH 7.0), 
2 mM EDTA, 1% NP-40, 10% glycerol, 1 mM MgCl2, 1 mM CaCl2, and 150 mM 
NaCl; fresh phosphatase and protease inhibitors were added immediately prior to 
tissue homogenization. The homogenates were sonicated on ice and centrifuged 
at 13,000g for 20 min. Proteins in the supernatant were separated by SDS-PAGE, 
electroblotted to PVDF membranes, and probed according to the manufacturers’ 
protocols. A horseradish peroxidase-linked secondary antibody (Cell Signaling 
Technology, Danvers, MA) was used to detect immunoreactive proteins. Images 
were recorded using a Fujifilm LAS-300 imager, and relative protein abundance 
was measured via densitometric analysis using TotalLab software.  
For transcriptional expression analysis via RT-PCR, RNA was extracted 
from tissues and cells using the RNeasy Plus Universal Kit (Qiagen, Germantown, 
MD), followed by cDNA synthesis. Real-time PCR amplification was performed 
with SYBR Green quantitative PCR (qPCR) Master Mix (SA Biosciences, 
Germantown, MD) using a 7900HT Fast Real-Time PCR System (Applied 
Biosystems, Foster, CA). Relative expression was determined by the 2-ΔΔCt 
method. A list of the antibodies and primers used can be found below. 
Antibodies used in these studies. 
Antibodies Source Identifier 
DAPI (4',6-Diamidino-2-
Phenylindole, Dihydrochloride)  ThermoFisher Cat#D1306 
WGA (Wheat germ agglutinin, 
Alexa Fluor 647 conjugate) ThermoFisher Cat#W32466 
Fluorescein labeled griffonia 
simplicifolia lectin I (GSL I) 
isolectin B4 
Vector Laboratories Cat#FL-1201 
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Sirius Red Sigma-Aldrich Cat#365548 
Rabbit monoclonal anti-p-Akt 
(S473) Cell Signaling Technology Cat#4060 
Rabbit polyclonal anti-Akt Cell Signaling Technology Cat#9272 
Rabbit monoclonal anti-p-PFK2 
(S483;PFKFB2) Cell Signaling Technology Cat#13064 
Rabbit polyclonal anti-PFK2 
(PFKFB2; heart isoform) Bethyl Labs Cat#A304-286A-M 
Rabbit monoclonal anti-HK1 Cell Signaling Technology Cat#2024 
Rabbit monoclonal anti-HK2 Cell Signaling Technology Cat#2867 
Rabbit polyclonal anti-PFK1 Santa Cruz Biotechnology Cat#sc-67028 
Rabbit polyclonal anti-PFK2 
(PFKFB1; liver isoform) Novus Biologicals Cat#NB100-92391 
Rabbit polyclonal anti-PFK2 
(PFKFB3; ubiquitous isoform) Proteintech Cat#13763-1-AP 
Rabbit monoclonal anti-PKM1/2 Cell Signaling Technology Cat#3106 
Rabbit polyclonal anti-GFAT1 Santa Cruz Biotechnology Cat#sc-134894 
Rabbit polyclonal anti-GS Cell Signaling Technology Cat#3893 
Mouse monoclonal anti-LDHB Abcam Cat#ab85319 
 
 
PCR primers used in these studies. 
Sequence-Based Reagents 
Gene of 
Interest Forward Reverse 
Cited4  CATGGACACCGAGCTCATC CTGACCCCAGGTCTGAGAAG 
Cebpb  GGGGTTGTTGATGTTTTGGT TCGAAACGGAAAAGGTTCTCA 
Nfatc2  CACAGATACGGTGACCCCT GTGGGATCGGGTTCTTCTTC 
HPRT  AGGACCTCTCGAAGTGTTGG AGGGCATATCCAACAACAAAC 
 
Analysis of cardiac ultrastructure. Transmission electron microscopy analysis, left 
ventricular tissue was dissected into 3 mm3 pieces and fixed in 2.5% 
glutaraldehyde overnight.  The samples were then post-fixed in 2% aqueous 
osmium tetroxide, dehydrated in ascending concentrations of ethanol and 
embedded in Araldite 502 (Electron Microscopy Sciences, Hatfield PA). One-
micron thick sections were stained with toluidine blue for screening under a light 
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microscope. Selected blocks in which the muscle had a longitudinal orientation 
were cut into 800 Å thick sections, mounted on 200-mesh copper grids, doubly 
stained with uranyl acetate and lead citrate, and examined in a Phillips CM-10 
electron microscope with a LaB 6 cathode (Phillips Electronic Instruments Co., 
New York, NY) operating at 80 kV. 
 
Metabolomic Analysis. Hearts were freeze-clamped in situ using liquid nitrogen-
cooled Wollenberger Tongs, which helps to capture the metabolome as it is in the 
beating mouse heart in vivo. Samples were prepared by Metabolon using their 
automated MicroLab STAR® system (Hamilton Company, Reno, NV). First, tissue 
homogenates were made in water at a ratio of 5 uL per mg of tissue. For quality 
control, several recovery standards were added prior to the first step in the 
extraction process. To remove protein, dissociate small molecules bound to protein 
or trapped in the precipitated protein matrix, and to recover chemically diverse 
metabolites, proteins were then precipitated with methanol (final concentration 
80% v/v) under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed 
by centrifugation. For quality assurance and control, a pooled matrix sample was 
generated by taking a small volume of each experimental sample to serve as a 
technical replicate throughout the data set. Extracted water samples served as 
process blanks. A cocktail of standards known not to interfere with the 
measurement of endogenous compounds was spiked into every analyzed sample, 
allowing instrument performance monitoring and aiding chromatographic 
alignment. 
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The extract was divided into fractions for analysis by reverse phase 
(RP)/UPLC-MS/MS with positive ion mode electrospray ionization (ESI), by 
RP/UPLC-MS/MS with negative ion mode ESI, and by HILIC/UPLC-MS/MS with 
negative ion mode ESI. Samples were placed briefly on a TurboVap® (Zymark) to 
remove the organic solvent. All methods utilized a Waters ACQUITY UPLC and a 
Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer 
interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap 
mass analyzer operated at 35,000 mass resolution. The sample extract was 
reconstituted in solvents compatible with each MS/MS method. Each reconstitution 
solvent contained a series of standards at fixed concentrations to ensure injection 
and chromatographic consistency. One aliquot was analyzed using acidic positive 
ion conditions, chromatographically optimized for hydrophilic compounds. In this 
method, the extract was gradient eluted from a C18 column (Waters UPLC BEH 
C18-2.1x100 mm, 1.7 µm) using water and methanol, containing 0.05% 
perfluoropentanoic acid (PFPA) and 0.1% formic acid (FA). For more hydrophobic 
compounds, the extract was gradient eluted from the aforementioned C18 column 
using methanol, acetonitrile, water, 0.05% PFPA and 0.01% FA. Aliquots analyzed 
using basic negative ion optimized conditions were gradient eluted from a separate 
column using methanol and water, containing 6.5 mM ammonium bicarbonate (pH 
8). The last aliquot was analyzed via negative ionization following elution from a 
HILIC column (Waters UPLC BEH Amide 2.1×150 mm, 1.7 µm) using a gradient 
consisting of water and acetonitrile with 10 mM ammonium formate (pH 10.8). The 
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MS analysis alternated between MS and data-dependent MSn scans using 
dynamic exclusion. The scan range covered 70–1000 m/z. 
Raw data were extracted, peak-identified and processed using Metabolon’s 
proprietary hardware and software. Compounds were identified by comparison to 
library entries of purified, authenticated standards or recurrent unknown entities, 
with known retention times/indices (RI), mass to charge ratios (m/z), and 
chromatographic signatures (including MS/MS spectral data). Biochemical 
identifications were based on three criteria: retention index within a narrow RI 
window of the proposed identification, accurate mass match to the library±10 ppm, 
and the MS/MS forward and reverse scores between experimental data and 
authentic standards. Proprietary visualization and interpretation software 
(Metabolon, Inc., Durham, NC) was used to confirm the consistency of peak 
identification among the various samples. Library matches for each compound 
were checked for each sample and corrected, if necessary. Area under the curve 
was used for peak quantification. 
Original scale data (raw area counts) were analyzed using Metaboanalyst 
3.0 software (http://www.metaboanalyst.ca/).226 Metabolites with greater than 50% 
of the values missing were omitted from the analysis, and missing values were 
imputed by introducing values with half the minimum positive value in the original 
data.  An interquartile range filter was used to identify and remove variables 
unlikely to be of use when modeling the data. The data were log-transformed and 
auto-scaled (mean-centered and divided by the standard deviation of each 
variable). Univariate (e.g., volcano plots) and multivariate (e.g., PCA) analyses 
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were then performed.  For multiple comparison testing, q values were calculated 
as in R using a method embedded within the Metaboanalyst software, controlling 
for the false discovery rate.227 Radar charts were constructed in R using average 
Z-scores of significantly different metabolites from each biochemical pathway. 
 
Transcriptomic analyses. Hearts of male WT, GlycoLo and GlycoHi mice (15–16 
weeks of age) were subjected to transcriptomic analysis using the GeneChip® 
Mouse Genome 430 2.0 Array (Affymetrix, Inc.). Array data were analyzed using 
the affy228 and limma229 packages of R for Robust Multi-array Average (RMA) for 
normalization and for moderate t-statistics to derive p-values, respectively. The p-
values were adjusted using the Bejamini and Hochberg method for false discovery 
rate control.227 For the genes with multiple probe set IDs, the probe set with the 
highest standard deviation among all samples was kept for further analsyis. Gene 
Ontology analysis was performed using DAVID 
(https://david.ncifcrf.gov/home.jsp.230  
 
Data and Software Availability. Cytoscape software was used to visualize changes 
in metabolic pathways and networks and was facilitated using the MetaboLync 
Cytoscape Plugin (Metabolon, Inc). Metabolomic data were analyzed using 
Metaboanalyst 3.0 software. Gene array data has been deposited in the Gene 
Expression Omnibus databank (GSE100176) and will be made available to 
readers upon publication.   
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Statistical analysis. Statistical parameters including the value of n (number of 
mice), the definition of center, dispersion and precision measures (mean ± SEM or 
SD), and statistical significance is reported in the Figures and Figure Legends. A 
p value of ≤ 0.05 was considered statistically significant. In the Figures, asterisks 
denote statistical significance as calculated by unpaired or paired Student’s t test 
(for direct comparisons); Levene’s test was used to assess the equality of group 
variances between groups, and if found to be significantly different, a Welch-
modified t-test was used to assess significance. Multiple comparisons were 
assessed by one-way or two-way ANOVA followed by Bonferroni or Sidak Multiple 
Comparison tests (*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001), as 
appropriate. Statistical analysis was performed using GraphPad Prism 7, 
Metaboanalyst, and/or the R program. 
 
Results 
Exercise promotes physiologic cardiac growth.  Wild-type mice subjected to 4 
weeks of treadmill training showed a 48% increase in distance run and a 77% 
increase in work accomplished (Fig. 10A, B); successful exercise testing was 
validated by elevated blood lactate levels, indicating that the mice ran to 
exhaustion (Fig. 10C). In comparison with untrained mice, trained mice had 15% 
higher levels of circulating plasma IGF-1 (Fig. 10D), further demonstrating 
systemic adaptation to the training regimen. Exercise-adapted mice displayed 
physiologic cardiac growth characterized by a 10% increase in heart weight to tibia  
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Figure 10: Exercise training improves exercise capacity. Systemic adaptation 
to a 4-wk treadmill training protocol: Pre- and post-training (A) distance and (B) 
work; (C) Validation of a successful high-intensity exercise capacity test as 
indicated by levels of blood lactate measured at rest and immediately after the 
criteria for exercise-induced fatigue were met; and (D) Plasma levels of insulin-like 
growth factor-1 (IGF-1). Sed, sedentary; Exe, exercise. Data represented as mean 









Figure 11: Exercise training promotes physiologic cardiac growth. Effect of 
treadmill training on the exercise-induced cardiac growth program: (A) Gravimetric 
measurements of cardiac size (HW/TL, heart weight/tibia length); (B) 
Representative myocardial sections stained with wheat germ agglutinin (red) and 
isolectin B4 (green). Nuclei are stained with DAPI (blue); (C) Cardiomyocyte cross-
sectional area; (D) Capillary-to-myocyte ratio; (E) Phosphorylation of AKT (Ser473) 
24 h following the last training session; (F) Relative Mrna expression of Cebpb, 
Cited4, and Nfatc2. Data are represented as mean ± SEM; *p<0.05, **p<0.01, 

















Table 3: Echocardiographic data from sedentary and exercised WT mice. 
After acclimatization and an initial exercise capacity test, male FVB/NJ mice (15 
weeks of age) were subjected to exercise training 5 d a week for 4 wk. One day 
following the final exercise capacity test, the mice were anesthetized and cardiac 
structure and function were assessed by echocardiography. Abbreviations: Sed, 
sedentary; Exe, exercised; HR, heart rate; EDV, end-diastolic volume; ESV, end-
systolic volume; SV, stroke volume; EF, ejection fraction; CO, cardiac output; 
LVIDd, left ventricular internal diameter in diastole; LVIDs, left ventricular internal 
diameter in systole; LVPWd, left ventricular posterior wall in diastole; LVPWs, left 
ventricular posterior wall in systole; LVAWd, left ventricular anterior wall in diastole; 
LVAWs, left ventricular anterior wall in systole; RWT, relative wall thickness. 







Mean SD Mean SD
HR (bpm) 482 ± 32 492 ± 25
Endocardial Values
EDV (µl) 38 ± 3 45 ± 6**
ESV (µl) 11 ± 3 13 ± 2
SV (µl) 27 ± 3 32 ± 5**
EF (%) 71 ± 7 72 ± 4
CO (ml/min) 13 ± 2 16 ± 2**
Chamber Diameter
LVIDd (mm) 3.7 ± 0.2 4.0 ± 0.2**
LVIDs (mm) 2.2 ± 0.2 2.5 ± 0.2**
Wall Thickness
LVPWd (mm) 0.8 ± 0.1 0.9 ± 0.1*
LVPWs (mm) 1.2 ± 0.1 1.3 ± 0.1*
LVAWd (mm) 0.8 ± 0.1 0.8 ± 0.1
LVAWs (mm) 1.1 ± 0.2 1.1 ± 0.2
RWT 0.46 ± 0.07 0.42 ± 0.07
n 12 10
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length (HW/TL; Fig. 11A), a 24% increase in cardiomyocyte cross-sectional area, 
and a 35% increase in capillary-to-myocyte ratio (Fig. 11B–D). Furthermore, 
exercise increased chamber diameter and wall thicknesses, improved indices of 
cardiac function (EDV, SV, and CO; Table 3), and activated the pro-hypertrophic 
signaling intermediate protein kinase B (AKT)35, 39-42 (Fig. 11E). Exercise  
training downregulated Cebpb and upregulated Cited4, an observation which is 
consistent with previous findings showing necessary involvement of these 
transcriptional mediators in regulating physiologic growth.45, 46, 217-219 Moreover, the 
expression of Nfatc2, the deletion of which ameliorates pathological hypertrophy 
and heart failure but does not prevent physiological hypertrophy,231 was markedly 
lower in hearts from exercise-adapted mice (Fig. 11F). Collectively, these results 
indicate that exercise training elicits robust cardiac adaptation in mice. 
  
Metabolomic changes in the exercise-adapted heart at steady state. To examine 
global metabolic changes in exercise-adapted hearts, we first compared the 
relative abundance of 424 metabolites in hearts isolated from sedentary and 
exercise-adapted mice. To capture the metabolic state of the adapted heart as 
accurately as possible, the hearts were freeze-clamped in situ 24 h after the final 
exercise bout (Fig. 12A). Principal component analysis (PCA) showed little 
separation between the groups (Fig. 12B), and only 20 metabolites (out of 424 
measured) were found to be significantly different (Fig. 12C). Of these, only two 
metabolites had a q value below 0.05 (Table 4). These findings demonstrate that  
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Figure 12: Metabolomic changes in the exercise-adapted mouse heart. (A) 
Mice were either exercised for 4-wk (EXE) or remained sedentary (SED) under 
similar handling conditions.  Following a 6 h fast and 24 h after the final exercise 
session, hearts were freeze-clamped in situ.  The relative abundance of 
metabolites in the hearts was examined by LC/MS/MS; (B) 2D PCA analysis; (C) 
Volcano plot showing metabolites that changed ≥ 1.25-fold (p ≤ 0.05) in Exe hearts 
compared with Sed hearts. A list of metabolites found to be significantly different 
in exercise-adapted hearts can be found in Table S2. N = 9 Sed and 11 Exe mouse 
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Table 4: Significantly different metabolites in hearts from exercise-adapted 
mice. Hearts from WT, exercise-adapted (EXE) mice [(and corresponding WT 
sedentary controls (SED)] were freeze-clamped in situ, 24 h after the final exercise 
bout.  Metabolites extracted from the hearts were subjected to LC/MS analysis.  
Raw area counts from each identified metabolite were log-transformed, 
autoscaled, and then subjected to t-test analysis.  Missing values were imputed 
using half the minimum value of observed raw area count data, and metabolites 
with >50% values missing were omitted from the analysis.  Asterisks (*) indicate 
compounds that were not officially confirmed based on a standard, but whose 
identity matches the expected exact mass using the UHPLC/MS/MS2 accurate 
mass platform. Shown are those metabolites with a p value threshold of 0.05 and 

































































































































































































































































































































































































































































































































































































































































































































































































































































the steady-state abundance of most metabolites in the exercise-adapted heart is 
unchanged compared with that of sedentary mice.  
 
Exercise induces periodicity in glucose metabolism. Because the steady-state 
abundance of biochemical pathway intermediates may not be reflective of pathway 
flux,222, 232 and because several studies show that exercise changes cardiac 
metabolism (e.g.,40, 66), we next measured the metabolism of [5-3H]glucose in 
hearts from sedentary and  
exercise-adapted mice. Radiometric assays of perfused hearts showed a nearly 2-
fold increase in glucose utilization in exercise-adapted hearts compared with 
hearts from sedentary mice (Fig. 13A). Glycolytic enzymes were found in similar 
abundances in exercise-adapted hearts relative to hearts from sedentary mice 
(Fig. 14). These data indicate that changes in enzyme abundance are unlikely to 
contribute to the increase in glycolysis that occurs in the exercise-adapted heart. 
Because glycolysis is influenced by rate-limiting steps, such as occurs at 
the phosphofructokinase reaction, we next examined factors that regulate PFK1—
the rate-limiting and committed step of glycolysis.233, 234 The PFK1 reaction exerts 
more control on glycolysis than any other step235 and is dependent on several 
factors including: the levels of fructose-2,6,-bisphosphate (F-2,6-P2), substrate 
availability, energy charge, the levels of citrate and ATP, and pH. Because PFK2 
regulates the levels of F-2,6-P2, a potent activator of PFK1, we examined the 
phosphorylation status of the myocardial isoform of PFK2, PFKFB2.  
Phosphorylation of PFKFB2 at S483 can increase F-2,6-P2 levels and is known to 
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be under the influence of insulin-like growth factor-1/AKT signaling.35, 236-238 
Notably, both cardiac AKT phosphorylation and plasma insulin-like growth factor-
1 were elevated in exercise-adapted mice (see Fig. 11E and Fig. 10D). In 
agreement with radiometric findings, S483 phosphorylation of PFKFB2 (p-PFK2) 
was 50% higher in exercise-adapted hearts compared with hearts of sedentary 
mice (Fig. 13B, upper panel and 13C, left panel). Taken together, the radiometric 
and immunologic data provide convergent evidence that glycolysis is increased in 
the exercise-adapted heart and indicate that this increase in glycolytic activity may 
be attributable at least in part to PFK activation. 
Because exercise is a dynamic challenge that leads to rapid changes in 
metabolism, we next examined glycolytic changes that occur early after exercise, 
i.e., in the trained state during recovery. Because ex vivo measurements of flux in 
the recovery period following an exercise session are unlikely to provide 
meaningful data (e.g., due to lack of a metabolic steady-state), we measured levels 
of p-PFK2 as a possible indicator of phosphofructokinase activity and glucose 
utilization through glycolysis. Compared with corresponding sedentary controls, 
hearts excised from exercise-adapted mice 1 h after the last exercise session 
showed significantly diminished PFK2 phosphorylation (Fig. 13B, lower panel 
and 13C, right panel).   
To determine whether these changes in metabolism precede cardiac 
adaptation, we eliminated the variable of extended training and examined PFK2 
activation immediately after a single bout of exercise. For this, a separate group of  
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Figure 13: Exercise dynamically regulates PFK2 and glycolysis in the heart. 
Measurements of glucose metabolism in the heart: (A) Measurement of relative 
myocardial glucose utilization in isolated perfused hearts from mice that remained 
sedentary (Sed) or that were exercised for 4 weeks (Exe). Measurements were 
performed on hearts excised 24 h after the last exercise session; (B) 
Representative immunoblots from a separate cohort of mice of S483 
phosphorylation of the cardiac isoform of PFK2 (PFKFB2) in the sedentary and the 
exercise-adapted state: upper panel, levels of PFK2 phosphorylation 24 h after the 
last bout of exercise; lower panel, PFK2 phosphorylation occurring 1 h after the 
last exercise bout. (C) Quantification of PFK2 phosphorylation from blots 
represented in panel B; (D) Representative immunoblots of S483 phosphorylation 
of PFK2 in hearts of mice exercised for 1 d; these hearts were excised immediately 
after exercise, which would appear to be indicative of the state of PFK2 occurring 
during or immediately after exercise; (E) Schematic representation of glycolysis 
showing relationship of PFK activity with glycogen storage; (F) Myocardial 
glycogen content in hearts of Sed mice and in hearts excised immediately after 1 
bout of exercise; Circulating levels of (G) blood glucose, (H) blood lactate, and (I) 
plasma free fatty acids (FFA) in mice subjected to a single bout of exercise; (J) 
Schematic illustrating changes in glucose utilization occurring with acute and 
chronic exercise, i.e., exercise-induced metabolic periodicity. Data are 
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Figure 14: Exercise training does not alter the abundance of key glucose-
metabolizing enzymes. Western blot analysis of enzymes in glycolysis and 
glucose metabolism: (A) Representative western blots of hexokinase 2 (HK2), 
phosphofructokinase (PFK1), phosphofructo-kinase/fructose-bisphosphatase 2 
(PFKFB2; PFK2), phosphofructo-kinase/fructose-bisphosphatase 3 (PFKFB3; 
PFK2), pyruvate kinase (PKM1/2), pyruvate dehydrogenase kinase 1 (PDHK1), 
glutamine:fructose-6-phosphate aminotransferase 1 (GFAT1), glycogen synthase 
(GS), and lactate dehydrogenase b (LDHB); (B) Quantification of western blots 
from A. Data are represented as mean ± SEM; n = 6 per group; in all cases, p>0.05 





























mice was subjected to a single bout of exercise for 40 min.  Immediately following 
this exercise bout, mice were euthanized and the hearts were excised for 
biochemical analysis. We found that p-PFK2 levels in these hearts were 
remarkably lower than those in sedentary controls (Fig. 13D), suggesting that a 
bout of exercise might acutely decrease the rate of glycolysis in the heart. Because 
measurement of glycolytic rate ex vivo would likely obfuscate the metabolic 
changes that occur during or shortly after a bout of exercise (due to loss of 
hemodynamic, metabolic, and paracrine [e.g. catecholamine] influence), we chose 
to measure glycogen content as an additional surrogate of PFK activity and 
glycolysis. Thus, we hypothesized that, during exercise, PFK-mediated decreases 
in glycolytic rate should promote glycogen accumulation (Fig. 13E), which is 
consistent with the notion that decreases in PFK activity promote glycogenesis.239 
Indeed, glycogen content was elevated >5-fold in hearts collected immediately 
after a single bout of exercise (Fig. 13F). Notably, this elevation in cardiac 
glycogen is not related to the short (6 h) fasting period occurring in sedentary and 
exercised mice because independent experiments showed that fasting mice for 
this duration does not affect myocardial glycogen content (unfasted, 0.17±0.03 
µg/mg tissue; 6 h fasted, 0.18±0.05 µg/mg tissue; n=7–8 per group).  
Because substrate availability and delivery are key determinants of 
myocardial substrate preference and utilization,75, 78, 79, 100 we measured the 
circulating levels of glucose, lactate, and free fatty acids in mice immediately 
following a bout of exercise. Compared with pre-exercise levels, mice subjected to 
40 min of treadmill exercise showed a 50% decrease in blood glucose and a 2.5-
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fold increase in blood lactate (Fig. 13G,H). Moreover, plasma free fatty acids were 
significantly elevated (Fig. 13I), which along with the changes in blood glucose 
and lactate, would stimulate lactate and fat oxidation and diminish overall glucose 
utilization. These data are concordant with our biochemical measurements and 
provide convergent evidence suggesting that, during and immediately after 
exercise, the rate of myocardial glycolysis is diminished; however, upon adaptation 
and full recovery, the steady-state rates of glycolysis appear to be increased in the 
heart (Fig. 13J).  
 
Phosphofructokinase is a strong regulator of the glucose-fatty acid cycle in the 
heart. We next examined whether exercise-induced periodicity in glucose 
metabolism might be essential for structural and functional cardiac adaptation. This 
hypothesis is consistent with the notion that repetitive bouts of exercise are a 
trigger for the transcriptional adaptation in skeletal muscle.8  As tools to examine 
the relationship between changes in myocardial glucose metabolism and cardiac 
remodeling, we used genetically modified mice expressing kinase-deficient 
(GlycoLo) or phosphatase-deficient (GlycoHi) point-mutant isoforms of PFK2 under 
the control of the α-MHC promoter, which constitutively decrease or increase PFK1 
activity and myocardial glycolytic rate.220, 221 Compared with cardiomyocytes 
isolated from WT mice, the abundance of F-2,6-P2 was >2-fold lower in GlycoLo 
cardiomyocytes and >5-fold higher in GlycoHi cardiomyocytes (Fig. 15A). The rate 
of glycolysis in perfused hearts was in accordance with transgene-induced 
alterations in F-2-6-P2 (Fig. 15B). Consistent with the notion that PFK activity 
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regulates glycogen storage,239 GlycoLo hearts showed 1.6-fold higher myocardial 
glycogen content, and GlycoHi hearts demonstrated 4-fold lower levels of glycogen 
(Fig. 15C). 
 To determine how glycolysis affects myocardial metabolism, we measured 
the steady-state abundance of myocardial metabolites in both GlycoLo and GlycoHi 
hearts (Fig. 15D). PCA showed that the relative abundances of metabolites could 
discriminate between the genotypes (Fig. 15E). Volcano plot analysis 
demonstrated that, out of the 424 metabolites measured, 108 metabolites in 
GlycoLo hearts (Fig. 16A, Table 5) and 109 metabolites in GlycoHi hearts (Fig. 16B, 
Table 6) were significantly different from WT hearts. Visualization of changes in 
the metabolic network demonstrated the greatest impact on the lipid superfamily, 
with acylcarnitines (subfamily 1) showing robust, diametrically opposite changes 
in the GlycoLo and GlycoHi hearts (Fig. 15F, G). Z-score analyses illustrate 
remarkable increases in medium and long chain acylcarnitines in GlycoHi hearts; 
the corresponding species were lower in abundance in GlycoLo hearts (Fig. 17A 
and Tables 5, 6). In addition, long chain fatty acids (saturated and unsaturated) 
were lower in GlycoLo mice, while many of the same species were elevated in 
GlycoHi mice (Fig. 15F, G, Fig. 17A, and Tables 5, 6). Interestingly, GlycoLo hearts 
demonstrated elevated levels of aconitate, homocitrate, and α-ketoglutarate (Fig. 
15F, G and Table 5), suggesting that high rates of lipid oxidation in these hearts 
might flood the Krebs cycle. Glycolytic intermediates were lower in GlycoHi mice, 
while most glycolytic intermediates were unchanged in abundance in GlycoLo  
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Figure 15: Cardiac F-2,6-P2 regulates myocardial glucose and lipid 
metabolism. Metabolic phenotyping of GlycoLo and GlycoHi mice: (A) Levels of F-
2,6-P2 in cardiomyocytes isolated from WT, Glyco
Lo, and Glyco
Hi
 mice. N = 3–6 per 
group; (B) Relative myocardial glucose utilization in isolated perfused hearts. n = 
5–7 per group; (C) Myocardial glycogen content. N = 7–9 per group; (D) Schematic 
of 106hosphor106ics analysis of WT, GlycoLo, and GlycoHi hearts; (E) 2D PCA 
analysis; (F) Metabolic network visualization of metabolites in GlycoLo and GlycoHi 
hearts, compared with corresponding WT hearts. Circle size is indicative of the 
magnitude of change (blue and red circles indicate significantly decreased or 
increased metabolites abundance compared with WT controls, respectively). 
Numbers represent metabolites in the following subpathways: 1: Acylcarnitines; 2: 
Monacylglycerols; 3: Monohydroxy fatty acids; 4: Phospholipid metabolism; 5: 
Lysolipids; 6: Polyunsaturated fatty acids; 7: Sphingolipids; 8: Dicarboxylic fatty 
acids; 9: Long chain fatty acids; 10: Glycolysis; 11: Fructose, Mannose, Galactose 
metabolism; 12: Pentose metabolism; 13: TCA cycle; 14: Purine metabolism, 
(hypo)xanthine/inosine; 15: Purine metabolism, adenine; 16: Gly, Ser, Thr 
metabolism; 17: BCAA metabolism; 18: Met, Cys, SAM, Tau metabolism; (G) 
Overview of changes in major metabolic subpathways in GlycoLo and GlycoHi 
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Figure 16: Metabolomic changes in the GlycoLo and GlycoHi mouse hearts. 
Following a 6 h fast, hearts were freeze-clamped in situ. The relative abundance 
of metabolites in the hearts was measured by LC/MS/MS. Volcano plot showing 
metabolites that changed ≥ 1.25-fold (p ≤ 0.05) in (A) GlycoLo and (B) GlycoHi 
hearts compared with WT hearts; A list of metabolites found to be significantly 
different in these hearts can be found in Tables S3 and S4. N = 9 WT, 10 GlycoLo, 
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Table 5: Significantly different metabolites in hearts from WT and GlycoLo 
mice. Metabolites extracted from the hearts of WT and cardiac-specific kd-PFK2 
transgenic mice (GlycoLo mice) were subjected to LC/MS analysis.  Raw area 
counts from each identified metabolite were log-transformed, autoscaled, and then 
subjected to statistical analyses (t-test).  Missing values were imputed using half 
the minimum value of observed raw area count data, and metabolites with >50% 
values missing were omitted from the analysis.  Asterisks (*) indicate compounds 
that were not officially confirmed based on a standard, but whose identity matches 
the expected exact mass using the UHPLC/MS/MS2 accurate mass platform. 
Shown are those metabolites with a p value threshold of 0.05 and a fold change 
threshold of 1.25.  n = 9 WT mice and n = 10 GlycoLo mice. #S-methylmethionine 
was not detected in any of the WT samples, and campesterol was detected only 
in one WT sample; thus, the relative fold change values are based upon imputed 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6: Significantly different metabolites in hearts from WT and GlycoHi 
mice. Metabolites extracted from the hearts of WT and cardiac-specific pd-PFK2 
transgenic mice (GlycoHi mice) were subjected to LC/MS analysis.  Raw area 
counts from each identified metabolite were log-transformed, autoscaled, and then 
subjected to t-test analysis.  Missing values were imputed using half the minimum 
value of observed raw area count data, and metabolites with >50% values missing 
were omitted from the analysis.  The asterisk (*) indicates compounds that were 
not officially confirmed based on a standard, but whose identity matches the 
expected exact mass using the UHPLC/MS/MS2 accurate mass platform. Shown 
are those metabolites with a p value threshold of 0.05 and a fold change threshold 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig 17: Modulation of cardiac glycolytic rate regulates lipid, carbohydrate, 
and amino acid metabolism. Spider charts showing average z-scores of (A) lipid 
(B) carbohydrate and (C) amino acid and peptide metabolites that were 
significantly different in GlycoLo or GlycoHi hearts compared with WT controls. N = 


















mice (Fig. 15F, G and Fig. 17B). Changes in the steady-state abundances of 
glycolytic and lipid metabolites are most consistent with increased propensity for 
glucose oxidation in GlycoHi hearts and increased lipid oxidation in GlycoLo 
hearts. These changes would be sufficient to explain the accumulation of 
acylcarnitines and diminished levels of glycolytic intermediates occurring in 
GlycoHi hearts, and the lower levels of acylcarnitines in GlycoLo hearts. 
Polarization of myocardial metabolism also resulted in modest changes in amino 
acid metabolites (see Fig. 17C and Tables 5, 6). Collectively, these results show 
the high degree to which phosphofructokinase regulates the glucose-fatty acid 
cycle in the heart. 
 
Constitutively low glycolytic activity promotes structural and transcriptional 
changes consistent with the exercise-adapted heart. To examine whether PFK 
activity regulates cardiac growth, we assessed the structure and function of 
GlycoLo and GlycoHi hearts. Both the GlycoLo and GlycoHi hearts showed a mild 
increase in cardiac size, which was associated with increased cardiomyocyte 
cross-sectional area (Fig. 18A-C, E, F); however, significantly increased capillary-
to-myocyte ratio was observed only in GlycoLo hearts (Fig. 18A, D). Picrosirius red 
staining showed no noteworthy myocardial fibrosis in either strain (Fig. 18A). 
Interestingly, GlycoLo hearts showed elevated EDV and slightly increased wall 
thicknesses compared with WT mice (Table 7), which is similar to that found in 
WT, exercise-adapted mice (see Table 3). In contrast, GlycoHi hearts had  
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Figure 18: Constitutive changes in glycolysis promote cardiac growth and 
hypertrophy. Structural and molecular indices of cardiac growth/hypertrophy: (A) 
Representative myocardial sections stained for: left panels, wheat germ agglutinin 
(red), isolectin B4 (green) and DAPI (blue); and right panels, picrosirius red; (B,E) 
Gravimetric measurement of cardiac size (HW/TL, heart weight/tibia length); (C,F) 
Cardiomyocyte cross sectional area; (D,G) Capillary-to-myocyte ratio; (H) Basal 
phosphorylation of AKT (Ser473); (I,J) Relative Mrna expression of genes 
associated with the physiological growth program. Data are represented as mean 



















Table 7: Echocardiographic parameters from GlycoLo and GlycoHi mice 
compared with WT controls. Cardiac structure and function were evaluated in 
20-week-old, male, cardiac-specific, kd-PFK2 mice (GlycoLo mice), pd-PFK2 mice 
(GlycoHI mice) and WT littermates by echocardiography. Abbreviations: HR, heart 
rate; EDV, end-diastolic volume; ESV, end-systolic volume; SV, stroke volume; 
EF, ejection fraction; CO, cardiac output; LVIDd, left ventricular internal diameter 
in diastole; LVIDs, left ventricular internal diameter in systole; LVPWd, left 
ventricular posterior wall in diastole; LVPWs, left ventricular posterior wall in 
systole; LVAWd, left ventricular anterior wall in diastole; LVAWs, left ventricular 
anterior wall in systole; RWT, relative wall thickness. *p<0.05, **p<0.01 vs. 








WT GlycoLo WT GlycoHi
Mean SD Mean SD Mean SD Mean SD
HR (bpm) 486 ± 22 486 ± 26 492 ± 52 494 ± 38
Endocardial Values
EDV (µl) 44 ± 4 49 ± 5* 50 ± 4 54 ± 7
ESV (µl) 12 ± 3 15 ± 4 15 ± 2 20 ± 5**
SV (µl) 32 ± 3 34 ± 3 35 ± 4 34 ± 4
EF (%) 72 ± 4 70 ± 6 70 ± 4 63 ± 5**
CO (ml/min) 15 ± 2 16 ± 2 17 ± 2 17 ± 2
Chamber Diameter
LVIDd (mm) 3.9 ± 0.2 4.0 ± 0.3 4.1 ± 0.2 4.4 ± 0.3*
LVIDs (mm) 2.3 ± 0.3 2.3 ± 0.3 2.5 ± 0.3 2.9 ± 0.3**
Wall Thickness
LVPWd (mm) 0.8 ± 0.1 0.9 ± 0.1* 1.0 ± 0.2 1.0 ± 0.1
LVPWs (mm) 1.3 ± 0.2 1.4 ± 0.2 1.5 ± 0.2 1.4 ± 0.1
LVAWd (mm) 0.9 ± 0.1 0.9 ± 0.1 1.1 ± 0.2 1.2 ± 0.2
LVAWs (mm) 1.3 ± 0.2 1.3 ± 0.2 1.6 ± 0.3 1.6 ± 0.2
RWT 0.43 ± 0.07 0.47 ± 0.10* 0.51 ± 0.10 0.45 ± 0.07
(n=) 10 10 11 11
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elevated ESV, lower EF%, and larger chamber diameters, suggesting a more 
dilated cardiac phenotype (Table S5). 
To determine whether the signaling mediators and transcriptional programs 
underlying exercise-induced cardiac growth43, 45, 46, 218 are affected by constitutive 
changes in glucose utilization, we next examined the phosphorylation of AKT and 
the relative expression of Cebpb and Cited4. While no differences in basal p-AKT 
(S473) were observed in either strain (Fig. 18H), Cebpb expression was lower and 
Cited4 expression was higher in GlycoLo hearts compared with WT counterparts 
(Fig. 18I). Expression of these genes was unchanged in GlycoHi hearts (Fig. 18J). 
Although Nfatc2 showed a trend toward lower expression in GlycoLo hearts, this 
did not reach statistical significance. These data suggest that constitutively low or 
high rates of glycolysis cause mild cardiac hypertrophy and that a low rate of 
glycolysis, in the absence of AKT activation, is sufficient to promote a structural, 
functional, and transcriptional phenotype resembling the exercise-adapted heart. 
 
Metabolic inflexibility causes mitochondrial structural and functional abnormalities.  
Because constitutive polarization of metabolism toward either glucose or fat 
oxidation could have deleterious effects on mitochondrial structure and function, 
we examined mitochondrial ultrastructure by transmission electron microscopy 
and measured respiration in mitochondria isolated from the hearts of both GlycoLo 
and GlycoHi mice. As shown in Fig. 19A, qualitative analysis of electron 
micrographs showed disorganization of mitochondrial cristae and diminished 
cristae density compared with WT littermates. Consistent with this observation, 
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mitochondria from both GlycoLo and GlycoHi hearts showed lower respiration in the 
presence of pyruvate+malate or succinate (Fig. 19B,C). In addition, respiratory 
control ratios (RCR) were found to be lower in cardiac mitochondria from both 
transgenic strains, suggesting diminished coupling of mitochondrial electron 
transport to ATP synthesis (Fig. 19D). Thus, while constitutively low glycolysis 
imparts some structural, functional, and transcriptional features characteristic of 
the exercise-adapted heart, the mitochondrial compartment is damaged by 
metabolic inflexibility.   
 
Constitutively low glycolysis is sufficient for maximal cardiac growth. With the 
observation that GlycoLo hearts have a cardiac phenotype partially resembling the 
exercise-adapted heart, we next asked whether these mice are capable of 
performing more work or adapting to a greater degree than their WT counterparts. 
To address this question, we subjected both WT and GlycoLo mice to exercise 
testing prior to and following 4 weeks of treadmill training. Although GlycoLo mice 
were able to adapt systemically to the training regimen, they were not able to run 
farther or perform more work than WT mice (Fig. 20A,B). Unlike WT mice, which 
showed a ~15% increase in cardiac size, GlycoLo mice showed no further increase 
in cardiac growth following training (Fig. 20C). Similarly, myocardial expression of 
Cebpb and Cited4 were not found to be different in exercised GlycoLo mice 
compared with sedentary GlycoLo mice (Fig. 20D), suggesting that their baseline 
cardiac phenotype is sufficient to meet the increased cardiovascular demands 
brought about by exercise. These results suggest that constitutively low glycolytic 
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Figure 19: Metabolic inflexibility disrupts cristae structure and causes 
mitochondrial dysfunction. (A) Electron micrographs of WT, GlycoLo, and GlycoHi
 
hearts. Arrows indicate areas of decreased cristae organization and density 
compared to WT controls; (B) State 3 and (C) State 4 respiration in isolated cardiac 
mitochondria measured using complex I (Pyruvate+Malate)- and complex II 
(Succinate)-specific substrates; (D) Respiratory control ratios. Data are 
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Figure 20: Low myocardial glycolytic rates are sufficient for maximal cardiac 
growth. Effects of exercise training on exercise capacity, cardiac growth, and 
mitochondrial function in WT and GlycoLo mice: Pre- and post-training (A) distance 
and (B) work; (C) Percent cardiac growth in exercise-adapted (Exe) mice 
compared to sedentary (Sed) controls. N = 10–11 per group; (D) Relative Mrna 
expression of genes associated with the physiological growth program. N = 5 per 
group; (E) State 3 respiration in isolated cardiac mitochondria using complex I 
(Pyruvate+Malate)-, complex II (Succinate)-, and fatty acid oxidation 
(Palmitoylcarnitine+malate)-specific substrates. N = 3 per group. Data are 





A B C D
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rate is sufficient to maximally activate physiologic cardiac growth. 
Because exercise could have beneficial effects on mitochondrial function,39 
we next posited that it might restore mitochondrial function in GlycoLo hearts. In 
WT mice, exercise did not affect state 3 respiration in the presence of any substrate 
tested, and, in GlycoLo mice, exercise did not reverse mitochondrial dysfunction 
caused by their metabolic phenotype (Fig. 20E).  
 
Glycolysis regulates gene expression in the heart. To gain further insight into the 
extent to which glycolysis might regulate myocardial gene expression, we 
assessed relative transcript abundance in GlycoLo and GlycoHi hearts. Results of 
Genechip® arrays showed that the expression of 2001 genes were significantly 
different in GlycoLo and GlycoHi hearts compared with hearts of corresponding WT 
mice (Up: GlycoLo, 7; GlycoHi, 309; Down: GlycoLo, 22; GlycoHi, 295 genes); 14 
differentially expressed genes overlapped in GlycoLo and GlycoHi hearts). As 
shown in Fig. 21A, the top 100 genes include genes critical for: intermediary 
metabolism, neurotransmission and ion channel activity/transport, DNA 
damage/repair, cell proliferation/differentiation, cell signaling, gene transcription, 
inflammation and stress responses, detoxification and xenobiotic metabolism, and 
cytoskeletal/contractile function. We were particularly interested in genes that are 
differentially regulated by glycolysis, i.e., affected in diametric opposition with 
respect to low or high glycolytic activity (Fig. 21B). In addition to Cited4, we found 
that glycolysis regulates the expression of genes involved in one-carbon 
metabolism and downstream methylation reactions (Pah, Phgdh, Mtr), lipid 
	 133	
Figure 21: Myocardial glycolysis coordinately regulates gene transcription 
in the heart. Results of transcriptomic analyses: (A) Robust Multi-array Average 
(RMA) analysis of top 100 genes that were found to be the most different based 
on the standard deviation across the samples; (B) Genes found to be 
coordinately regulated by glycolysis: Bars indicate genes with fold-changes at 
least 1.25-fold lower or higher in PFK2 mutant mice compared with WT controls. 
All genes shown were significantly different between GlycoLo and GlycoHi mice at 
p<0.05, after adjustment for the false discovery rate.  Significant differences from 
the WT controls (dotted line) using the same statistical analysis is shown by the 
asterisks (*FDR-adjusted p-value<0.05); (C) Gene ontology analysis of 
processes significantly regulated by low rates of glycolysis; and (D) Gene 
ontology analysis of processes significantly regulated by high rates of glycolysis. 








metabolism (Insg1, Angptl3), gluconeogenic activity (Fbp2), cell division (Cenpf), 
osmoregulation (Cenpf, Aqp4), transcription (Tox3), G-protein signaling (Ramp1), 
calcium-related processes (Rcan1, Cacna1g). Gene Ontology analysis showed 
that low rates of glycolysis had a strong influence on genes involved in in oxidation-
reduction processes, lipid metabolism, and responses to cAMP (Fig. 21C). High 
glycolytic rates also influenced genes involved in metabolism, responses to cAMP, 
responses to hormonal stimuli, and transcription. Additionally, genes involved in 
angiogenesis as well as differentiation showed highly significant changes (Fig. 
21D). Collectively, the findings of this study indicate that the activity of 
phosphofructokinase has pervasive effects on the metabolic, transcriptional, 
structural, and functional characteristics of the adult heart. 
 
Discussion 
In this study, we provide evidence suggesting that exercise dynamically 
regulates myocardial glycolytic activity at the level of phosphofructokinase. To 
assess the importance of exercise-induced periodicity in glucose metabolism, we 
used transgenic mice expressing mutant transgenes that constitutively increase or 
decrease phosphofructokinase activity in the heart. Expression of a dominant-
negative form of PFK2 (GlycoLo) in the heart decreased glycolytic rate and was 
sufficient to modulate the Cebpb/Cited4 transcriptional program that regulates 
physiologic cardiac growth.45, 46, 219 Mice in which myocardial glycolytic rate is 
constitutively high also showed slight hypertrophy, but these hearts did not engage 
the physiologic growth gene program. The corollary of these findings is that 
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exercise-induced changes in phosphofructokinase activity are necessary to 
activate transcriptional programs dictating cardiac growth and hypertrophy. This is 
supported by our transcriptomics data from both GlycoLo mice and GlycoHi mice, 
which revealed coordinated regulation of not only the Cited4 gene, but genes 
important for epigenetic regulation, lipid metabolism, gluconeogenic activity, 
contractility, and angiogenesis as well. Nevertheless, constitutive changes in 
myocardial metabolism incited damage to the mitochondrial compartment. 
Collectively, these results suggest that episodic decreases in glycolytic activity 
caused by exercise are required for physiologic cardiac remodeling and that 
metabolic flexibility is important to maintain mitochondrial health in the heart. 
Our findings in the heart are reminiscent of exercise-induced changes in 
skeletal muscle, where transient and repetitive changes in gene expression, likely 
initiated by acute disruption of metabolic equanimity during exercise, stimulate 
adaptation.8 Although testing the role of metabolic periodicity in the heart is difficult, 
the post-translational regulation of PFK2 that we found to occur with exercise 
provided a unique opportunity to test not only how glucose utilization affects the 
cardiac phenotype, but how restricting fuel flexibility regulates cardiac structure, 
function, and gene expression as well. The dominant-negative approach to 
overcome the activity of endogenous myocardial PFK2, i.e., expression of the 
kinase-deficient form of PFK2, was sufficient to trigger a physiologic cardiac growth 
phenotype: GlycoLo hearts showed lower Cebpb and higher Cited4 expression, 
which mirrored the transcriptional changes found in the exercise-adapted heart. 
This transcriptional signature was complemented by a cardiac growth phenotype 
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replete with enlarged myocytes and increased capillary density as well as cardiac 
chamber volumes, wall thicknesses, and functional values that were nearly 
identical to that found in the exercise-adapted heart. GlycoLo hearts appear to have 
a maximal functional and structural physiologic growth phenotype because they 
could not further activate the physiologic growth gene program or undergo 
additional cardiac growth in response to the exercise regimen. Importantly, the 
phenotype of GlycoLo hearts developed in the absence of AKT activation, which 
has been suggested to underlie exercise-induced downregulation of Cebpb and 
upregulation of Cited4 and the general cardiac growth phenotype.27, 218 Thus, 
these data help form a model in which exercise-induced modulation of glucose 
metabolism is a proximal regulator of physiologic cardiac growth.  
Several factors appear to contribute to acute, exercise-induced decreases 
in glycolysis and phosphofructokinase activity. The lower circulating blood glucose 
levels and increased levels of blood lactate and free fatty acids that we found to 
occur immediately after a single bout of exercise suggest diminished glycolytic 
activity occurring in the heart during and in the early recovery period after exercise.  
Indeed, lactate and fatty acids are preferred substrates of the heart that suppress 
glucose utilization both in vivo75, 77, 84 and ex vivo.78, 79 Moreover, previous studies 
in humans and animal models suggest that changes in these substrates during 
exercise contribute to diminished exercise oxygen extraction ratios for glucose and 
lower glucose uptake and utilization.87, 109   Not only do increases in circulating 
lactate and fatty acids with exercise appear to favor lower rates of glucose 
utilization, they divert glucose from glycolysis to glycogen synthesis, which is 
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thought to be caused in part by diminished phosphofructokinase activity.86, 130, 240 
Consistent with this idea, our results show diminished phosphorylation of S483 of 
PFK2 and increased levels of glycogen, which support the hypothesis that PFK1 
activity and glycolysis are diminished with prolonged exercise or during the early 
recovery period.  In the context of glucose utilization, changes in PFK1 are 
particularly important because this node of metabolism represents the major 
control point of glycolysis, exerting 65% control over flux through the pathway.235  
Although constitutively low glycolytic rates appeared sufficient to drive 
physiologic growth, metabolic inflexibility in both the GlycoHi and GlycoLo hearts 
appeared sufficient to cause some pathology as well. While GlycoHi hearts were 
enlarged, they did not demonstrate significantly increased capillary-to-myocyte 
ratios; and, functionally, they presented with a mildly diminished ejection fraction, 
significantly higher end systolic volume, and larger chamber diameters.  These 
findings are in agreement with previous studies221 and suggest that chronically 
high rates of glycolysis promote a more pathological form of hypertrophy. 
Furthermore, that mitochondria isolated from both GlycoHi and GlycoLo hearts 
showed mitochondrial dysfunction suggests that deleterious changes in 
mitochondria occurring in the heart in the context of type II diabetes or heart 
failure—conditions associated with excessive myocardial reliance on fatty acids or 
glucose, respectively 88, 241—could be in part caused by severe metabolic 
inflexibility. Although genetic downregulation of Cebpb and upregulation of Cited4  
protect against pathologic insults,45, 46 mice with constitutively low glycolysis 
subjected to pressure overload display exacerbated pathological remodeling,242 
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which we suggest may be due to poor mitochondrial health caused by metabolic 
inflexibility.  
Although at steady state the exercise-adapted heart showed higher 
glycolytic activity, we found relatively few changes in metabolite abundance. We 
speculate that higher myocardial metabolic flux in the absence of changes in the 
steady state abundance of metabolites may be an indication of a physiological form 
of metabolic remodeling that occurs in the exercise-adapted heart.  However, it 
should be noted that our results contrast somewhat with a previous finding that 
showed modestly lower abundances of acylcarnitines and organic acids in hearts 
of female mice adapted to two months of voluntary wheel running.243  The 
discrepancy between these two studies could be due to sex differences, strain 
differences, differences in the training modality and/or intensity. Additionally, these 
differences could be due to different methods by which hearts are handled prior to 
freezing for metabolomics analysis, which is an important consideration given the 
high-energy utilization of mouse heart.  
Although our data support the idea that PFK-mediated modulation of 
metabolism influences transcriptional programs relating to cardiac growth and 
remodeling, it is possible that fat utilization or lactate oxidation, which are regulated 
in concert with glucose metabolism, are also important triggers of cardiac 
adaptation. Future studies to determine how exercise acutely changes the cardiac 
metabolome could help answer whether changes in metabolites in each pathway 
during or shortly after exercise promote biofeedback that coordinates 
transcriptional programming. Moreover, identifying how exercise intensity and 
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duration regulate cardiac metabolism and gene transcription would be important 
for optimizing cardiac adaptations and for further understanding links between 
metabolism and cardiac growth. Particularly intriguing is the question of how such 
changes in metabolism may regulate epigenetic modifications. In our study, we 
found that glycolysis regulated Phgdh, Mthfd2, and Mtr, which code for proteins 
critical for serine biosynthesis, one-carbon metabolism, and methylation reactions. 
This could be significant because Cited4 is epigenetically regulated: 
hypermethylation of Cited4-associated CpG islands causes lower expression of 
Cited4 in oligodendroglial tumors.244 While our data do not address this 
mechanism, they suggest that low glycolytic rates could prevent such methylation 
events, thereby permitting Cited4 transcription, especially when appropriate stimuli 
are present.   
In summary, our results indicate that low rates of glycolysis during or shortly 
after exercise regulate gene programs important for cardiac growth and that 
invariantly high rates of glycolysis promote a more pathological form of 
hypertrophy. While metabolic inflexibility is damaging to mitochondria, changes in 
glucose utilization due to regular exercise appear to be important to maintain 
mitochondrial health and to derive maximal cardiac benefits from physical activity. 
In addition, by integrating metabolomic and transcriptomic data, these studies 
provide new insights into how PFK-mediated changes in metabolism regulate gene 
expression in the heart. Additional work is needed to further disclose how exercise-
mediated changes in metabolism regulate gene transcription and tissue 
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remodeling and how these changes could be targeted to maximize the beneficial 
cardiovascular effects of exercise.ii
ii This chapter previously appeared as an article in the journal Circulation. The original 
citation is as follows: Gibb AA, et al. Exercise-induced changes in glucose metabolism 
promote physiologic cardiac growth. Circulation, 2017. 
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CHAPTER IV 
INTEGRATION OF FLUX MEASUREMENTS TO RESOLVE CHANGES IN 
ANABOLIC AND CATBOLIC METABOLISM IN CARDIAC MYOCYTES 
 
Introduction 
Glycolysis is the central pathway of intermediary carbon metabolism. Not 
only does catabolism of glucose via glycolysis provide useable energy for the cell, 
but it contributes glycolytic intermediates that serve as branch-point metabolites 
for the entry of glucose-derived carbon into ancillary pathways of glucose 
metabolism. These pathways are required for de novo synthesis of cellular 
components. For example, the activity of the pentose phosphate pathway (PPP) is 
required for nucleotide biosynthesis and the maintenance of cellular redox state, 
whereas the hexosamine biosynthetic pathway (HBP) regulates posttranslational 
protein modifications, protein processing, and stress responses. The synthesis of 
glycero(phospho)lipids  and  serine  are also dependent on the production of 
glycolytic intermediates.245 In the heart, the PPP is activated during hypertrophy132-
134 and heart failure,135 and modulating the activity of this pathway regulates the 
severity of cardiac pathology.136-141 Similarly, O-linked β-N-acetylglucosamine (O-
GlcNAc)-modified proteins, which require synthesis of the sugar donor UDP-
GlcNAc via the HBP,147, 246 are elevated in hypertrophied and failing hearts.223, 247-
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249 Although less is known about the glycerolipid pathway (GLP), increased activity 
of this pathway may underlie pathologic cardiac hypertrophy.142 In addition, 
numerous studies have identified aberrant ancillary pathway behavior in the 
context of diabetes [e.g., as reviewed in 250, 251]. 
The activities of ancillary pathways of glucose metabolism are regulated in 
part through expression of their rate-limiting or committed-step enzymes, cofactor 
availability, allosterism, and/or post-translational modifications [e.g., 252-258]. Flux 
through these pathways may be regulated by other means as well. Specific 
enzymatic reactions in the glycolytic pathway, especially the phosphofructokinase 
1 (PFK1) reaction, can coordinate the activity of ancillary pathways in several cell 
types143-146; however, the effects of PFK activity and glycolytic rate on biosynthetic 
pathway flux in the heart remain unclear. Understanding how PFK regulates 
ancillary biosynthetic pathway activity is important because its activity is modulated 
by increased work ex vivo,259, 260 and catecholamines261 and pressure overload in 
vivo.262  
In this study, we examined how PFK activity regulates biosynthetic 
pathways in cardiomyocytes. For this, we altered PFK1 activity by expressing 
mutant forms of phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK2) in 
primary rat neonatal cardiomyocytes. This method of regulating glycolysis 
leverages the strong allosteric regulation of PFK1 by F-2,6-P2184, 220, 221, 263 and is 
relevant to mechanisms regulating cardiovascular homeostasis. For example, 
kinases known to be important for cardiac responses to stress27, 264 are strong 
regulators of PFK2 activity.236, 265-267 By integrating radiometric assays, stable 
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isotope tracing, and extracellular flux analyses, we demonstrate that the amount 
of glucose available for entry into ancillary pathways appears relatively high and 
that the PFK node of glycolysis exerts varying degrees of control over glucose 
incorporation in the end products of the PPP, the HBP, and the GLP by not only 
diverting glucose carbon into these pathways, but by regulating mitochondrial 
activity and cataplerosis as well.   
 
Experimental Procedures 
Materials. DMEM growth media, containing L-glutamine, D-glucose, and pyruvate, 
was purchased from US Biological (Swampscott, MA, USA). Insulin, transferrin 
and selenium (500×) were purchased from Lonza (Walkersville, MD, USA). 
Humulin R was from Eli Lilly (Indianapolis, IN, USA). All other reagents were from 
Sigma-Aldrich Corp. (St. Louis, MO, USA), unless indicated otherwise. 
 
Rodent models. All procedures were approved by the University of Louisville 
Institutional Animal Care and Use Committee and were in accordance with NIH 
guidelines. The euthanasia procedures were consistent with the AVMA Guidelines 
for the Euthanasia of Animals. Neonatal rat cardiomyocytes (NRCMs) were 
isolated from 1- to 2-day-old Sprague-Dawley rats as previously described.149, 268, 




Gene transfer and expression analysis. Replication-deficient adenoviral vectors 
were constructed and purified by Vector BioLabs (Malvern, PA, USA) using cDNA 
for mutated forms of rat liver 6-phosphofructo-2-kinase/Fru-2,6-P2 bisphosphatase 
(PFKFB1 isoform of PFK2). The enzyme was engineered to have single amino 
acid point mutations to foster a kinase deficient- (S32D and T55V; GlycoLo) or 
phosphatase deficient- (S32A and H258A; GlycoHi) form of PFK2.220, 221, 270-272 A 
1.4 kb BamHI/Nhe1 fragment of a pLenti6-3×FLAG-pd-PFK2 plasmid was 
subcloned into a Dual-CCM(+) shuttle vector, which has dual CMV promoters to 
drive both green fluorescent protein (GFP) and the insert. The backbone of the 
adenoviral vector is type 5 (dE1/E3). An Ad-GFP control virus, in which GFP is 
driven by the CMV promoter, was also purchased from Vector BioLabs. 
Cardiac myocytes were transduced with adenovirus for 4 h in fresh media, 
followed by PBS wash and addition of fresh media. For all viral treatments, a 
multiplicity of infection (MOI) of 50 was used. Functional expression of the target 
protein was confirmed by immunoblotting and eGFP fluorescence. For measuring 
protein abundance, cells were lysed in a common lysis buffer containing 20 mM 
HEPES, 110 mM KCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, and phosphatase and 
protease inhibitors. Cell lysates were then centrifuged at 13,000g for 20 min and 
the supernatant was collected. Protein was measured using the standard Lowry 
Assay (Bio-Rad Laboratories, Hercules, CA, USA) and separated by SDS-PAGE, 
electroblotted to PVDF membranes, and probed for PFKFB1 (Novus Biologicals, 
Littleton, CO, USA) according to manufacturer’s protocol. A horseradish 
peroxidase-linked secondary antibody (Cell Signaling Technology, Danvers, MA, 
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USA) was used to detect and visualize the protein band with a Typhoon 9400 
variable mode imager (GE Healthcare, Chicago, IL, USA). 
 
Radiolabeled glycolysis assay. The rate of glucose utilization was determined 
using [5-3H]-glucose as previously described.224, 273, 274 Briefly, after 48 h of 
transduction, the media was replaced with 2 ml of fresh, serum-free media 
containing 5.5 or 25 mM glucose with the addition of 2 µCi/ml [5-3H]-glucose 
(Moravek Biochemicals, Brea, CA, USA). Following incubation for 3 h, 100 µl of 
media was collected and added to 100 µl of 0.2 M HCl in a microcentrifuge tube. 
This tube, with the tube cap removed, was placed in a scintillation vial containing 
500 µl of dH2O to allow for evaporation diffusion of [3H]2O in the microcentrifuge 
tubes into the scintillation vials. To account for incomplete equilibration of [3H]2O 
and background, known amounts (µCi) of [5-3H]-glucose and [3H]2O (Moravek 
Biochemicals) were placed into microcentrifuge tubes, and these were placed into 
separate scintillation vials containing 500 µl dH2O. After incubation at 37ºC for 72 
h, the microcentrifuge tube was removed from the vial, 10 ml of scintillation fluid 
was added, and scintillation counting was performed using a Tri-Carb 2900TR 
Liquid Scintillation Analyzer (Packard Bioscience Company, Meriden, CT, USA). 
Glucose utilization was then calculated as reported by Ashcroft et al.,224 with 
considerations for the specific activity of [5-3H]-glucose, incomplete equilibration 
and background, dilution of [5-3H]- to unlabeled-glucose, and scintillation counter 
efficiency. To normalize glucose utilization to total protein, the cells were first 
washed with PBS (to remove any adherent radioactivity) and then lysed in common 
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lysis buffer. After centrifugation, protein concentration was measured using the 
Lowry assay kit (Bio-Rad Laboratories).  
 
Stable Isotope Tracing. NRCMs were incubated in 6-well plates for 18 h in glucose-
free DMEM media containing 1 mM pyruvate and 4 mM glutamine and 
supplemented with 25 mM [13C6]-glucose. Cell reactions were then quenched in 
cold acetonitrile, and extracted in acetonitrile:water:chloroform (v/v/v, 2:1.5:1), as 
described previously,184, 275-277 to obtain the polar, nonpolar, and insoluble 
proteinaceous fractions. The nonpolar (lipid) layer was collected, dried under a 
stream of nitrogen gas, and reconstituted in 0.1 ml of 
chloroform:methanol:butylated hydroxytoluene (2:1 + 1 mM) mixture. The extract 
was diluted 10× with 1 mM butylated hydroxytoluene solution in methanol and used 
for Fourier transform ion cyclotron resonance-mass spectrometry (FTICR-MS) 
analysis. 
 For stable isotope nucleotide analysis, the samples were prepared using a 
previously published protocol,184, 277 with slight modifications. Briefly, lyophilized 
polar extracts were reconstituted in 50 μl of 5 mM aqueous hexylamine, adjusted 
to pH 6.3 with acetic acid (solvent A). Samples were then loaded onto a 100-μl 
capacity C18 tip (Thermo Fisher Scientific, Waltham, MA, USA) followed by 
washing twice with 50 μl of solvent A. The metabolites were eluted with 70% 
solvent A and 30% 1 mM ammonium acetate in 90% methanol, pH 8.5 (solvent B). 
The resulting eluates were diluted 3× with methanol and analyzed via FTICR-MS. 
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[13C6]-glucose and [13C3]-lactate measurements in the media. For quantification of 
[13C6]-glucose and [13C3]-lactate in cell media, 10 μL of media were mixed with 
9990 μL of 5 mM NH4OH in methanol containing 5 μM [D2]-glucose and 5 μM [D2]-
lactate internal standard and used without any additional pre-treatment for FTICR-
MS analysis and quantification.  Blank incubations without cells were run in 
parallel. The concentrations of [13C]-labeled glucose and lactate were assessed 
using seven-point calibration curves (0.3125 µM to 20 µM). 
 
FTICR-MS Analysis. Lipid and nucleotide spectra and [13C]-glucose/lactate 
spectra were acquired using a hybrid linear ion trap-FT-ICR mass spectrometer 
(Finnigan LTQ FT; Thermo Electron, Bremen, Germany), equipped with a TriVersa 
NanoMate ion source (Advion Bio-Sciences, Ithaca, NY, USA) with an A 
electrospray chip (nozzle inner diameter, 5.5 μm). The TriVersa NanoMate was 
operated by applying 1.5 kV with 0.5 psi head pressure in positive ion mode and 
1.6 kV and 0.7 psi in the negative mode. High mass accuracy data were collected 
using the FT-ICR analyzer over a mass range from 150 to 1600 Da (lipids; + and 
– mode) for 15 min at the target mass resolution of 400,000 at 400 m/z. For 
quantification of 13C6-glucose and 13C3-lactate in cell media, data were collected in 
the negative ion mode for 2 min over a mass range from 50 to 250 Da at the target 
mass resolution of 100,000 at 400 m/z. Prior to acquisition, the LTQ-FT was tuned 
and calibrated according to the manufacturer’s default recommendations to 
achieve mass accuracy of 2 ppm or less. 
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Stable Isotope Data Analyses. The FT-ICR MS data were exported as exact mass 
lists into a spreadsheet file using Qual-Browser 2.0 (Thermo Electron). 
Isotopologue peak deconvolution, assignment, natural isotope abundance 
stripping, and quantification were performed using MetSign software, as described 
previously by us.184, 278   
  
Extracellular flux analysis of cellular energetics. To measure cellular energetics in 
intact cardiomyocytes, the Seahorse Bioscience XF24 extracellular flux analyzer 
was used as previously described.279 For this, 75,000 cells were plated into each 
well. An hour before each experiment, the media was replaced with 675 µl of assay 
media, i.e., unbuffered DMEM containing glucose (5.5 mM), glutamine (4 mM), and 
pyruvate (1 mM), pH 7.4. Following 1 h in a 37ºC, CO2-free incubator, the cells 
were placed in the instrument for analysis. Basal oxygen consumption rates (OCR) 
and extracellular acidification rates (ECAR) were measured using a programmed 
protocol: 3 cycles of 2 min mix, 2 min wait, and 3 min measure. To interrogate the 
effects of each treatment on cardiomyocyte bioenergetics, the following 
compounds were injected into each well with 2 cycles of 2 min mix, 2 min wait, 3 
min measure following each injection: Port A, oligomycin (Oligo; 1 µM); Port B, 
carbonyl cyanide-p-(trifluoromethoxy)phenylhydrazone (FCCP; 1 µM); and Port C, 
antimycin A and rotenone (AA/Rot; 10 µM / 1 µM). The OCR and ECAR values 
were normalized to the total amount of protein in each well. 
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Statistical Analysis. All values are mean ± S.E.M. All comparisons were made to 
the relevant control group and performed using one-way analysis of variance 
(ANOVA) with Dunnett’s correction for multiple comparisons. The null hypothesis 
was rejected when p > 0.05. 
 
Results 
PFK regulates glycolysis and the distribution of glucose.  To understand the role 
of PFK activity in cardiac myocyte metabolism, we expressed kinase-deficient 
(GlycoLo) or phosphatase-deficient (GlycoHi) PFK2 mutant constructs in NRCMs, 
which are conducive to well-controlled and detailed metabolic flux analyses. The 
mutant genes were driven by a CMV promoter (Fig. 22A), and the bicistronic 
vector also contained GFP, used to determine relative transduction efficiency. As 
shown in Fig. 22B, the vast majority of NRCMs were transduced with virus. These 
PFK2 mutants were intentionally derived from the liver-specific isoform of PFK2 
(i.e., PFKFB1) so that expression of the proteins could be assessed by 
immunoblotting, without obfuscation by other isoforms (e.g., PFKFB2/PFKFB3). 
Myocytes transduced with the GlycoLo or the GlycoHi constructs showed strong 
bands at the predicted molecular mass for the mutant forms of PFK2, whereas 
cells transduced with Ad-GFP showed no expression of PFKFB1 (Fig. 22C). 
Although GlycoHi-expressing cells routinely displayed a higher level of mutant 
protein expression relative to GlycoLo-expressing cells, the strength of the relative 
effect of each PFK2 mutant on cellular glycolytic rate was equal, with a 2.1-fold 
increase and 2.2-fold decrease in glycolytic rate for the GlycoHi and GlycoLo  
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Figure 22: Phosphofructokinase activity regulates glucose metabolism in 
isolated cardiomyocytes. Glucose utilization analyses in neonatal rat 
cardiomyocytes: (A) Constructs of kinase-deficient and phosphatase-deficient 
PFK2 engineered to decrease (GlycoLo) or increase (GlycoHi) glycolytic rate, 
respectively; (B) GFP expression in cardiomyocytes 48 h after transduction (50 
MOI) with adenoviruses expressing GFP only or the GlycoLo or GlycoHi 
adenoviruses; (C) Immunoblot of mutant PFK2 protein expression; (D) Glycolytic 
rate measured with [5-3H]-glucose under 5.5 or 25 mM glucose culture conditions. 
n = 3–5 independent isolations per group; (E) 13C6-glucose uptake; (F) 13C3-lactate 
production, and (G) the percentage of glucose converted to lactate following 18 h 
incubation with isotopic glucose.  Data in Panels E–G represent three replicates 
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constructs, respectively (Fig. 22D). This effect on glycolytic rate was independent 
of glucose concentration, as rates were similar for groups incubated with either 5.5 
or 25 mM glucose.  
To examine the effect of each mutant PFK2 enzyme on aerobic glycolysis, 
we replaced the normal growth media with media containing [13C6]-glucose and, 
after 18 h, measured the relative levels of [13C6]-glucose and [13C3]-lactate in the 
media. As shown in Fig. 22E, the levels of [13C6]-glucose consumed by the cell 
was 1.8-fold higher in GlycoHi-expressing cells compared with Ad-GFP, with no 
difference in GlycoLo-expressing cells. Levels of [13C3]-lactate extruded into the 
media was 2.5-fold higher in GlycoHi cells compared with GFP control cells and 
>10-fold higher compared with GlycoLo virus transduced cells (Fig. 22F). As shown 
in Fig. 22G, 29% of [13C6]-glucose was metabolized to [13C3]-lactate in GFP control 
cells, whereas in GlycoLo-expressing cells, 6% of labeled glucose was metabolized 
to lactate; in GlycoHi-expressing cells, 44% of labeled glucose was converted to 
lactate.   
Assessment of [13C6]-glucose uptake, [13C3]-lactate production, and [5-3H]-
glucose utilization provides estimates of not only how much glucose entered the 
cell and was later extruded as lactate, but also how much made it through the 
enolase step of glycolysis, where the tritiated label is eliminated as 3H2O. The 
mean values of glucose uptake and lactate production (provided by stable isotope 
tracing) and of radiometric measurements were used to calculate the amount of 
glucose unaccounted for by catabolism to pyruvate. In GFP control 
cardiomyocytes, only 44% of glucose was catabolized past the enolase step in 
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glycolysis; of this fraction, the majority (65%) was converted to lactate (Fig. 
23A,B). These data show that, under control conditions, a substantial amount of 
glucose taken up by NRCMs is not catabolized to pyruvate and that the majority of 
glucose that is catabolized to pyruvate is fated for lactate production. 
As shown in Fig. 1E, glucose uptake was not different between GFP and 
GlycoLo cells, yet GlycoLo myocytes demonstrated 2-fold lower glucose utilization 
through the enolase step of glycolysis and 5-fold lower lactate production.  In these 
cells, 78% of glucose-derived carbon was partitioned upstream of the enolase 
reaction, leaving 22% available for pathways downstream of enolase (Fig. 23B). 
Although lactate production was markedly suppressed in GlycoLo cells, the 
absolute amount of glucose-derived carbon available for either mitochondrial 
oxidation, transamination to alanine, or carboxylation to oxaloacetate was identical 
to that of control cells. Interestingly, while GlycoHi cells showed 80% higher levels 
of glucose uptake compared with GFP control cells (see Fig. 1E), 44% of glucose 
(by mass) was not catabolized via glycolysis. Nevertheless, a portion of glucose 
equivalent to that apportioned upstream of enolase (0.67 nmol/h/µg protein) taken 
into the cell could be accounted for as lactate (0.66 nmol/h/µg protein), and 21% 
of glucose carbon that was catabolized past the enolase reaction was available for 
fates other than lactate production (Fig. 23B).  
 
PFK activity regulates glucose carbon partitioning into the PPP in NRCMs.  To 
determine how the activity of PFK regulates critical anabolic reactions derived from 
glycolysis, we modulated glycolytic rate by expressing the GlycoLo or GlycoHi PFK2  
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Figure 23. Phosphofructokinase-mediated glucose distribution in isolated 
cardiomyocytes. Schematics illustrating glucose utilization in myocytes 
transduced with GFP, GlycoLo or GlycoHi adenoviruses. Measurements from 
radiometric and isotopic glucose utilization assays were used to delineate glucose 
distribution in neonatal rat cardiomyocytes transduced with each virus. (A) 
Schematic illustrating glucose distribution in control (GFP) myocytes.  Distributions 
of glucose are drawn to relative scale. (B)  Pie chart illustrating distribution of 
glucose: Numbers (in nmol/h/µg protein) and percentages (%) indicate the 
absolute and relative distribution of glucose ascribed to the portions of glucose 
metabolism: upstream of enolase (light red), through enolase (grey shading), 
converted to lactate (yellow) and available for transamination to alanine, 
anaplerotic formation of oxaloacetate (OAA), or glucose oxidation (light blue). Pie 
charts are drawn to scale. Both schematics consider glucose uptake and lactate 
production provided by 13C-glucose tracing and by glucose utilization measured by 







mutants in cardiomyocytes and then assessed carbon incorporation into end 
products of ancillary biosynthetic pathways using stable isotope-resolved 
metabolomics.280 Expression of the GlycoHi mutant modestly diminished 
incorporation of glucose-derived carbon into ATP. Lower fractional enrichment of 
13C in GlycoHi-expressing cells is attributable to decreased carbon allocation into 
the phosphoribosyl ring of the nucleotide (m+5 isotopologue) (Fig. 24A, 24B), 
suggesting diminished flux of 13C-labeled glucose-6-phosphate (G6P) through the 
oxidative PPP (oxPPP). The higher level of the m+0 isotopologue of ATP (i.e., the 
unlabeled ATP pool) in GlycoHi cells further indicates that the flux of 13C6-G6P 
through the oxPPP was lower in GlycoHi cells. Similar changes were observed in 
other purines such as GTP (Fig. 24C). Myocytes expressing the GlycoLo mutant 
showed 13C fractional enrichment values into ATP that were similar to GFP-
transduced control cells (Fig. 24A, 24B), suggesting that low PFK activity does not 
strongly affect purine synthesis in these cells.  
For the pyrimidines CTP and UTP, we found a higher m+0 isotopologue 
value in GlycoHi cells and a lower m+0 isotopologue value in GlycoLo cells 
compared with GFP controls. These data suggest that high rates of glycolysis 
diminish incorporation, and that low rates of glycolysis increase incorporation, of 
glucose-derived carbon into pyrimidines (Fig. 24D, 24E). Interestingly, both the 
GlycoLo and the GlycoHi NRCMs showed increased levels of CTP and UTP having 
only the ribose ring labeled (m+5 isotopologue). These data could indicate that 
either decreasing or increasing glycolysis augments oxPPP flux. This 
interpretation would be consistent with the observation that both GlycoLo and  
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Figure 24: Phosphofructokinase coordinates pentose phosphate pathway 
activity. Isolated cardiomyocytes were transduced with GFP, GlycoLo, or GlycoHi 
adenoviruses and incubated with 13C6-glucose for 18 h. Stable isotope tracing of 
nucleotides in NRCMs incubated with media containing U-13C-glucose: (A) Atom-
resolved map illustrating the biological and biochemical history of 13C incorporation 
into the purine AMP (phosphates in ATP omitted to conserve space); Fractional 
enrichment values of 13C in (B) ATP and (C) GTP after incubation with 13C-glucose; 
(D) Atom-resolved map illustrating the biological and biochemical history of 13C 
incorporation into the pyrimidine UMP; Fractional enrichment values of 13C in (E) 
UTP and (F) CTP after incubation with 13C-glucose. Colored x-axis labels correlate 
to the labeled molecule biosynthetic components indicated in the atom-resolved 
maps. Graph represents three replicates per group from one isolation. *,$ p<0.05, 
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GlycoHi cells show more glucose available for entry into ancillary biosynthetic 
pathways (see Fig. 2); however, it is also possible that higher levels of m+5 labeling 
could be due to an accumulation of these pyrimidine isotopologues, where the 
contribution of 13C-glucose to de novo synthesis of the uridine ring is diminished. 
Indeed, examination of the m+7 and m+8 isotopologues of UTP, which likely 
correspond to addition of carbons from 13C-labeled aspartate to the molecule (see 
Fig. 3D), show that both the GlycoLo and GlycoHi cells have less incorporation of 
13C, which is known to derive from Krebs cycle- (m+7) or pyruvate carboxylase-
engendered (m+8) oxaloacetate. The m+6 isotopologue likely corresponds to 
complete 13C5-labeling of the ribose ring and 13C1 labeling of aspartate, occurring 
as a result of scrambling during the 2nd turn of the Krebs cycle, as suggested 
previously.281 Overall, these data suggest that high PFK activity modestly 
diminishes oxPPP flux and 13C incorporation into purines. Pyrimidine synthesis 
appears to be more robustly affected by PFK activity, with high rates of glycolysis 
diminishing incorporation of glucose-derived carbon into UTP and CTP molecules. 
 
High PFK activity diminishes glucose-derived carbon incorporation into UDP-
HexNAc. The molecular synthesis of UDP-N-acetyl hexosamines requires end 
products or intermediates of several metabolic pathways, including those from the 
Krebs cycle, the pyrimidine biosynthetic pathway, glutamine, and glycolysis; 
hence, these pathways collectively contribute to UDP-HexNAc synthesis (Fig. 
25A). To determine how the glycolytic activity affects glucose-derived carbon 
allocation into the HBP, we measured fractional enrichment of 13C from [13C6]-
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glucose into UDP-HexNAc in NRCMs transduced with GlycoLo or GlycoHi virus. 
After 18 h, >90% of the UDP-HexNAc pool integrated 13C-glucose-derived carbon 
(Fig. 25B), which suggests that UDP-HexNAc has a faster rate of glucose carbon 
incorporation relative to purines and pyrimidines. That the m+0 isotopologue was 
higher in GlycoHi cells indicates that high rates of glycolysis diminish glucose 
carbon incorporation into UDP-HexNAc. The lower 13C enrichment of many 
isotopologues (e.g., m+7, m+14, m+15, m+16) appeared to be due to diminished 
input of metabolites that require mitochondrial transformation of 13C-glucose-
derived carbon; however, the m+5, m+6, and m+11 isotopologues (which are the 
forms of UDP-HexNAc with the ribose, hexose, and ribose+hexose moieties 
constituted with 13C, respectively) demonstrate significantly higher fractional 
enrichment in GlycoHi cells. Given that both the GlycoLo and the GlycoHi cells had 
similar levels of glucose available for reactions upstream of enolase (see Fig. 2), 
the simplest explanation for this result is that the mitochondrial cataplerotic 
metabolites (deriving from the 13C-glucose-derived carbon source) are limiting for 
the synthesis of UDP-HexNAc; as a result, the m+5 and m+6 isotopologues of the 
metabolite accumulate as 13C incorporation from cataplerotic metabolites slows 
down. This would be consistent with findings in pyrimidines, which suggest that 
cataplerotic generation of aspartate is limiting for the incorporation of glucose-
derived carbon into CTP and UTP.  
Although low rates of glycolysis did not affect the overall level of 
incorporation of glucose-derived carbon into UDP-HexNAc, that the m+11 
isotopologue in GlycoLo cells was higher than that in control cells suggests that low  
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Figure 25: High phosphofructokinase activity diminishes glucose carbon 
incorporation into UDP-HexNAc. Isolated cardiomyocytes were transduced with 
GFP, GlycoLo, or GlycoHi adenoviruses and incubated with 13C6-glucose for 18 h. 
Stable isotope tracing of UDP-HexNAc in NRCMs incubated with media containing 
13C-glucose: (A) Atom-resolved map illustrating the biological and biochemical 
history of 13C incorporation into UDP-GlcNAc; (B) Fractional enrichment values of 
13C in UDP-HexNAc (which includes both UDP-GlcNAc and UDP-GalNAc) after 
incubation with 13C6-glucose Colored x-axis labels correlate to the labeled 
molecule biosynthetic components indicated in the atom-resolved maps. Graph 
represents three replicates per group from one isolation. *,$ p<0.05, **,$$ p<0.01, $$$ 

















PFK activity promotes channeling of F6P not only into the HBP (contributing six 
13C), but, because the ribose ring is included (contributing five 13C), the PPP as 
well (Fig. 25A, 25B). Changes in the m+8 isotopologue are difficult to interpret 
because this isotopologue could be comprised of 13C-labeled N-acetyl hexosamine 
as well as stably labeled UDP. Altogether, these results suggest that high PFK 
activity decreases glucose carbon allocation into UDP-HexNAc primarily via 
limiting the mitochondria-derived and cataplerotic intermediates (e.g., acetyl CoA, 
aspartate) derived initially from 13C-glucose.  
 
PFK regulates glycerolipid synthesis in cardiomyocytes.  In cardiac myocytes, 
glycerolipid synthesis requires free fatty acids (FFAs) and glycerol-3-phosphate 
(G3P). While FFAs can be derived from transporter-mediated uptake  across the 
plasma membrane,282 myocytes have a relatively low capacity for free glycerol 
uptake; therefore, there is little contribution of glycerol kinase to G3P synthesis.283, 
284 However, G3P can be generated from DHAP by glycerol-3-phosphate 
dehydrogenase (Fig. 26A). Nevertheless, it is unclear whether or how the rate of 
glycolysis affects glycerolipid synthesis. We found that in comparison with cells 
transduced with GFP virus, the GlycoLo cells showed diminished incorporation of 
13C from 13C6-glucose into the glycerol (m+3) moiety of phosphatidylcholine (PC; 
Fig. 26B), phosphatidylinositol (PI; Fig. 26C), phosphatidylethanolamine (PE; Fig. 
26D), and phosphatidylserine (PS; Fig. 26E). Incorporation of 13C6-glucose-
derived carbon into fatty acids in PC, PI, PE, and PS was not different in GlycoLo 
cells compared with control cells, suggesting that only the synthesis of the glycerol 
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backbone portion of these phospholipids is affected by low rates of glycolysis. 
High glycolytic rates affected 13C incorporation into phospholipids to a 
lesser extent.  Although PE synthesis showed a slight increase in 13C fractional 
enrichment in glycerol (and a concomitant decrease in fractional enrichment of the 
unlabeled pool) (Fig. 26D), PI showed diminished labeling characterized by lower 
incorporation of 13C into fatty acids. Glycerol 13C labeling in PI from GlycoHi cells 
was identical to that of control cells. This dichotomy in labeling patterns in different 
phospholipids could suggest the presence of unique enzyme complexes that 
participate in metabolic channeling for the synthesis of distinct glycerolipids. 
Consistent with this idea, triacylglycerol (TAG) labeling was remarkably different 
from that of other glycerolipids. As shown in Fig. 26F, TAG species collectively 
showed little 13C in the glycerol moiety. Furthermore, low rates of glycolysis had 
little effect on glucose carbon incorporation into TAGs; however, GlycoHi cells 
showed lower 13C incorporation into fatty acids. Collectively, these results suggest 
that, in isolated NRCMs, low rates of glycolysis diminish phospholipid synthesis by 
the DHAPàG3P pathway and that high rates of glycolysis decrease incorporation 
of glucose-derived carbon into the fatty acyl chains of PI and TAGs. 
 
PFK activity regulates mitochondrial activity in NRCMs: Stable isotope labeling 
patterns of several end products of the PPP, HBP, and GLP suggest that high PFK 
activity diminishes the relative abundance of those 13C isotopologues that require 
metabolites derived from mitochondria. This suggests that cataplerosis285 is 
diminished under conditions of high PFK activity. Because cataplerotic reactions  
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Figure 26: Phosphofructokinase regulates glycerolipid biosynthesis. Stable 
isotope tracing of phospholipids and triacylglycerols in cardiomyocytes incubated 
with media containing 13C6-glucose for 18 h: (A) Atom-resolved map illustrating the 
biological and biochemical history of 13C incorporation into glycerolipids; Fractional 
enrichment values of 13C into: (B) phosphatidylcholine (PC); (C) 
Phosphatidylinositol (PI); (D) phosphatidylethanolamine (PE); (E) 
phosphatidylserine (PS); and (F) triacylglycerols (TAG). Graph represents three 
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depend upon mitochondrial activity, we next measured respiration in cells 
expressing either the control construct (GFP) or the GlycoHi or GlycoLo constructs. 
GlycoHi-expressing cells showed 50% lower basal oxygen consumption, whereas 
GlycoLo-expressing cells showed significantly higher basal OCR values (Fig. 27A, 
27C). These PFK-mediated changes in mitochondrial OCR are likely due to the 
Crabtree effect, which is characterized by decreases in mitochondrial activity under 
conditions of increased glucose availability or glycolytic activity.286-289 Although 
addition of oligomycin showed marginal effects on ATP-linked OCR, proton leak 
was significantly diminished in GlycoHi cells. Upon addition of a mitochondrial 
uncoupler, GlycoLo and GlycoHi cells showed relative changes in maximal 
respiratory rate and in reserve capacity that mirrored the pattern found for basal 
OCR and proton leak (Fig. 27A, 27C).  These data are consistent with the notion 
that high PFK activity diminishes mitochondrial activity, which limits the cataplerotic 
generation of metabolites required for the synthesis of end products of the PPP, 
HBP, and GLP. 
Although cells transduced with the GlycoHi virus had >2-fold elevation in 
basal extracellular acidification (ECAR) compared with Ad-GFP controls, we 
observed no differences in ECAR in NRCMs expressing the GlycoLo PFK2 mutant 
(Fig. 27B). Addition of oligomycin increased ECAR to similar values in all groups, 
suggesting that inhibition of mitochondrial ATP production overrides PFK2-
mediated changes in glycolysis. Although extracellular acidification is a surrogate 
measure of lactate extrusion and aerobic glycolysis, protons are also generated 
during respiration via pyruvate dehydrogenase-mediated production of CO2 (i.e.,  
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Figure 27: Phosphofructokinase activity regulates mitochondrial activity in 
isolated cardiomyocytes. Extracellular flux analyses of NRCMs: (A) Oxygen 
consumption traces (OCR), (B) Extracellular acidification rate (ECAR), and (C) 
Calculated indices of respiration of cardiomyocytes transduced with GFP, GlycoLo, 
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CO2 à HCO3- + H+)290, 291; thus, the inconsistency of ECAR with absolute 
measurements of glycolytic rate and 13C3-lactate in GlycoLo cells (see. Fig. 1) is 
likely due to an increase in mitochondrial activity. Taken together, measurements 
from radiometric assays, stable isotope tracing, and extracellular flux analyses 
indicate that PFK regulates ancillary pathways by not only direct partitioning of 
glucose (e.g., in the PPP and the GLP) but by regulating mitochondrial cataplerotic 
reactions as well.  
 
Discussion 
Most studies of cardiac metabolism have focused primarily on the catabolic 
reactions required for energy provision.292 Considerably less effort has been 
devoted to understanding the regulation of ancillary pathways of glucose 
metabolism in the heart and how these pathways integrate with catabolic reactions. 
In this study, we examined how PFK activity, which immediately precedes the 
“lysis” step in glycolysis, regulates several 6-carbon- and 3-carbon-initiated 
anabolic pathways that require glycolytic intermediates.  Our results demonstrate 
that in cardiac myocytes PFK regulates glucose carbon incorporation into ancillary 
biosynthetic pathways by: (1) directly regulating carbon flow into purines and 
phospholipids; and (2) indirectly influencing mitochondrial cataplerotic activity 
required for the generation and subsequent incorporation of glucose-derived 
carbon into products of the PPP, HBP, and GLP. These studies also illustrate how 
radiometric measurements, stable isotope tracing, and extracellular flux analyses 
can be integrated to examine substrate fate and develop detailed understanding 
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of how interventions simultaneously affect anabolic and catabolic metabolism.   
We chose to study the integration of anabolism and catabolism in the 
context of glycolytic regulation at the PFK node. This enzyme controls 65% of the 
flux through glycolysis in the heart,235 making it the major regulator of glycolytic 
activity. It is unlikely that, under the experimental conditions used, glucose entry 
was a major limiting step for its metabolism because NRCMs express both GLUT1 
and GLUT4.110 Our stable and radiometric isotope tracing measurements show 
that, under control conditions, <50% of glucose taken into myocytes is catabolized 
past the enolase reaction. This suggests a majority of the glucose entering the 
myocyte is not used for energy production, but is likely used by biosynthetic 
pathways. Although PFK activity was found to be a potent determinant of 
glycolysis-engendered lactate production, it did not have diametrically coordinate 
effects on the relative amounts of glucose found upstream of the enolase reaction. 
Surprisingly, both a decrease and an increase in glycolytic activity led to the 
accumulation of glucose upstream of the enolase reaction; however, the 
mechanisms by which low and high PFK activity augment the levels of glucose-
derived carbon upstream of the enolase reaction appear to differ: when PFK 
activity was high, glucose uptake was increased, but glucose utilization was 
elevated; when PFK activity was low, glucose uptake was the same as that found 
in control cells, but glucose utilization was remarkably diminished. These results 
suggest that conditions of low PFK activity promote accumulation of metabolites 
(likely upstream of the PFK step), and that conditions of high glycolytic activity 
support levels of glucose-derived carbon upstream of the enolase reaction by 
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augmenting glucose uptake. Additionally, our data suggest that the level of glucose 
available for glucose oxidation, alanine transamination, or pyruvate carboxylation 
was relatively stable and independent of PFK activity. 
Although studies in some cell types such as adipocytes suggest that the 
HBP is a relatively minor pathway, utilizing only 2–3% of incoming glucose,293 our 
stable isotope tracing data suggest that the rate of entry of glucose-derived carbon 
into this pathway may be higher in cardiac myocytes. The unlabeled pool of UDP-
HexNAc was below 10% in all groups, suggesting that sugar donors such as UDP-
GlcNAc and UDP-GalNAc are synthesized and utilized at high rates. In contrast, 
>20% of the pool of nucleotides was unlabeled and 13C enrichment of the glycerol 
moiety of glycerolipids was below 20%.  These findings appear to indicate that the 
HBP utilizes more glucose-derived carbon than either the PPP or the GLP. Given 
that up to 20% of glucose taken up by the heart could enter the PPP,294 our 
comparisons of 13C enrichment in end products of these pathways suggests that 
HBP flux in cardiomyocytes may be much higher than currently appreciated. 
Our results are consistent with previous findings in epithelial cells,144 
fibroblasts,295, 296  and developing embryos297 which show that glycolysis regulates 
glucose entry into the PPP. Our findings are also consistent with computational 
predictions of the role of PFK in regulating the PPP in the intact heart.235 Similar to 
findings in neurons,298 in cardiac myocytes high glycolytic rates driven by PFK 
decreased the incorporation of glucose carbon into the ribose ring of purines. This 
suggests that high rates of glycolysis decrease the flux of glucose through the 
oxPPP. Nevertheless, we identified remarkable differences in 13C labeling in ATP 
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and GTP versus CTP and UTP. Although both classes of nucleotides use the 
metabolic precursor ribose-5-phosphate to form the ribose ring, purine ring carbon 
atoms originate from N10-formyltetrahydrofolate, CO2 and glycine, while pyrimidine 
ring carbons come from carbamoyl phosphate and glutamine, as well as aspartate 
generated by cataplerosis.299 In the timeframe examined, purines did not 
demonstrate incorporation of carbons that derive from metabolic products of the 
serine biosynthetic pathway and one-carbon metabolism. Hence, it is possible that 
glycine and N10-formyltetrahydrofolate derived from the serine biosynthetic 
pathway might be inadequate to participate in purine ring synthesis during the 18 
h incubation time used in our experiments. Alternatively, unlabeled serine and 
folate present in the media could be used by these cells for de novo purine 
biosynthesis. 
The decrease in mitochondrial activity detected by extracellular flux analysis 
in GlycoHi cells, paired with stable isotope tracing results in pyrimidines, suggests 
low cataplerotic generation of aspartate. Oxaloacetate generated in the Krebs 
cycle or via pyruvate carboxylation is transaminated to aspartate, which is 
subsequently used for pyrimidine biosynthesis. That the m+7 and m+8 
isotopologues were lower in GlycoHi cells shows that these pathways were 
diminished under conditions of high PFK activity. From these data, we inferred that 
the decrease in de novo pyrimidine biosynthesis in the GlycoHi cells may be due to 
lower rates of cataplerosis. Because tricarboxylic acid anions are delicately 
balanced by the input and output of intermediates involved in mitochondrial 
substrate oxidation, anaplerosis, and cataplerosis,285 we reasoned that 
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mitochondrial activity measurements could provide convergent evidence of PFK-
mediated regulation of auxiliary glucose biosynthetic pathways. Indeed, the 
decrease in mitochondrial activity in GlycoHi cells, paired with the observation that 
13C-aspartate entry into pyrimidines was low, suggests that inhibition of pyrimidine 
synthesis under conditions of high glycolytic activity is due to low rates of 
cataplerosis.    
 Similar reasoning as well as previous modeling, validation, and biochemical 
interpretation of 13C isotopologue data for UDP-GlcNAc300 were used to determine 
how PFK affects the HBP, which is important given the known role of UDP-
hexosamines in modulating N- and O-linked glycosylation.147, 246 The fact that the 
unlabeled pool of UDP-HexNAc was higher in GlycoHi cells suggests that the net 
effect of high PFK activity is a decrease in HBP flux, and, like that found for 
pyrimidines, this appears to be in part due to diminished mitochondrial activity. 
Nevertheless, there are limitations for interpreting current data on HBP flux. 
Because building UDP-HexNAc requires metabolites from many sources, it is 
possible that the contribution of carbon from non-labeled pools of metabolites may 
hinder interpretation. A potential solution to this problem would be to use a pulse-
chase approach, where isotopic labeling in the system is first saturated (e.g., with 
both 13C and 15N) and then the stably labeled substrate(s) are replaced with 
unlabeled substrate(s). The disappearance of the stable label over time in 
isotopologues of UDP-HexNAc should, with higher confidence, reveal which 
intersecting metabolic pathways limit HBP activity and UDP-Glc(Gal)NAc 
synthesis under a given set of conditions.  
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To date, little evidence exists for whether or how glycolysis regulates GLP 
activity. Interestingly, G3P formed via glycerol-3-phosphate dehydrogenase 1 has 
been shown to inhibit PFK2 and activate fructose bisphosphatase 2,301 suggesting 
feedback regulation of the GLP on both glycolytic and gluconeogenic activity. An 
indication that the glycolytic rate regulates GLP flux and glycerolipid synthesis is 
provided by studies showing that genetic deletion or overexpression of PFKFB3, 
a highly active form of PFK2, in adipose tissue coordinately regulates fat deposition 
and obesity,302, 303 which is consistent with the notion that glycolysis in adipocytes 
regulates TAG synthesis and storage. We found that low PFK activity directly limits 
glucose-derived carbon incorporation into the glycerol backbone of several 
phospholipids including PC, PI, PE, and PS; however, this was not the case with 
triacylglycerols, where 13C incorporation into glycerol was not different, but fatty 
acyl chain labeling was diminished in GlycoHi cells. These results suggest that the 
fatty acid pool derived from cataplerotic reactions is differentially channeled to 
route newly synthesized fatty acids for esterification into triacylglycerols rather than 
phospholipids.  
There are several limitations to our study. Although NRCMs are beating 
cardiac myocytes, they rely on glycolysis for energy to a much greater extent than 
the adult heart.239  Thus, findings regarding pathways that involve metabolites 
generated by cataplerosis may not entirely reflect metabolism in the adult heart. 
Glucose carbon fate in NRCMs appears to differ from the adult heart primarily at 
the level of coupling between glycolysis and glucose oxidation. In the adult human 
heart, previous studies show that 26% of extracted glucose undergoes oxidation 
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and 12% is released as lactate.84 In contrast, in NRCMs, we show that <13% of 
glucose carbon undergoes oxidation and ~24% is released as lactate. 
Nevertheless, our finding that a large portion of exogenous glucose extracted by 
cardiac myocytes is apportioned for metabolic pathways other than glycolysis and 
glucose oxidation is supported by human in vivo isotope tracing studies in the 
myocardium, which demonstrate that 60% of exogenous glucose extracted by 
contracting myocytes enters a slow turnover pool amenable to entry into ancillary 
biosynthetic pathways.84 Another consideration is that the NRCM culture media is 
devoid of fatty acids, which could influence the coupling between glycolysis and 
glucose oxidation as well as biosynthetic pathway activity.  Last, it is important to 
consider that our stable isotope analyses did not include glycogen, glycine, serine, 
or sorbitol, which limits our understanding of how glycolysis regulates glycogen 
biosynthesis, serine biosynthesis, and the polyol pathway. Nevertheless, 
computational models created by Cortassa et al.235 suggest that the polyol 
pathway is under strong control by activation or inhibition of PFK. Similarly, 
previous studies show that PFK activity regulates glycogen abundance in the 
heart.220, 221 Such a behavior would be consistent with coordinate regulation of 
ancillary biosynthetic pathway activity by PFK. 
In summary, by using several methods to measure metabolic pathway 
activity, we found that >40% of glucose consumed by NRCMs is not catabolized 
to pyruvate, and that PFK has strong effects on the coupling between glucose 
oxidation and glycolysis. Pairing results from stable isotope-resolved 
metabolomics with extracellular flux analysis demonstrated that PFK activity 
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regulates glucose carbon incorporation directly into the ribose and the glycerol 
moieties of purines and phospholipids, respectively, and that high PFK, by 
indirectly limiting mitochondrial activity, diminishes 13C incorporation into 
pyrimidines, UDP-N-acetyl-hexosamine(s), and the fatty acyl chains of 
phosphatidylinositol and triglycerides. These insights could help elucidate how 
pathological or physiological changes in glucose metabolism regulate the anabolic 
behavior and remodeling of the myocardium.iii 
iii This chapter previously appeared as an article in the Biochemical Journal. The original 
citation is as follows: Gibb AA, et al. Integration of flux measurements to resolve changes in 
anabolic and catabolic metabolism in cardiac myocytes. Biochem J. 2017. 
 





The studies presented here were designed to develop an understanding of 
the effects of exercise on cardiac metabolism and the potential role of these 
changes in regulating the adaptive response, i.e., physiologic growth. We 
reasoned that, because changes in metabolism present not only a material cause 
but can also have direct and indirect roles in intracellular signaling, exercise-
induced changes in cardiac metabolism are essential for adaptation to training. 
Our general hypothesis is that exercise-induced changes in glycolytic flux are 
essential for activation of the physiological growth program. To test this hypothesis, 
we assessed the effects of acute and chronic exercise on myocardial metabolism, 
in particular glycolysis, and whether these changes contributed to the physiologic 
growth of the heart.  
 To establish a model in which to test our hypothesis, we first examined 
nocturnal/diurnal behavior, treadmill exercise compliance, and systemic as well as 
cardiac-specific exercise adaptations in two commonly used mouse strains, 
C57BL/6J, and FVB/NJ mice. As discussed in Chapter II, metabolic cage analysis 
indicated a strong nocturnal nature of C57BL/6J mice, whereas FVB/NJ mice 
showed no circadian element to activity, food or water intake, VO2, or VCO2. Initial 
	 180	
exercise capacity tests revealed that, compared with C57BL/6J mice, FVB/NJ mice 
are capable of achieving nearly 2-fold higher workloads prior to exhaustion. 
FVB/NJ mice tested during the day were capable of achieving significantly more 
work compared with their night-tested counterparts. Following 4 weeks of training, 
FVB/NJ mice showed significant increases in exercise capacity as well as 
physiologic cardiac growth characterized by enlarged myocytes and higher 
mitochondrial DNA content. C57BL/6J mice showed no increases in exercise 
capacity or cardiac growth regardless of whether they exercised during the day or 
the night. This lack of adaptation in C57BL/6J mice was attributable, at least in 
part, to their progressive loss of compliance to the treadmill training protocol. From 
these results, we conclude that the FVB/NJ strain is a useful and robust mouse 
model for examining cardiac adaptations to treadmill exercise and that treadmill 
training during daytime hours does not negatively affect exercise compliance or 
capacity. 
 In Chapter III, we examined the effects of exercise on myocardial 
metabolism and the role these changes may play in contributing to exercise-
induced cardiac growth. As discussed, we found that exercise acutely decreased 
glucose utilization by modulating circulating substrates and reducing 
phosphofructokinase activity; however, upon exercise adaptation and recovery 
there was an increase in myocardial phosphofructokinase activity and glycolysis.  
To assess the relevance of these changes in glycolytic activity, we determined how 
cardiac-specific expression of mutant forms of 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase (PFK2) affect cardiac structure, function, metabolism, and 
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gene programs relevant to cardiac remodeling. Cardiac-specific expression of a 
kinase-deficient PFK2 transgene (GlycoLo mice) lowered glycolytic rate and 
regulated the expression of genes known to promote cardiac growth. Hearts of 
GlycoLo mice had larger myocytes, enhanced cardiac function, and higher 
capillary-to-myocyte ratios. Expression of phosphatase-deficient PFK2 in the heart 
(GlycoHi mice) increased glucose utilization and promoted a more pathological 
form of hypertrophy devoid of transcriptional activation of the physiologic cardiac 
growth program. Modulation of phosphofructokinase activity was sufficient to 
regulate the glucose-fatty acid cycle in the heart; however, metabolic inflexibility 
caused by invariantly low or high phosphofructokinase activity caused modest 
mitochondrial damage. Transcriptomic analyses showed that glycolysis regulates 
the expression of key genes involved in cardiac metabolism and remodeling. 
Collectively, these findings suggest that the exercise-induced decreases in 
glycolytic activity stimulate physiologic cardiac remodeling and that metabolic 
flexibility is important for maintaining mitochondrial health in the heart. 
 To gain insight into how these changes in glycolytic activity could contribute 
to cardiac growth, we assessed the impact of changes in glycolytic activity on 
cardiomyocyte anabolic metabolism. In Chapter IV, we show that expression of 
mutant forms of PFK2 in rat neonatal cardiomyocytes coordinately regulate 
catabolic and anabolic metabolism. An important finding was that >40% of glucose 
consumed by myocytes was unaccounted for via catabolism to pyruvate, which 
suggests entry of glucose carbons into ancillary pathways branching from 
metabolites formed in the preparatory phase of glycolysis. Analysis of 13C fractional 
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enrichment patterns from stable isotope tracing experiments suggests that PFK 
activity regulates glucose carbon incorporation directly into the ribose and the 
glycerol moieties of purines and phospholipids, respectively. Pyrimidines, UDP-N-
acetyl-hexosamine, and the fatty acyl chains of phosphatidylinositol and 
triglycerides showed lower 13C incorporation under conditions of high PFK activity; 
the isotopologue 13C enrichment pattern of each metabolite indicated limitations in 
mitochondria-engendered oxaloacetate, acetyl CoA, and fatty acids. Consistent 
with this notion, high glycolytic rate diminished mitochondrial activity and the 
coupling of glycolysis to glucose oxidation. These findings suggest that a major 
portion of intracellular glucose in cardiac myocytes is apportioned for ancillary 
biosynthetic reactions and that PFK coordinates the activities of the pentose 
phosphate, hexosamine biosynthetic, and glycerolipid synthesis pathways by 
directly modulating glycolytic intermediate entry into auxiliary glucose metabolism 
pathways and indirectly regulating mitochondrial cataplerosis. 
 Collectively, the data obtained from these studies support the notion that 
acute and chronic exercise is associated with changes in myocardial metabolism 
and that the periodic decreases in myocardial glucose utilization occurring during 
exercise are a stimulus for physiologic cardiac growth. Additionally, metabolic 
flexibility, maintained in the exercised heart, appears to be a primary distinguishing 
feature of mitochondrial health in the heart. These findings are summarized in Fig. 




Figure 28: Exercise-induced effects on cardiac metabolism and its role in 
regulating cardiac growth and mitochondrial health. Acute exercise increases 
the circulating levels of FFA and lactate which act to decrease the utilization of 
glucose by the myocardium; however, in the exercise-adapted state sustained 
increases in circulating hormones contribute in part to enhanced glucose 
utilization. At the cellular level, allosteric regulation of the rate-limiting step of 
glycolysis, PFK1, is coordinately affected to and influence glucose utilization both 
during exercise and in the adapted state. These exercise-induced decreases in 
glycolysis are sufficient to promote physiological growth of the heart. While 
decreases in glucose utilization are a key trigger for cardiac growth, exercise-
induced metabolic flexibility is essential for the preservation of mitochondrial health 































































Metabolic Regulation of Cardiac Growth 
 While exercise promotes cardiovascular wellness and overall health, the 
mechanisms by which this is accomplished remain unclear. The three salient 
findings from our studies, related to the heart, are: (1) that periodic decreases in 
myocardial glycolytic activity are sufficient to promote physiologic cardiac 
growth304; (2) that maintenance of metabolic flexibility in the heart is essential for 
mitochondrial health304; and (3) that glycolytic activity in cardiomyocytes 
coordinates the biosynthesis of nucleotides, nucleotide sugars, and 
glycero(phospho)lipids.305 Our findings have several implications, germane to both 
the basic understanding of cardiac remodeling as well as future targets for therapy. 
The finding that exercise acutely diminishes glucose utilization and that this 
change in metabolism activates the gene program for physiologic growth provides 
new knowledge and a metabolic target that could be leveraged for preventing 
adverse remodeling in response to stress. In particular, controlled pharmacologic 
modulation of the PFK node of metabolism could be used to activate the cardiac 
growth gene program as well as to stimulate the heart to use multiple substrates, 
which appears to be required for optimal mitochondrial function. Also, the finding 
that PFK activity regulates ancillary biosynthetic pathway activity rouses new 
concepts about the importance of coordinated anabolic activity in modulating 
hypertrophic responses to stress. These findings and their potential impact with 
respect to myocardial health and remodeling are discussed in detail below. 
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Myocardial glycolysis coordinates cardiomyocyte biosynthetic activity: A principle 
finding from our studies was that PFK activity in cardiomyocytes coordinated the 
biosynthesis of materials required for growth (Fig. 29). One pathway affected by 
PFK and glycolytic activity was the PPP, which contributes to growth by: (1) 
replenishing NADPH levels required for anabolic reactions and the regeneration of 
GSH; (2) synthesizing nucleotides for DNA repair and replication; and (3) providing 
metabolites that can act as direct signaling modulators. Previously it has been 
shown that glycolysis regulates glucose entry into the PPP in several cell types. In 
particular, developing embryos increase PPP flux by decreasing PFK enzyme 
abundance, rewiring glucose metabolism for normal development.297 In the context 
of the adult heart, pathological hypertrophy132-134 and heart failure135 are both 
associated with an increase in PPP activity. During short-intensive exercise, the 
activities of the enzymes of the oxidative part of the PPP have been found to be 
slightly diminished; however, in the immediate recovery period, an increase in 
enzymatic activity was observed that persisted for up to 3 h.306 While the effectors 
of increased PPP activity are not well known, a recent study identified that 
overexpression of PGC-1α in skeletal muscle increased the enzymatic activities 
and end-products of the PPP.307 This finding is important as upregulation of PGC-
1α is well-known to be initiated by acute bouts of exercise.  
Our results provide additional mechanistic insight as to how PPP activity is 
increased in the exercising and recovering heart. Our in vivo results show that 
during and in the early recovery phase of exercise, PFK activity is diminished. This 
likely results in the redistribution of glucose into other ancillary pathways, such as  
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Figure 29: Metabolic regulation of the biosynthetic pathways involved in 
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the PPP, that are upstream of PFK. In fact, several lines of evidence support this 
assumption, such as the increase in myocardial glycogen shown to occur at this 
time. Our in vivo model of diminished PFK activity (i.e., GlycoLo) validated that 
regulation at this node of metabolism increases PPP activity as GlycoLo mice 
displayed increased abundances of several PPP-derived metabolites. Our in vitro 
studies also suggest that increased PPP activity may be a more coordinated and 
selective process, as low rates of glycolysis increased the biosynthesis of 
pyrimidines without affecting the purine pool.  
Collectively, these results suggest that an increase in PPP activity occurs 
when PFK activity is diminished. This results in increased nucleotide biosynthesis 
for DNA replication and amino acid synthesis as well as regeneration of the 
NADPH pool for anabolic reactions. As growth is an anabolic event, the cell must 
appropriately coordinate the biosynthesis of these building blocks, priming itself for 
the recovery phase when growth takes place. Also, the increase in PPP activity 
may have a direct role in signaling the growth of the heart. Results from our 
metabolomic screening showed that AICAR, an AMP-analog derived from the 
PPP, was significantly elevated in GlycoLo mice compared to WT controls based 
on a simple unpaired t-test. This increase in AICAR was associated with a 
significant increase in AMPK activation (data not shown). This result could suggest 
that changes in PPP activity are not only important for the building blocks for 
growth, but also for regulating signaling pathways that instigate the growth 
program. 
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Our in vivo and in vitro data also collectively suggest that an increase in 
PFK activity, such as occurs during the homeostatic phase in the exercise-adapted 
heart, would be important for the synthesis of glycerol(phospho)lipids. In particular, 
the synthesis of the glycerol moiety via the GLP is required to provide the backbone 
for fatty acid esterification and phospholipid synthesis. We found that the synthesis 
of abundant phospholipids in the cardiomyocyte, such as phosphatidylcholine, 
phosphotidylethanolamine, and phosphatidylinositol,308 appear to be regulated 
strongly by PFK-mediated changes in glycolytic activity.305 Higher levels of these 
phospholipids would be required for de novo expansion of cellular membranes as 
well as for maintaining larger myocytes, in response to stressors such as exercise. 
 We also found that changes in glycolytic activity cause significant 
phospholipid remodeling. This observation is important as it has been shown that 
changes in phospholipid composition, as occurs when phosphatidylethanolamine 
synthesis is reduced, results in impaired cardiac function.309 Similarly, chronic 
heart failure and diabetic cardiomyopathy, conditions in which metabolism 
becomes inflexible, are associated with disturbances in cardiac sarcolemmal 
membrane phospholipid homeostasis.310 In the exercise-adapted heart, proper 
phospholipid homeostasis is maintained, with little to no change in phospholipid 
composition.308 This could be a result of the acute periodic episodes of altered PFK 
and glycolytic activity instigated by exercise as opposed to the constitutive 
changes observed in disease. 
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Metabolic flexibility and mitochondrial health: Another key finding from our studies 
is that metabolic flexibility appears to be essential for maintaining mitochondrial 
health. While it is generally accepted that mitochondrial dysfunction develops in 
pathologic forms of hypertrophy, where metabolism becomes inflexible, the exact 
mechanisms driving dysfunction remain ill-defined. Several proposed mechanisms 
that have been suggested to contribute to mitochondrial dysfunction include 
mitochondrial DNA depletion and swelling,311 disorganization and reduced density 
of the cristae structures,312 increased oxidative stress,313 and mitochondrial 
uncoupling.314 Our findings in vivo indicate that invariant inflexibility of cardiac 
metabolism is sufficient to promote a mild form of mitochondrial dysfunction, 
suggesting that the metabolic phenotypes of the heart in pathology (e.g., chronic 
heart failure and diabetic cardiomyopathy) may in fact initiate the decline in 
mitochondrial health. 
 In line with this idea, several of the manifestations of mitochondrial 
dysfunction were identified in our in vivo mouse models. In both GlycoLo and 
GlycoHi hearts, we observed disorganization and a decreased density of 
mitochondrial cristae. Additionally, results from our metabolomics data suggest 
that metabolic inflexibility results in chronic oxidative stress, indicated by elevations 
in the lipid peroxidation product, 4-hydroxy-2-nonenal (4-HNE). Data from our in 
vitro studies may provide insight as to why this oxidative stress occurs, as 
increased rates of cardiomyocyte glycolysis diminished the biosynthesis of 
glutathione (data not shown), a key antioxidant. Lastly, it is possible that the 
mitochondria are more uncoupled which could contribute to the dysfunction 
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observed. As reviewed by Lopashuk, the oxidation of FFA contributes to 
mitochondrial uncoupling.82 Therefore, in instances of excessive FAO such as 
occurs in the GlycoLo heart, chronic uncoupling of the mitochondria could be 
detrimental. Our data indicate that the mitochondria from GlycoLo hearts are, in 
fact, more uncoupled than control hearts. 
 Mitochondrial dysfunction is also likely a consequence of changes in 
phospholipid homeostasis. As already discussed, both our in vivo and in vitro data 
indicate that changes in PFK and glycolytic activity affect phospholipid metabolism. 
Therefore, changes in one or several of the phospholipids found in the 
mitochondrial membrane could affect mitochondrial health. One of the most 
abundant phospholipids of the inner mitochondrial membrane is cardiolipin, which 
plays an important role in regulating the enzymatic activity of the electron transport 
chain.315, 316 In heart failure, mitochondrial cardiolipin content is reduced and is 
correlated with mitochondrial dysfunction.317-319 While we did not measure the 
cardiolipin abundance or its biosynthesis, identifying whether cardiolipin 
metabolism is affected by changes in glycolytic activity could provide novel 
mechanistic insights into mitochondrial damage in disease. Taken together, these 
results provide evidence that metabolic flexibility is essential for the maintenance 
of a healthy mitochondrial pool. Furthermore, our results provide a potential 
therapeutic target, the PFK node of glycolysis, to increase metabolic flexibility and 
improve mitochondrial health in disease. 
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Periodic decreases in myocardial glycolysis activate the cardiac growth program: 
As discussed, our data collectively indicate that changes in PFK and glycolytic 
activity coordinate biosynthetic pathways (e.g., PPP, GLP) that are required for 
cardiomyocyte growth. In addition, our data also suggest that metabolism plays a 
critical role in the activation of gene sets that promote cardiac growth. Most 
notably, our findings suggest that decreases in myocardial glycolytic rate, such as 
occurs during exercise, is sufficient to activate the Cebpb/Cited4 axis. While it has 
previously been shown that the activation of AKT was required for this 
transcriptional regulation,45 we found that low rates of glycolysis were sufficient to 
activate the physiologic gene program, suggesting that changes in metabolism are 
likely a proximal cause of cardiac growth.  
 Results from our studies suggest that PFK activity regulates anabolic 
pathways required for the synthesis of the amino acids alanine, serine, and glycine. 
The stimulation of the serine biosynthetic pathway (SBP), in particular, would not 
only increase serine/glycine biosynthesis, but it would control the one-carbon 
metabolic reactions (i.e., those involving methyl tetrahydrofolate metabolites) that 
are known to modulate the epigenetic landscape.320 Our data show not only that 
the abundance of these metabolites are changed by PFK activity (i.e., increased 
in GlycoHi), but that glycolysis regulates the transcription of enzymes involved in 
one-carbon metabolism (e.g., Phgdh). This could be significant because Cited4 is 
epigenetically regulated whereby hypermethylation of its CpG island causes lower 
expression.244 Our results are in line with the general consensus showing that 
altered metabolism regulates the epigenetic landscape.321-323 While additional 
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work establishing the mechanistic link between metabolism and epigenetics is 
required, our results provide new insights into the regulation of gene expression 
via metabolism. 
 Expanding on the observation that metabolites involved in one-carbon 
metabolism (e.g., serine, methionine, cysteine) are affected by PFK activity, the 
metabolic flexibility induced by exercise at this same metabolic node could 
contribute to the regulation of gene transcription. As these metabolites are involved 
in the methylation events of DNA and RNA, controlled modulation of the SBP 
pathway, by exercise-induced changes in PFK activity, could readily increase and 
decrease methylating agents such as 5-methyl-THF, altering gene transcription at 
the level of epigenetics. Our results support this notion as several genes, including 
Cited4, were coordinately regulated; however, we have yet to address whether 
changes in the SBP contribute to the physiologic gene program. The idea that PFK 
activity affects the epigenetic landscape is important, as it provides a potential 
therapeutic target that can be leveraged to prevent adverse remodeling. 
 
Future Directions 
Our results clearly demonstrate a key role for metabolism in regulating the 
cardiac growth response to stress; however, several questions remain 
unanswered. For instance, an experiment that would help to further identify how 
metabolic pathways integrate to promote the physiologic growth program would be 
to identify which pathways are similarly altered in the GlycoLo and acutely 
exercising heart. For example, if one-carbon metabolites involved in methylation 
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are similarly reduced in their abundance, this would provide further evidence of the 
metabolic regulation of epigenetic modifications. Similarly, if flux through the HBP, 
which we show to be affected by PFK and glycolytic activity, is similarly affected in 
exercising and GlycoLo hearts, identification of the proteins that are analogously 
post-translationally modified could provide additional targets to further dissect the 
mechanisms that promote physiologic growth of the heart. Furthermore, identifying 
how exercise intensity and duration regulate these metabolic pathways and gene 
transcription would be important for optimizing cardiac adaptations and for further 
understanding links between metabolism and cardiac growth. 
Understanding how modulation of other nodes of glucose metabolism may 
also provide insight as to the regulation imposed by metabolism on cardiac growth. 
For example, cardiac-specific pyruvate dehydrogenase complex deficiency results 
in a mild form of cardiac hypertrophy in mice,324 an interesting observation as it 
could be reasoned that this genetic modification likely results in a phenotype 
similar to our GlycoLo mouse. In mice subjected to pressure overload, 
cardiomyocyte overexpression of hexokinase resulted in the attenuation of 
pathological hypertrophy.139 Lastly, an interesting clinical finding in patients with 
glycogen storage diseases is the presentation of a mild form of hypertrophic 
cardiomyopathy.325 This suggests that myocardial glycogen contributes to the 
growth of the heart and may be relevant to our findings as we see that exercise 
and diminished PFK activity increase myocardial glycogen content. Therefore, it 
would be interesting to determine whether glycogen accumulation during exercise 
contributes to the cardiac growth response. These studies, in addition to our 
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results, provide ample evidence of the role of metabolism in regulating the growth 
responses to stress and indicate additional nodes of glucose metabolism that 
potentially coordinate the biosynthetic pathways. 
The conclusions from our studies also open up the possibility to explore the 
contributions of metabolism in other forms of cardiac growth and hypertrophy. For 
instance, little is known about the metabolic changes that occur in pregnancy-
induced physiological hypertrophy. In healthy women, pregnancy is associated 
with a transient increase in cardiac size, similar to that observed in the exercised 
heart.326 This growth response has been linked to the activation of AKT and 
ERK1/2 signaling pathways, both known to influence and control cellular 
metabolism.327-329 with this knowledge in hand, it would be interesting to test 
whether pregnancy-induced cardiac growth is associated with similar changes in 
PFK activity and transcription regulation of Cebpb and Cited4 as we observed in 
our exercise model.  
The transcriptomics results from our study provided a large data set in which 
to ask new and exciting questions in the field of cardiac health in disease. For 
example, the expression of gluconeogenic genes, fructose-1,6-bisphosphatase 2 
(Fbp2) and phosphoenolpyruvate (Pck1), were found to be altered by glycolytic 
activity in the heart, with Fbp2 in a coordinate manner. The fact that these genes 
are modifiable in an organ thought to have limited gluconeogenic potential is 
noteworthy. This observation provides the opportunity to test the hypothesis that 
an increase in myocardial gluconeogenic enzyme activity would be 
cardioprotective from pathologic insult or promote myocyte proliferation by 
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increasing the bioavailability of carbons for ancillary biosynthetic flux and through 
regulation of gene transcription. Similarly, we found that centromere protein F 
(Cenpf), a gene associated with chromosome segregation during mitosis,330 was 
found to be coordinately regulated by glycolysis. Interrogation of the metabolic 
regulation of such cell division genes in cardiomyocytes, thought to be terminally 
differentiated and relatively incapable of division and proliferation, may provide 
novel therapeutic approaches to regenerate the myocardium following injury. 
 In conclusion, we demonstrate a clear role of exercise-induced changes in 
metabolism in coordinating the growth response of the heart and the importance 
of metabolic flexibility in maintaining cardiac health. It is my hope that the 
knowledge derived from these studies will form the basis for the development of 
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   Department of Health and Sport Science 
Exercise Physiology Program 
   University of Louisville 
   Louisville, KY 
 
08/2011 – 12/2012 Adjunct Instructor 
   Department of Health and Sport Science 
Exercise Physiology Program 
   University of Louisville 
   Louisville, KY 
 
08/2012 – present Doctoral Candidate 
   Department of Physiology 
   University of Louisville 
   Louisville, KY 
 
 
OTHER POSITION AND EMPLOYMENT 
 
01/2010 – 09/2011 Clinical Exercise Physiologist – Kentucky One Healthcare, 
Cardiac Rehabilitation, Louisville, KY
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09/2011 – 08/2012 Fitness Coordinator – Corporate Fitness Works, Humana 
Corporate Headquarters, Louisville KY 
02/2016 – present Research Associate - Department of Medicine, University of 





Nov 2014  Isotope Tracers in Metabolic Research: Principles and 
practices of kinetic analysis; Mouse Metabolic Phenotyping 
Center (MMPC) Consortium, Training 
Conference/Workshop. Nov. 10-14, Cleveland, OH.  
 
 
PROFESSIONAL MEMBERSHIPS AND ACTIVITIES 
 
2008 – present American College of Sports Medicine (ACSM), Student 
Member 
2014 – present American Heart Association (AHA), Student Member 
2015 – present American Physiological Society (APS), Student Member 




HONORS AND AWARDS 
 
2005 – 2009  Gateway Scholarship, Ohio University 
2009 – 2011 Graduate Assistantship, Department of Exercise Physiology, 
University of Louisville 
2012 – 2014  Integrated Programs in Biomedical Sciences (IPIBS) 
Fellowship Award, University of Louisville 
2016 NIKE, Inc. Loren G. Myhre Environmental and Exercise 
Physiology Predoctoral Research Award, EEP Section of the 
American Physiological Society (APS) 
2016   Physiology Departmental Graduate Student Travel Award 
2016 – present American Heart Association Predoctoral Fellowship Award 
2016 – 2019 Nominated for a 3-year sponsored membership to AAAS by 
the associate dean of graduate and postdoctoral studies, 
University of Louisville 










1. Salabei JK, Gibb AA, Hill BG. Comprehensive measurement of respiratory 
activity in permeabilized cells using extracellular flux analysis. Nat Protoc 
9(2):421-38, 2014. 
 
2. Cummins TD, Holden CR, Sansbury BE, Gibb AA, Shah J, Zafar N, Tang Y, 
Hellmann J, Rai SN, Spite M, Bhatnagar A, Hill BG. Metabolic remodeling of 
white adipose tissue in obesity. Am J Physiol Endocrinol Metab 307(3):E262-
77, 2014. 
 
3. Salabei JK, Lorkiewicz PK, Mehra P, Gibb AA, Haberzettl P, Hong KU, Wei X, 
Zhang X, Li Q, Wysoczynski M, Bolli R, Bhatnagar A, Hill BG. Type 2 diabetes 
dysregulates glucose metabolism in cardiac progenitor cells. J Biol Chem 
291:13634-48, 2016. 
 
4. Gibb AA, Gilbert LA, Riggs DW, Conklin DJ, Bhatnagar A, Hill BG. FVB/NJ 
mice are a useful model for examining cardiometabolic adaptations to treadmill 
exercise. Front Physiol 7:636, 2016. 
 
5. Gibb AA, Lorkiewicz PK, Zheng YT, Zhang X, Bhatnagar A, Jones SP, Hill BG. 
Integration of flux measurements to resolve changes in anabolic and catabolic 
metabolism in cardiac myocytes. Biochem J, 474: 2785-2801, 2017. 
 
6. Gibb AA, Epstein PN, Uchida S, Zheng YT, McNally LA, Obal D, Katragadda 
K, Trainor P, Conklin DJ, Brittian KR, Tseng MT, Wang J, Jones SP, Bhatnagar 
A, Hill BG. Exercise-induced changes in glucose metabolism promote 
physiologic cardiac growth. Circulation, 2017. (In Press) 
 
 
Manuscripts in Review 
 
1. Osuma E, Riggs D, Gibb AA, Hill BG. High throughput measurement of 
metabolism in planarians reveals activation of glycolysis during regeneration. 
Regeneration, 2017.  
 
2. Liu M, Ding C, Luo F, Albeituni S, Hu X, Hamada M, Takahashi S, Gibb AA, 
Kloecker G, Zhang H, Buosamra II M, Fan TW, Lane A, Hill BG, Yan J. 
Transcription factor c-Maf controls anti-tumor immunity by programming 






Manuscripts in Preparation 
 
1. Gibb AA & Hill BG. Metabolic regulation of myocardial remodeling. (Invited 
Review, Circ Res) 
 
2. Pena Claderin E, McNally L, Gibb AA, Hill BG, Hellmann J. A diet high in fat 
inhibits exercise-induced biosynthesis of pro-resolving lipid mediators. 




1. Center for Metabolic Origins of Disease 
Sanford Burnham Prebys Medical Discovery Institute 
Title: Metabolic regulation of cardiac adaptation to exercise. 
Host: Doug Lewandowski, Ph.D. April, 2017. 
 
2. Center for Translational Medicine 
Lewis Katz School of Medicine, Temple University 
Title: Metabolic regulation of cardiac adaptation to exercise. 
Host: John Elrod, PhD. August, 2017. 
 
3. Abstract Selection for Oral Presentation 
Session Title: Symposium – Energy School II 
Title: Phosphofructokinase coordinates mitochondrial and ancillary 
biosynthetic pathway activities in the cardiomyocyte 





1. Salabei JK, Gibb AA, Jones SP, Bhatnagar A, Hill BG. Regulation of the 
hyperproliferative vascular smooth muscle cell phenotype by mitochondrial 
fission. Free Radic Biol Med 65: S2, 2013. 
 
2. Holden CR, Wysoczynski M, Sansbury B, Hellmann J, Zafar N, Gibb A, 
Bhatnagar A, and Hill BG. Nutrient excess promotes accumulation of bone 
marrow-derived progenitor cells in adipose tissue. FASEB J 28(S1): 641.12, 
2014. 
 
3. Gibb AA, Sansbury BE, DeMartino AM, Harbeson MA, Jones SP, Bhatnagar 
A, Hill BG. Regulation of glucose metabolism in the failing heart. 2nd Annual 




4. Gibb AA, Sansbury BE, DeMartino AM, Harbeson MA, Jones SP, Bhatnagar 
A, Hill BG. Regulation of glucose metabolism in the failing heart. Research 
Louisville, 2014. 
 
5. Gibb AA, Bhatnagar A, Hill BG. Role of cardiac glycolysis in adaptations to 
exercise. Circ Res 117: A387, 2015. 
 
6. Gibb AA, Bhatnagar A, Hill BG. Myocardial glycolytic rate regulates exercise 
capacity and cardiac hypertrophy. Southeast Regional IDeA Conference, 2015. 
 
7. Gibb AA, Gilbert LA, Brittian KR, Jones SP, Bhatnagar A, Hill BG. Myocardial 
glycolytic rate regulates exercise-induced physiologic cardiac growth. FASEB 
J 30(S1):1239.7, 2016. 
 
8. Gibb AA, Gilbert LA, Lorkiewicz P, Trainor P, Tseng MT, Epstein PN, 
Bhatnagar A, Hill BG. Altered cardiomyocyte glycolysis causes cardiac 
hypertrophy and mitochondrial dysfunction. Circulation 134:A19448, 2016. 
 
9. Gibb AA, Lorkiewicz PK, Zheng YT, Zhang X, Bhatnagar A, Jones SP, Hill BG. 
Phosphofructokinase coordinates mitochondrial and ancillary biosynthetic 
pathway activities in the cardiomyocyte. ABP Bioenergetics, 2017. 
 
10. Gibb AA, Epstein PN, Uchida S, Zheng YT, McNally LA, Trainor P, Conklin DJ, 
Brittian KR, Tseng MT, Jones SP, Bhatnagar A, Hill BG. Metabolic regulation 
of exercise-induced cardiac growth. APS Bioenergetics, 2017. 
 
11. Zheng YT, Gibb AA, McNally LA, Liu S, Merchant M, Hill BG. Multimeric 
metabolic enzyme complexes in the adult mammalian heart. APS 
Bioenergetics, 2017. 
 




American Heart Association Predoctoral Fellowship, Great Rives Affiliate 
Title: Metabolic Regulation of Myocardial Adaptations to Exercise 
The goal of this project is to understand the role of metabolism, specifically 
glucose metabolism, in the adaptive responses associated with exercise training. 
$52,000, 2016-2018. 
Priority Score: 1.42; Application Percentile Rank: 0.33%. 
 
Intramural Grant 
College of Education Internal Funding Award (University of Louisville) 
Equipment procurement for teaching aid technology (CleveMed Software) 
Spring 2011 
Direct Costs: $5,000 − Role: Lead 
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INVITED JOURNAL REVIEWER 
 
1. Toxicological Sciences (1 Review) 
 
 
ASSISTED JOURNAL REVIEWER 
 
1. Circulation Research (2 Reviews) 






Fall 2009  Instructor, University of Louisville, Louisville KY 
Weight Training HSS 109 
Fitness Walking HSS 114 
 
Spring 2010  Instructor, University of Louisville, Louisville KY 
Indoor Soccer HSS 150 
 
Summer 2010  Instructor, University of Louisville, Louisville KY 
Outdoor Soccer HSS 136 
Weight Training HSS 109 
 
Fall 2010  Instructor, University of Louisville, Louisville KY 
Physical Fitness and Conditioning HSS 110 
Fitness Walking HSS 114 
Volleyball HSS 137 
 
Spring 2011  Instructor, University of Louisville, Louisville KY 
Weight Training HSS 109-06  
Weight Training HSS 109-07  
Physical Fitness and Conditioning HSS 110-01 
Physical Fitness and Conditioning HSS 110-02 
 
Fall 2011  Adjunct Instructor, University of Louisville, Louisville KY 
   Principles in Electrocardiography EXP 611 
Mean course evaluation – 4.63/5.0 
 
Fall 2012   Adjunct Instructor, University of Louisville, Louisville KY 
   Principles in Electrocardiography EXP 611 
Mean course evaluation – 4.88/5.0 
***Highest semester mean within the department 
 
